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Abstract
The development of specific antiviral drugs directly targeting the hepatitis C virus
(HCV) is clinically important, as the current standard interferon/ribavirin combina-
tion treatment is only partially effective, expensive and often associated with severe
side effects. Inhibitors of the NS3 protease (PI) thereforerepresent a promising alter-
native or additional therapy. To date, the development andin vitro evaluation of PIs is
restricted to the genotype 1/2 based replicon and the genotype 2a full length viral cell
culture system. However, proteases of the different HCV genotypes vary substantially
in their amino acid sequence and secondary structure and require separate evaluation
of their efficacy before they go into clinical trials.
To address this issue, a panel of intra- and intergenotypic recombinants based on the re-
combinant infectious clone Jc1 (pFK JFH1/J6/C-846) was developed in this work. The
viability of these recombinants was assessed in the Huh7.5 cell culture system, where
replicating viruses were detected by HCV-NS5A immunostaining. Intergenotypic re-
combinants containing genotype 1a, 1b, 3a, 4a and 6a derivedproteases were repli-
cation defective, whereas the recombinant with genotype 5aderived protease repli-
cated efficiently after acquiring cell culture adaptive mutations. The replacement of
not only the NS3 protease gene region, but also its cofactor NS4A, allowed the gen-
eration of replication competent intra- and intergenotypic recombinants for all 6 ma-
jor genotypes. Replacing the NS3 protease of the recombinants with that of patient-
derived proteases also generated replicating recombinants, greatly expanding the panel
of intergenotypic recombinants available for phenotypingand PI evaluation. How-
ever, intra- and intergenotypic recombinants showed substantial differences in their
replication kinetics, which may be influenced by naturally occurring polymorphism
between genotypes and the differential requirement of adaptive/attenuating cell cul-
ture mutations. Genotype 1a recombinants replicated very poorly, which may be due
to incompatibilities between the type 1a NS3/4A protease and the type 2a backbone.
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50 % inhibitory concentrations (IC50) of different PIs were measured using Foci Form-
ing Units/ml (FFU/ml) reductions and replication inhibition assays. The different re-
combinants showed consistent, genotype-associated differenc s in their susceptibility
to the PI BILN 2061, with genotypes 2a, 3a and 5a derived recombinants showing
approximately 100-fold lower susceptibility than genotype 1b, 4a and 6a derived re-
combinants. These observations are consistent with major diffe ences in response rates
found in recent treatment trials of genotype 1, 2 and 3 infected patients. Differences
in susceptibility were also observed for VX-950, with genotype 1b, 2a and 6a de-
rived recombinants being twice as susceptible than genotype 3a, 4a and 5a derived
recombinants. Passaging the intra- and intergenotypic recombinants under increasing
concentrations of PI allowed the identification of PI resistance mutations. Resistance
mutations to BILN 2061 mapped to the previously identified positi ns 156 and 168
within the NS3 protease, with a great diversity of amino acidsubstitutions observed
within each genotype. Reintroduction of the identified resistance mutations into the
original recombinant viruses conferred increased resistance towards BILN 2061 and
some mutations also affected replication kinetics of the recombinants. The developed
system will be of major value for the phenotypic characterisation of naturally occurring
and treatment induced resistance mutations within all 6 major HCV genotypes towards
different PIs. This will allow treatment response predictions for newly developed PIs
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1.1 History of Hepatitis C Virus
Viral hepatitis is the main cause of liver cancer and the mostc mmon reason for liver
transplantations. It is a major public health issue and prevalent around the world.
The problem of non-A, non-B viral hepatitis (NANBH) became evid nt in 1975 after
serological tests for hepatitis A virus (HAV) and hepatitisB virus (HBV) became avail-
able. Until then HAV and HBV were considered to be the major aetiological agents
of transfusion-associated hepatitis (TAH). HAV is a positive-stranded RNA virus in
the genusHepatovirusin the family Picornaviridae. Primary transmission route is
the faecal-oral route and it is a major concern in developingcountries with poor sanita-
tion (Melnick (1982); Matthews (1979)). HBV is a hepatotropic double-stranded DNA
(dsDNA) virus with a circular genome classified within the genusOrthohepadnavirus,
which is a member of the familyHepadnaviridae. It causes inflammation of the liver,
which can lead to cirrhosis and hepatocellular carcinoma and h s also been associated
with increased risk of pancreatic cancer recently (Hassanet l. (2008)).
Serological testing for HAV and HBV in TAH showed that most cases did not have
serological markers of either of these viruses (Feinstoneet al. (1975)). In this clin-
ical survey on 22 patients, 9 patients had an antibody response to cytomegalovirus
(CMV), also known to cause liver damage. However, it was difficult to relate this se-
roconversion to their hepatitis. Furthermore, all patients had pre-existing antibodies
to Epstein-Barr virus (EBV), another virus associated with liver damage. This lead to
the hypothesis that at least some of these serologically-negativ TAH were caused by
other infectious agents not yet identified. Later it was shown that as many as 10 %
of transfusions resulted in NANBH and that the incidence of hepatitis was associated
to alanine aminotransferase (ALT) levels in the donor blood(Bermanet al. (1979);
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Aachet al. (1981)). NANBH was later demonstrated to cause persistent liver dam-
age in the majority of cases, which could lead to liver cirrhosis in up to 20 % of cases
(Hoofnagle & Alter (1985)). It took another 14 years before th aetiological agent of
NANBH was identified. The search was hampered by the inabilityto culture the agent
in organ or cell culture. But the development of the chimpanzee model, in which acute
and chronic NANBH could be induced by experimental infectionwith NANBH pa-
tient blood proved to be a considerable step forward (Taboret al. (1978); Alteret al.
(1978); Hollingeret al. (1978)). A serological study following up cardiovascular p-
tients, who had received donor blood, provided evidence that NANBH could be trans-
missible between humans. The existence of an additional virus(es), named hepatitis
type C was suggested (Princeet al. (1974)). The ability of this virus to pass through
80 nm membranes, the apparent lack of nucleic acid homology with HBV and the sen-
sitivity to chloroform led to suggestions that the aetiological agent of NANBH was a
small, enveloped RNA virus (Feinstoneet al. (1983); Bradleyet al. (1983, 1985)).
In 1989, a random-primed complementary DNA (cDNA) library was constructed from
plasma containing the so far uncharacterised NANBH agent. Screening of expressed
recombinant proteins from the cDNA library with serum from ap tient, diagnosed
with NANBH, revealed a cDNA clone that was shown to encode an antige associated
specifically with NANBH infections. Using Southern blot analysis it was shown that
this clone, named 5-1-1, was derived from an RNA molecule present in NANBH infec-
tions and not from chimpanzee or human DNA. Clone 5-1-1 and subsequent overlap-
ping clones derived from the same cDNA library hybridised toa large, single-stranded
(ss) RNA molecule of about 10,000 nucleotides that was present only in NANBH-
infected samples. In addition, it could be shown that an antige directly derived from
the RNA molecule itself was immunoreactive in NANBH-infectedchimpanzees but
not in those infected with HAV or HBV, indicating that it was positive-stranded like
the Flaviviridae genomes. Other proof of the aetiological origin of clone 5-1-1 pro-
vided the fact that the majority of NANBH patients in a small cohort had circulating
antibodies specific for the gene products of clone 5-1-1 (Chooet al. (1989)). Based on
these findings the aetiological agent of NANBH was named hepatitis C virus (HCV).
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The development of a first-generation blood screening test wa based on antigen c100-
3, produced in recombinant yeast from 5-1-1 and adjacent HCV clones. Using c100-
3, an enzyme immunoassay for circulating antibodies against c100-3 was developed.
This assay showed that circulating HCV antibodies were traceable in most infectious
blood donors and chronically infected NANBH patients. It could also be demonstrated
that HCV was the major global cause of parentally-transmitted NANBH (Kuo et al.
(1989)).
Many applications were now possible, the most important being the development of a
blood test to protect the blood supply, as well as diagnostics and new, more effective
drugs for the treatment of HCV patients. In 1990 the first generation blood test be-
came available and universal screening of donor blood was initiated in most Western
countries. The first generation assay detecting antibodiesagainst HCV led to a 70 %
decrease in HCV infection incidence rates down to 1.5 %. A moresensitive second
generation assay, introduced in 1992, nearly extinguishedt HCV transmission rate
(Alter & Houghton (2000)). Today the main risk for HCV infection is intravenous drug
use.
1.2 The Molecular Virology of HCV
1.2.1 Genome structure and classification
Worldwide about 170 million individuals are estimated to beinf cted with HCV (WHO
(1999); Shepardet al. (2005)). Following the discovery of the aetiological agentof
hepatitis C in 1989 (clone 5-1-1), several other clones werer constructed from over-
lapping cDNA clones (Chooet al. (1991); Takamizawaet al. (1991); Okamotoet al.
(1991); Katoet al. (1990)). Sequence comparison between these strains showedonly
80-90 % homology, reflecting the diverse nature of an RNA virusand the existence
of several subtypes. From comparative analysis of these genom s, the structure and
organisation of the virus was determined. It was demonstrated that the virus has an
RNA genome of approximately 9,500 nucleotides (nt) with a single open reading frame
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(ORF) encoding for a 3,010 to 3,033 amino acid long single polyr tein. The ORF is
flanked by a well conserved 5’ untranslated region (5’UTR), postulated to be 341 nt
long, and a more variable 3’UTR. The polyprotein itself couldbe processed by cellu-
lar proteases and viral proteases as proposed for other flaviviruses. This generated the
structural proteins core (C), E1 and E2 (envelope proteins) ad p7, as well as the down-
stream encoded non-structural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B.
Comparative sequence analysis of the HCV genome and encoded polyprotein showed
that HCV has a basic genetic organisation and polyprotein structu e similar to those
of pestiviruses and flaviviruses (Chooet al. (1991)). Computer analysis revealed that
HCV possessed statistically significant similarity to 2 sequences in the protein data
bank, the NS3 protein of dengue type 2 and the putative replicase of carnation mot-
tle virus (CARMV), a member of theCarmovirusfamily. This was unexpected as
CARMV is a plant virus. It was suggested that this finding adds support to the hy-
pothesis that there is an evolutionary relationship between animal and plant viruses
(Miller & Purcell (1990)).
Since then HCV has been classified as a member of theFlaviviridae family (Fig. 1.1).
Members of this family are small, enveloped viruses and contain a positive-sense, ss-
RNA genome, which encodes a single polyprotein (Thiel (2005)). The family ofFla-
viviridae is divided into the 3 genera ofFlavivirus, HepacivirusandPestivirus, but
also includes the unassigned viruses Hepatitis G Virus (HGV)/ B Virus C (GBV-C)
and GBV-A. HCV and GBV-B are the only members of the genusHepacivirus. GBV-
A and GBV-B were discovered in tamarins infected with the seraof patient (ini-
tials GB) with mild hepatitis and are closely related to HCV (Deinhardtet al. (1967);
Simonset al. (1995)). GVB-B is the phylogenetically closest relative to HCV and
GVB-B infected tamarins develop an acute infection that evolves to chronicity similar
to HCV infection (Bukhet al. (1999); Martinet al. (2003)). GBV-C, formerly known
as HGV, is closely related to GBV-A and GBV-B and shares about 25-30 % sequence
similarity with HCV (Learyet al. (1996)). GBV-C infects humans, but has not been
associated with any disease. However, it is believed that GBV-C can prolong HIV
















































































































































































































































Figure 1.1: Phylogenetic tree of the Flaviviridae Family.The Flaviviridae are a
family of viruses divided into the 3 genera Flavivirus, Hepacivirus and Pestivirus.
It also includes the unassigned viruses HGV/GBV-C and GBV-A. HCV and GBV-B






The 9.6 kilo base pairs (kb) long HCV genome is translated intoone long polypro-
tein that undergoes co-translational and post-translation l proteolytic processing in the
cytoplasm or endoplasmic reticulum (ER) of the infected cell. Host and viral pepti-
dases process the polyprotein from the N-terminal region into at least 10 structural and
non-structural proteins: core, E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B.
Some reports have suggested the existence of an 11th protein, translated from an al-
ternative ORF overlapping the core gene at nucleotide +1 (Walewskiet al. (2001);
Xu et al. (2001); McMullanet al. (2007)). The structural proteins comprise the N-
terminal third of the polyprotein and the non-structural proteins are located within the
C-terminal “two thirds” (Fig. 1.2).
An important characteristic of the HCV genome is its high degre of genetic vari-
ability, with different regions varying widely in their mutation rate (Martellet al.
(1992); Pawlotsky (2006)). The most variable are the regions E1 and E2, whereas
the 5’UTR and the terminal segment of the 3’UTR show the highest degree of se-
quence conservation among different HCV variants. The 5’UTR,which is around
341 nt long, contains an internal ribosomal entry site (IRES). The IRES, which con-
tains the 4 highly structured domains I-IV, is essential forthe cap-independent transla-
tion of the viral RNA (Bukhet al. (1992); Brownet al. (1992); Hondaet al. (1999);
Tsukiyamaet al. (1992); Wanget al. (1993)). These structures are mostly conserved
among HCV and related viruses (Brownet al. (1992); Hondaet al. (1999)). As seen
in other viruses with IRES-mediated expression, the HCV 5’UTRcontains critical el-
ements for translation, as well as cis-acting replication elem nts (CREs). CREs are
defined stem-loop structures located in the 5’UTR, core, NS5B(stemloop 5BSL3.2)
and the 3’UTR that operate incis and are required for genome replication. Disruption
of their structure blocks RNA replication. In addition, long-range interactions (kissing-
loop) between the elements regulating replication have been d scribed (Friebet al.




Figure 1.2: Genomic organisation and gene products of HCV.The single-stranded
positive sense RNA strand is translated into one single polypeptide, which is then pro-
cessed by cellular and viral peptidases/proteases. Depictd in yellow are the structural
genes and in red the non-structural genes.
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It has been shown that (i) the sequences upstream of the IRES are essential for viral
RNA replication, (ii) the first 125 nt of the HCV 5’UTR are sufficient for RNA replica-
tion, but for efficient RNA replication the complete 5’UTR is necessary and (iii) stem-
loop II of the IRES is crucial for replication (Friebeet al. (2001)). Furthermore, it has
been demonstrated that the 5’UTR is capable of binding to a liver-specific microRNA,
miR122, resulting in enhanced HCV RNA replication (Joplinget al. (2005)).
The 3’UTR varies in length from 200-235 nt and includes a short va iable region,
a poly(U/UC) tract with average length of 80 nt and a nearly invariant 98 nt long
X-tail region (Kolykhalovet al. (1996); Tanakaet al. (1995, 1996)). The 3’X-tail
forms 3 stable stem-loop structures, also called “clover-leaf”, that are highly conserved
among all genotypes and are essential for RNA replication. The 3’X region and the
52 nt upstream of the poly(U/UC) tract are crucial for RNA replicat on, while the rest
of the 3’UTR plays a role in the enhancement of replication (Yi & Lemon (2003);
Friebe & Bartenschlager (2002)).
Features of the viral proteins
Core
The core protein is an RNA binding protein that forms the nucleo apsid and is syn-
thesised as the most N-terminal component of the polyprotein. The newly synthesised
polyprotein has an internal signal sequence between core and the envelope protein E1
that targets it to the ER, where E1 is translocated into the ER. Cleavage by the ER signal
peptidase at position 191 liberates the N-terminal end of E1into the ER and leaves core,
in a immature form, attached to the ER membrane (Santoliniet al. (1994); Yasuiet al.
(1998)). The signal peptide is then further cleaved by a signal peptide peptidase and
core is released from the ER membrane into the cytosol (McLauhl net al. (2002);
Hussyet al. (1996); Santoliniet al. (1994)). This now mature form of core is trans-
ferred from the ER membrane to the surface of lipid droplets (LDs), where it interacts
with NS5A, which is also attached to LDs (McLauchlanet al. (2002); Barbaet al.
(1997)). The core protein has also been located in the outer mi ochondrial membrane,
where it has been associated with oxidative stress (Schweret al. (2004); Okudaet al.
(2002); Boudreauet al. (2009)). Core is a multifunctional protein probably essen-
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tial for viral replication, maturation and pathogenesis. It has, for example, also been
shown to induce hepatic steatosis in transgenic mice (Moriyaet al. (1997)). Besides
its involvement in the formation of the HCV virion, core also has numerous regula-
tory functions, including modulation of signalling pathways, cellular and viral gene
expression, cell transformation, apoptosis and lipid metabolism (McLauchlan (2000);
Suzuki & Suzuki (2006)).
E1 and E2 envelope proteins
E1 and E2 are the glycosylated envelope proteins essential for virus entry and hence
good targets for specific antiviral inhibitors and neutralising antibodies (Hellet al.
(2006); Goffardet al. (2005)). These type-I trans-membrane proteins are N-glycosylat-
ed in their large N-terminal ectodomains and are anchored into membranes by the hy-
drophobic C-terminal transmembrane domains (TMDs) (Opet al. (2001)). E1 and
E2 can form 2 types of complexes, properly folded heterodimers which are stabilised
by noncovalent interactions and misfolded disulfide-like aggregates (Dubuissonet al.
(1994)). The exact mechanism of cell entry is not clear, although several putative
cell surface receptors of HCV or recombinant E2 protein have be n identified. Us-
ing soluble E2, different potential HCV receptor(s) have been identified: Cluster of
Differentiation 81 (CD81) tetraspanin (Pileriet al. (1998)), scavenger receptor class
B type I (SR-BI) (Scarselliet al. (2002)), claudin-1 (Evanset al. (2007)), heparan
sulphate (Barthet al. (2003)), and the mannose binding lectins DC-SIGN and L-
SIGN (Lozachet al. (2003); Pohlmannet al. (2003); Gardneret al. (2003)). DC-
SIGN stands for dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin and LC-SIGN for liver/lymph node-specific intercellular adhesion molecule-3-
grabbing integrin. Additionally, the low-density lipoprotein (LDL) receptor has been
suggested to play a role in HCV entry, because HCV associates wih LDL and very
low-density lipoprotein (VLDL) in serum (Lozachet al. (2003); Monazahianet al.
(1999)). Of these putative HCV receptors, CD81 and SR-BI have been shown to play
a direct role in HCV entry (Cocquerelt al. (2006)). Other receptors, not expressed
on hepatocytes, such as DC-SIGN and L-SIGN may play a role in the establishment of
a persistent infection. DC-SIGN, expressed on dendritic cells (DCs), and L-SIGN, ex-
pressed on endothelial cells in liver sinusoids, capture HCVparticles and may thereby
9
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facilitate infection of nearby hepatocytes (Cormieret al. (2004)). Further details to
HCV cell entry are described in section 1.2.3.
E1 and E2 are also the gene regions with the highest genetic diversity in the HCV
genome. E2 contains hypervariable domains (e.g., HVR1) which are the most variable
regions of the HCV genome (Hijikataet al. (1991); Weineret al. (1991); Katoet al.
(1992)). A hyperimmune rabbit serum, raised against a synthetic peptide correspond-
ing to HVR1 of HCV isolate H77, was able to protect from infection with H77 in cell
culture. However, the serum was not able to protect from an infection with H90 (a
genetically divergent isolate from the same patient), demonstrating that neutralisation
of HCV was at least partly mediated by isolate-specific antibodies recognising HVR1
(Shimizuet al. (1996)). The huge variability of HCV within HVR1 is likely to play an
important role in HCV persistence. It allows HCV to escape fromthe pressure exerted
by the host immune response. This was also demonstrated in a patient with agam-
maglobulinaemia, who, during a follow up of 2.5 years, did not show any variability
within the HVRs (Kumaret al. (1994)). In vitro experiments later showed that cross-
genotype neutralisation is possible, indicating that it might be possible to identify and
raise cross-neutralising antibodies, which is important for the development of active
and passive immunisation strategies (Scheelet al. (2008)).
p7 protein
p7 is a small hydrophobic polypeptide that spans the ER double membrane and is es-
sential for the production of infectious virionsin vivo(Sakaiet al. (2003); Brohmet al.
(2009)). It has been classified as a viroporin, as it is a smallchannel-forming viral
membrane protein that affects the infectivity of the virus and can be blocked by aman-
tadine (Gonzalez & Carrasco (2003); Griffinet al. (2003)). The family of viroporins
includes proteins like influenza M2 and human immunodeficiency virus type-1 (HIV-
1) viral protein u (vpu), which alter membrane permeabilityand facilitate the release of
viral particles. The ion channels formed by p7 may play an important role in the life-





NS2 is a transmembrane protein with a highly hydrophobic N-terminus, which forms
3-4 transmembrane helices within the ER membrane and a zinc-stimulated cysteine
protease that cleaves the NS2-NS3 junction, for which it requir s the N-terminal part
of NS3 as a cofactor (Schregelet al. (2009)). It has also been suggested to play an
important role in viral assembly and release (Pietschmannet al. (2006)). Recently it
has been shown that NS2 also is involved in the inhibition of cyclophilin A (CypA),
a NS5B modulator, mediated by CypA inhibitors such as cyclosporine A (CysA) and
DEBIO-025 (Cieseket al. (2009)). Furthermore, several crossover sites for natural
or artificial infectious intergenotypic HCV chimaeras have been mapped within NS2
(Kalininaet al. (2002); Pietschmannet al. (2006)).
NS3/4A complex
NS3 is a multi-functional protein with a N-terminal serine protease and a C-terminal
RNA helicase/NTPase domain. Composed of 2 beta-barrel domains, the protease has
a chymotrypsin-like fold, with His57, Asp81 and Ser139 being the catalytic triad. Its
activity is enhanced by the NS4A cofactor, a 54-residue amphipat ic peptide with a hy-
drophilic N-terminus and a hydrophobic C-terminus (Kimet al. (1996); Faillaet al.
(1994)). The N-terminal 21 amino acids of NS4A form a transmembraneα-helix,
which is required for the integral membrane association of the NS3/4A complex (Brass
et al. (2008)). NS4A associates non-covalently with the NS3 protein, which has no
transmembrane domains, and thereby anchors it to ER/ER-like membranes (Wolket al.
(2000)). However, NS3 has been reported to have an amphipathic α0-helix, which in-
teracts in-plane with the membrane surface, providing additional association with the
membrane (Brasset al. (2008)). The NS3/4A complex is essential for viral polypro-
tein processing and RNA replication (Faillaet al. (1994)). It cleaves the polyprotein
downstream of NS3, which generates the essential components for he formation of
the replication complex and was therefore one of the first targets for the development
of new anti-HCV molecules (Lindenbach & Rice (2005); De Francesco & Migliaccio
(2005)). It is responsible for the proteolytic cleavage at 4junctions of the HCV
polyprotein precursor: NS3/NS4A (self cleavage), NS4A/NS4B, NS4B/NS5A and
NS5A/NS5B. NS4A is essential for processing at the NS3/NS4A,NS4A/NS4B and
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NS4B/NS5A sites and enhances cleavage efficiency between NS5A and NS5B. Amino
acids 21-32 of NS4A are sufficient for its cofactor activity (Bartenschlageret al. (1993,
1995); Faillaet al. (1995); Linet al. (1995a); Tanjiet al. (1995); Tomeiet al. (1996)).
The NS3 protease also cleaves intranswithin the NS3 helicase domain, with the NS3
helicase and NS4A as cofactors.
However, the amino acid residues of NS4A involved in the internal cleavage of NS3
are different from those required for the cofactor activityof the NS3 serine protease
(Shojiet al. (1999); Yanget al. (2000); Panet al. (2009); Kouet al. (2007)). The
NS3/4A protease has an unusually shallow substrate-binding pocket, which requires
substrate binding with high affinity and avidity. This posesa big problem in the design
of efficient NS3 inhibitors (Kimet al. (1996); De Francescoet al. (1998)).
NS3/4A is furthermore involved in the blocking of the host cell innate immune re-
sponse (Foyet al. (2003)). NS3/4A has been shown to interfere with the double-
stranded RNA (dsRNA) signalling pathway, thereby suppressing the interferon (IFN)
induction in HCV replicating cells. dsRNA, a replication product generated by most
viruses, is recognised by Toll-like receptor 3 (TLR3) and thecytosolic RNA heli-
case retinoic acid-inducible gene I (RIG-I). The protease int rferes with the cellular
RIG-I pathway through cleavage of the adaptor protein of the IFN regulatory factor-
3 (IRF-3) and the IFN promoter stimulator protein IPS-1 (alsocardif/VISA/MAVS)
(Meylanet al. (2005)). IPS-1 is thereby dislodged from the mitochondrialmembrane
and the signalling to the antiviral immune response is disrupted (Liet al. (2005c)).
NS3/4A also cleaves TRIF, which links the TLR-3 response to IRF-3 and NF-κB ac-
tivation (Li et al. (2005b)). TRIF stands for Toll-IL-1 receptor domain-contaiing
adaptor inducing IFN-β. The process of IFN disruption is discussed in more detail in
section 1.6.2.
The NS3 C-terminus encodes a DexH/D-box RNA helicase responsible for RNA un-
winding and can be structurally divided into NTPase domain,RNA binding domain
and a helical domain. Members of the DexH/D-box helicase superfamily 2 unwind
RNA-RNA substrates in a 3’- to -5’ direction (Taiet al. (1996); Choet al. (1998)).
Structural analysis has suggested that the NS3 helicase exits as a dimer with the NT-
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Pase of one helicase building an interface with the RNA binding omain of the other
(Choet al. (1998)). The helicase plays a role in the initiation of RNA replication to-
gether with NS5A and NS5B (Zhonget al. (2005); Murayamaet al. (2007a)). It joins
unwinding of dsRNA, or of ssRNA regions with extensive secondary structures, to ATP
hydrolysis. Unwinding of dsRNA is done in a highly coordinated cycle of fast ripping
and local pausing with regular spacing along the duplex substrate (Serebrov & Pyle
(2004); Levinet al. (2005)). The helicase activity is furthermore positively modulated
by the NS3 protease domain and NS4A (Fricket al. (2004)). Although attractive as
an antiviral target, the development of specific inhibitorslags behind those of protease
and polymerase inhibitors (Kwonget al. (2005)).
NS4B protein
NS4B is a relatively poorly characterised integral membrane protein, which is pre-
dicted to contain at least 4 transmembrane segments, a cytosolic N-terminal part and a
cytosolic C-terminal part containing an amphipathicα-helix mediating membrane as-
sociation (Lundinet al. (2003); Gouttenoire t al. (2009)). The amphipathicα-helix
is also involved in the induction of the membranous web, a specific membrane alter-
ation that serves as a scaffold for the RNA replication complex (Eggeret al. (2002)).
NS4B has been reported to be palmitoylated at two C-terminal cysteine residues and
to form oligomers (Yuet al. (2006a)). Similar to other HCV non-structural proteins,
NS4B has been reported to play a role in virus assembly and releas (Joneset al.
(2009)). Furthermore, NS4B has been demonstrated to have anNTPase activity and to
play a role in HCV pathogenesis (Thompsonet al. (2009); Gouttenoire t al. (2010)).
NS5A protein
The NS5A protein is a membrane anchored zinc-metalloprotein that is observed in
basally (56 kDa) and hyperphosphorylated (58 kDa) forms (Tellinghuisenet al. (2004,
2005)). NS5A hyperphosphorylation inhibits HCV replication and in accordance with
that, cell culture adaptive mutations are often identified at the phosphorylation site
(Tellinghuisenet al. (2005); Evanset al. (2004); Blightet al. (2000); Kriegeret al.
(2001)). NS5A has been shown to interact with other HCV nonstructural proteins,
namely the RNA-dependent RNA polymerase (RdRp) NS5B, an interaction which is
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essential for HCV RNA replication (Shimakamiet al. (2004); Shirotaet al. (2002)).
It has been demonstrated that NS5A binds to 3’-ends of HCV plusand minus strand
RNAs with high affinity and that this interaction is importantfor genome replication
(Huanget al. (2005)). Recently it was found that domain III of NS5A is implicated
in both RNA replication and assembly of hepatitis C virus particles in JFH1-infected
cells (Hugheset al. (2009)). NS5A also plays a crucial role in evading the host im-
mune response through inhibition of the IFN-induced dsRNA activ ted protein kinase
R (PKR), an important component of the IFN pathway (Galeet al. (1998)). The im-
portance of this interaction has been revealed in a very recent study, which showed that
mutations within the IFN sensitivity-determining region (ISDR) are associated with
rapid viral response during peg-IFN/ribavirin therapy (Enomoto & Maekawa (2010)).
Together with core, NS5A has been reported to associate withLDs (Brasset al. (2002);
Shi et al. (2002)). NS5A specifically interacts with Apolipoprotein E(ApoE), an in-
teraction suggested to be important for viral assembly and release of infectious viral
particles (Bengaet al. (2010)).
NS5B protein
NS5B is the RNA-dependent RNA polymerase (RdRp) with a glycine - aspartate
- aspartate (GDD) motif that produces catalytic activity. The C-terminal 21-amino
acid region forms anα-helical transmembrane domain, which is responsible for post-
translational targeting to the ER membrane. Membrane association of NS5B is indis-
pensable for HCV RNA replication, but disruption of the insertion sequence, which
abolished RNA replication, did not affect membrane associati n. This indicates that
the C-terminal domain might be involved in intramembrane protein-protein interac-
tions (Moradpouret al. (2004b); Schmidt-Mendet al. (2001)). The crystal structure
of NS5B shows a typical polymerase structure resembling a riht hand with palm, fin-
ger and thumb subdomain. The palm domain contains the fully encircled active site.
Finger and thumb interact with each other to create a tunnel through which a ssRNA is
directed to the active site (Agoet al. (1999); Bressanelliet al. (1999); Lesburget al.
(1999)). NS5B is structurally distinct from human RNA and DNApolymerases and
a crucial player in HCV RNA replication, making it an importanttarget for antiviral





The HCV infectious particle is composed of a nucleocapsid or rib nucleoprotein com-
plex containing the HCV genome. A phospholipid bilayer, intowhich E1 and E2 enve-
lope proteins are anchored, surrounds this inner structure. During virus assembly, the
infectious particle associates with VLDL and is (co-) secreted with VLDL. However,
the exact mechanism of this association remains to be elucidated (Gastaminzaet al.
(2008)). Studies carried out with HCV pseudoparticles (HCVpp) provided the first ev-
idence that the E1-E2 heterodimer is involved in virus entry(Bartoschet al. (2003b);
Drummeret al. (2003)). The E2 glycoprotein probably is one of the major players in
the interaction between the virus and its cellular receptors CD81 and SR-BI/claudin-
1/occludin. CD81, proven to be necessary for HCV entry, was thefirst (co)-receptor
shown to interact with HCV E2 (Flintet al. (1999); Cocquerelet al. (2003)). It has
been suggested to act as a post-binding entry molecule. In fact, studies with antibodies
against CD81 have shown that HCV virus infection is only inhibited after virus at-
tachment (Koutsoudakiset al. (2006)). SR-BI has been identified as another receptor
for HCV (Scarselliet al. (2002)). Binding of SR-BI to E2 HVR1 has been shown to
be very selective, as neither mouse SR-BI nor closely related human SR-CD36 were
able to bind E2 (Scarselliet al. (2002)). In addition, SR-BI plays an important role in
the high density lipoproteins (HDL) and VLDL metabolism (Van Ecket al. (2008)).
Similar to CD81, SR-BI acts as a post-binding receptor. Antibodies against SR-BI also
significantly reduced the infectivity of HCVpp (Bartoschet al. (2003a)).
In 2007 a new protein involved in HCV entry was discovered, claudin-1 (CLDN1)
a tight junction component. The expression of CLDN1 conferred susceptibility to
HCVpp infection in non-hepatic cell lines and antibodies against CLDN1 blocked
HCV infection. Kinetics of that inhibition indicate that CLDN1 acts late in the entry
process, after virus binding and interaction with the co-receptor CD81 (Evanset al.
(2007)). Two other members of the claudin family have also been implicated in the
HCV entry process, CLDN6 and CLDN9. Like CLDN1, CLDN6 and CLDN9 are
expressed in the liver, but unlike CLDN1 they are also expressed on peripheral blood
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mononuclear cells, which are another possible site of HCV replication (Zhenget al.
(2007); Meertenset al. (2008)). Several human cell lines, such as HeLa and HepH,
co-expressing CD81 and SR-BI still remained HCV resistant when overexpressing
CLDN1, suggesting that additional factors are required for HCV entry (Evanset al.
(2007)).
The pallet of receptors involved in HCV entry has been expanded by the discovery
of another tight junction protein, occludin. Downregulation of CLDN1 and occludin
by small interfering (siRNA) and short hairpin (shRNA) RNA interference inhibited
HCVpp and cell culture produced HCV (HCVcc) cell entry (Liuet al. (2009)). Recent
studies in mouse cells have identified occludin as an essential entry factor for HCV.
It was demonstrated that mouse cells expressing CD81 and occludin, together with
mouse CLDN1 and SR-BI, are capable of supporting HCV replication(Plosset al.
(2009)). Interestingly, it has been observed that HCV altersthe localisation of tight
junction proteins (Benedictoet al. (2008)). Additionally, CLDN1 and occludin ex-
pression levels were downregulated after infection, renderi g infected cells refractory
to HCVpp superinfection (Liuet al. (2009)). Thus, it appears that HCV infection
leads to a global reduction of tight junction proteins in HCV infected cells. As tight
junctions are critical in the maintenance of polarity in hepatocytes and their essential
functions, alteration of their expression level by HCV mightbe a possible explanation
for symptoms associated with HCV infection, such as cholestatic disorders.
Other factors involved in HCV entry are glycosaminoglycans (GAGs). These linear
polysaccharides act as binding sites for many viruses and have been suggested to be
low affinity receptors involved in the initial binding of thevirus. An interaction be-
tween E2 and surface heparan sulfate proteoglycans (HSPGs)has been demonstrated
to be essential for viral binding to the cell and might present the initial step in the
interaction between HCV and the cell surface (Barthet al. (2003)).
Lectins are another class of molecules involved in binding ad cell entry for many
viruses. DC-SIGN and L-SIGN are C-type (calcium-dependent) lectins containing
a carbohydrate recognition domain, enabling them to recognise and bind virus car-
bohydrates. Both bind sE2 and HCVpp, as well as natural virusesfrom sera of in-
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fected individuals through high mannose-type oligosaccharides (Lozachet al. (2003);
Pohlmannet al. (2003); Gardneret al. (2003)). However, L-SIGN and DC-SIGN are
not expressed on hepatocytes, excluding their role as receptors for HCV entry. A
possible role of L-SIGN and DC-SIGN involves the capture and transfer of HCV to
hepatocytes (Cormieret al. (2004); Lozachet al. (2003)).
The LDL receptor is another candidate receptor. It was foundthat HCV particles as-
sociate with lipoproteins in serum and that their infectivity correlates with HCV inter-
nalisation. The LDL receptor has been demonstrated to mediate HCV internalisation
by binding to virion-associated LDL particles (Agnelloet al. (1999)). However, the
function of the LDL receptor in HCV entry remains controversial as the role of LDL-
R in the in vitro HCVcc infection model has not been demonstrated yet. It has been
suggested that the binding is mediated by lipoproteins rathe than viral components.
In the currently proposed model for cell entry, virus binding and internalisation is trig-
gered by the interaction between HCV-associated lipoproteins (mainly VLDL) and the
lipoprotein receptors SR-BI and/or LDL-R and/or GAGs. Following interaction of the
virus with the SR-BI-CD81 complex, the virus is transferred by CD81 to tight junc-
tions, where it interacts with CLDN1 and occludin. From the tigh junctions the virus
then enters the cell via clathrin-mediated endocytosis andfusion, which is mediated by
the envelope glycoproteins and allows the virus to escape the lipoprotein degradation
pathway (Burlone & Budkowska (2009)).
Translation
Unlike cellular capped mRNA molecules, which are translatedvia cap-dependent mech-
anism, the uncapped RNA molecules of viruses, such as picornaviruses and flaviviruses,
are translated via a cap-independent IRES-mediated process(Tsukiyamaet al. (1992);
Wanget al. (1993)). The IRES-mediated translation is initiated by direct binding of
the 40S ribosomal subunit to IRES, followed by eukaryotic initiation factor-3 (eIF-3),
eIF-2: Met-tRNA:GTP and 60S subunit to subsequently form the80S complex, after




As described in section 1.2.2, the HCV polyprotein is processed by cellular proteases at
the junctions core/E1, E1/E2, E2/p7 and p7/NS2, followed byintramolecular cleavage
at NS2/NS3 by the NS2/3 protease and downstream cleavage betw en NS3/NS4A/
NS4B/NS5A/NS5B by the NS3/4A protease. Processing at the NS3/NS4A junction is
intramolecular and those at other sites are intermolecular.
RNA replication
RNA replication occurs via minus strand RNA intermediate at a si e of specific mem-
brane alteration, named the membranous web (Lohmannet al. (1999)). This was first
identified in the human hepatoma cell line Huh7 containing the subgenomic HCV repli-
cons (Gosertet al. (2003)). As mentioned above the membranous web is induced by
NS4B and is probably ER derived (Eggeret al. (2002)). HCV replication is influenced
by lipid metabolism. In cell culture it is inhibited by polyunsaturated fatty acids or the
inhibition of fatty acid synthesis. It is stimulated by satur ted and mono-unsaturated
fatty acids. Furthermore, it has been demonstrated that HCV RNA replication de-
pends on the geranylgeranylation of one or several host proteins (Yeet al. (2003);
Kapadia & Chisari (2005)). An additional host factor involved in RNA replication is
CypB, which was shown to interact with NS5B stimulating its RNA binding activity
(Watashiet al. (2005); Hecket al. (2009)). CysA is a natural inhibitor of CypB and
non-immunosuppressive CysA analogues are currently being developed as antivirals
against HCV (Paeshuyseet al. (2006); Gallay (2009)).
Secretion
The late stages of HCV replication still remain obscure. NS2,which has been shown
to be important in assembly and release of HCV particles, and possibly other nonstruc-
tural proteins are involved in these processes (Pietschmann et al. (2006)). Virions are
thought to bud from ER, or ER-like membranes, and exit the cell through the secretory
pathway. Furthermore, it has been shown that the productionand release of HCV in
Huh7 cells depends on the assembly and secretion of VLDL, providing a link between
the HCV secretion and lipid metabolism (Huanget al. (2007)). Evidence of an asso-
18
Introduction
ciation between HCV secretion and lipid metabolism has also come from observations
that the density of intracellular virus particles producedin vitro is much higher than
those of secreted HCVcc. Association of viral particles withVLDL during secretion
would lower their density (Gastaminzaet al. (2006, 2008)). Low-density, i.e., VLDL-
associated, HCV particles are efficiently secreted from the infected cells, whereas high-
density (immature) HCV particles are degraded actively in a proteasome-independent
manner. These observations are in agreement with the presence of very-low-density,
infectious virus particles in patient sera and the involvement of lipoprotein receptors
in cell entry. It has been suggested that by hitch hiking the VLDL pathway of as-
sembly, maturation, degradation and the secretory machinery of the cell, HCV obtains
its hepatocyte tropism and through mimicry its tendency to persist (Gastaminzaet al.
(2008)).
1.2.4 HCV genotypes
HCV isolates are classified into genotypes and subtypes (Simmondset al. (2005)).
There are 6 major genotypes that differ from each other by 31-33 % at the nucleotide
level (Fig. 1.3). Recently, a 7th genotype (7a) was discovered in Canadian and Bel-
gian patients, who are thought to have been infected in Central Africa (Murphy et al.
(2007)). The different genotypes are associated with different clinical outcomes and
geographical distributions, also see section 1.3.
The approximately equidistant genetic groups can be further divided up into a vary-
ing number of more closely related, genetically (and epidemologically) distinct sub-
types that differ from each other by 20-25 %. Due to the lack ofpr of-reading by
the NS5B polymerase and the very high replication rate of up to 1012 new virions
per day, many new variants of a HCV genome are created every day(Lamet al.
(1997); Neumannet al. (1998)). Within an individual a HCV subtype circulates in
the form of so-called “quasispecies”, a population of genetically heterogeneous HCV
genomes (Farciet al. (2000)). Currently over 80,000 HCV sequences are deposited on
3 HCV sequence databases: the European HCV database (euHCVdb (2010)), the Los
Alamos national laboratory HCV database (Kuikenet al. (2005)) and the Japanese
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hepatitis virus database (jaHCVdb (2010)). These provide sev ral tools for analysing
HCV sequences, protein structures and CD4+ and CD8+ T-cell epitopes (Kuikenet al.
(2006)).
Figure 1.3: Evolutionary tree of the principal genotypes of HCV found in industri-
alised countries. Phylogenetic analysis is based on complete g nome sequences of
HCV genotypes found in the main identified risk groups for HCV infection (inject-
ing drug users (IDUs), recipients of unscreened blood or blood products, other par-




1.3 Epidemiology and Global Distribution
1.3.1 Prevalence and incidence
The estimated global prevalence of HCV infection is 2-3 %, representing 170 mil-
lion people (WHO (1999); Shepardet al. (2005)). However, regional estimates vary
widely with less than 1.0 % in Northern Europe to over 2.9 % in Northern Africa and
Asia (Shepardet al. (2005)). The United Kingdom and the Scandinavian countries
have been reported to have among the lowest prevalence rates(0.01-0.1 %), whereas
the highest prevalence has been reported from Egypt (10-20 %) (Bird et al. (2001b,a);
Franket al. (2000)). The prevalence of infection in Egypt increases continuously
with age, and high rates of infection are observed in all age groups (Abdel-Azizet al.
(2000)). Over 90 % of all infections in Egypt are of genotype 4, indicating an increased
risk in the distant past (Rayet al. (2000)). It has been suggested that a campaign of
parenteral antischistosomal therapy, where medical equipment was not sterilised prop-
erly, played a major role in the spread of HCV in Egypt (Franket al. (2000)). Popu-
lous countries in the developed world with relatively low rates of HCV seroprevalence
include Germany (0.6 %) (Palitzschet al. (1999)), France (1.1 %) (Desenclos (2000))
and Australia (1.1 %) (Law (1999)). Slightly higher, but still low incidence rates have
been reported in the United States (1.8 %) (Alteret al. (1999)) and Japan (0.1-2 %)
(Chunget al. (2010)). Incidence rates mostly peaked around 2000 but are now de-
creasing in developed countries (Chunget al. (2010)). Relatively high incidence rates
were reported from Pakistan (5 %) (Waheedet al. (2009)). Worldwide an estimated
27 % of cirrhosis and 25 % of hepatocellular carcinoma (HCC) areatt ibuted to HCV
infection (Perzet al. (2006)).
1.3.2 Modes of transmission
The most efficient transmission of HCV is through large or repeated direct percuta-
neous exposure to blood, mainly through transfusion or transpl tation from infec-
tious donors or injecting drug use. In 1985 heat-inactivation of plasma products led
to a substantial reduction in infection with enveloped viruses. Prior to 1990, when the
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first-generation blood test became available and made it possible to screen for HCV,
most HCV transmissions were due to transfusion of blood and no-i activated blood
products, such as factor VIII and IX concentrates (Alter & Houghton (2000)). For
example, in a study of haemophiliacs who had received non-virus-inactivated concen-
trates, 80 % were positive for HCV post-treatment (Jarviset al. (1996)). Since then,
transfusion-associated HCV infection has virtually been eliminated in countries rou-
tinely screening for HCV in donors (Schreiberet al. (1996)). However, screening is
far less common in poorer countries and receipt of blood transfusions remains an im-
portant source for infection in developing countries (Hladik et al. (2006)).
A major role in the spread of HCV also play unsafe therapeutic injections performed
by both professionals and non-professionals. In 2000 the WHOestimated that yearly
2 million new HCV infections are acquired from contaminated halth care injections,
accounting for up to 40 % of all HCV infections worldwide (Hauri et al. (2004)).
In the United States and Australia, the predominant mode of transmission in the last
40 years has been injecting drug use. It now also accounts formost newly acquired
infections in many other countries, including those in Northe n, Western and South-
ern Europe. Although infection rates among injecting drug users (IDUs) have de-
clined dramatically since the late 1980s in developed countries (down from 80 % to
10-30 % (Deset al. (2003); Hopeet al. (2001))), they remain extremely high (up to
70 %) in second world countries, such as Bulgaria and Vietnam (Vassilevet al. (2006);
Quanet al. (2009)).
HCV is far less efficiently transmitted by mucosal exposures to blood or serum-derived
fluids (e.g., sex with an infected partner, birth to an infected mother) or by single
small dose percutaneous exposures (e.g., accidental needle sticks). An Italian study
has shown that the vertical transmission rate was overall very low with 2.7 % and was
restricted to infants born to HCV viremic mothers, but could increase up to 5.4 % in
HIV co-infected women (Ferreroet al. (2003)). Sexual transmission is possible, but
the risk depends on the type of sexual relationship. Personsin long-term monogamous
relationships are generally less likely to be infected (0-0.6 % per year) than persons
who often change their sex partner (0.4-1.8 % per year). These differences might be
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due to differences in sexual practices or differences in exposure rates to nonsexual
sources of HCV such as toothbrushes and shared razors (Terrault (2002)). Occu-
pational transmissions of HCV infection, mostly contaminated needle stick injuries,
are largely confined to health care workers and the average incide ce rate is 1.8 %,
with transmissions associated with hollow-bore needles and deep injuries (Puroet al.
(1995); Yazdanpanahet al. (2005)).
Numerous other biologically plausible modes of transmission include: cosmetic proce-
dures (tattooing, body-piercing), religious or cultural practices such as ritual scarifica-
tion, circumcision, acupuncture and cupping and intranasal drug use. Adequate studies
are missing for most regions of the world as sufficient data isnot available. However,
a study among American students has shown that there was no increased risk for HCV
or HBV infection in low-risk adults based solely on history ofcosmetic procedures
or snorting drugs (Hwanget al. (2006)). Nevertheless, in developing countries with
low sanitary standards, where medical equipment is often not properly sterilised, trans-
mission through cosmetic procedures or religious/cultural pr ctices are more likely to
occur, as discussed above in the case of parenteral antischis osomal therapy in Egypt
(Franket al. (2000)).
1.3.3 HCV geographical distribution
As previously described, HCV can be divided into 6 major genotypes which have dif-
ferent geographical distributions, also see section 1.2.4(Simmondset al. (2005)). In
the early 90s the most predominant genotypes in European blood d nors and HCV pa-
tients were genotypes 1b and 2 followed by 3 (Touzetet al. (2000)). Increased safety
in blood transfusion has changed the main risk of HCV transmision to IDUs and with
that the genotype distribution from genotypes 1b and 2 to genotypes 1a, 3a and 4a.
The predominant genotype in Southern Europe still is genotype 1b, followed by 1a, 3a
and 2, whereas type 1a and 3a followed by 2 predominate in Northern Europe. Geno-
type 4 is equally distributed throughout Europe except for the United Kingdom and
Norway (Estebanet al. (2008)). Genotype 5a, once believed to be restricted to South
Africa, has recently been reported to have been endemic in isolated areas of Central
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France and West Belgium for a long time (Henquellet al. (2004)). In Japan and other
Far Eastern countries genotype 1b, followed by 2a and 2b are responsible for most
infections (Haraet al. (1996); Yunet al. (2008)). The predominant genotypes in the
United States are 1a and 1b with genotype 2a, 2b, 3a and 4a occurring less frequently
(Shiboski & Padian (1996)).
Compared with Western countries and Japan, where a few genotype subtypes are pre-
dominant, in Africa, South East Asia and India highly divergent subtypes circulate.
Infections in West Africa are predominantly by genotype 2 (Jeannelet al. (1998);
Ruggieriet al. (1996); Candottiet al. (2003)), whilst genotype 1 and 4 are predom-
inant in Central African countries such as the Democratic Republic of Congo and
Gabon (Fretzet al. (1995); Xuet al. (1994); Ndjomouet al. (2003)). Similar ge-
netic diversity can be found within genotypes 3 and 6 in Southand Eastern Asia
(Tokitaet al. (1994a,b)).
These observations have led to the hypothesis that HCV has been pr sent in human
populations for a long time in parts of Africa and Asia, compared to industrialised
countries where HCV is less diverse and believed to have been introduced more re-
cently (Ndjomouet al. (2003); Simmonds (2001); Simmondset al. (2005)). The rapid
spread of relatively new viruses in industrialised countries from areas of endemic infec-
tion has mainly been due to blood transfusions, use of unsterili ed medical equipment
and most recently sharing injection equipment among IDUs and unsafe sex practices
among HIV positive men who have sex with men (MSM) (Cochraneet al. (2002);
Pybuset al. (2001); van de Laaret al. (2009)).
1.4 Experimental Models for HCV Research
1.4.1 Cell-basedin vitro HCV systems
The first subgenomic replicon system to study the non-structu al genes of HCV be-
came available in 1999. A genotype 1b subgenomic replicon had been created by
replacing the structural genes and p7 of the consensus genome of Con1b with that
24
Introduction
of a neomycin resistance gene (Lohmannet al. (1999)). To initiate translation of the
non-structural genes, they engineered a second IRES in frontof the HCV genes and
selected with neomycin for highly replicating replicons inspecific cell lines. The gen-
erated subgenomic replicon replicates autonomously in Huh7 cells and can be propa-
gated in cell culture for many years (Pietschmannet al. (2001)). This system allowed
for the first time to study the replication of the HCV genomein vitro and has proven
very valuable in studying antivirals targeting the NS3/4A protease or the NS5B poly-
merase. Since then, the replicon system has been further modified to include different
reporter systems, such as the firefly luciferase or fluorescent proteins, which enable
high-throughput screening for replication inhibitor efficacies (Kriegeret al. (2001);
Moradpouret al. (2004a)). The apparent disadvantage of this system is the lack of the
structural genes and therefore the inability to secrete infctious viral particles. Even
though later replicons were created that expressed all viral proteins, they remained
unable to secrete infectious viral particles (Blightet al. (2002); Pietschmannet al.
(2002)). This discrepancy might be explained by a recent report which showed that
cell culture adaptive mutations or replication enhancing mutations (REM) interfere
with viral assembly and secretion (Pietschmannet al. (2009)).
A big breakthrough came with the establishment of the consensus sequence of the
genotype 2a clone JFH1. JFH1 was isolated from a Japanese patient with fulmi-
nant hepatitis C, and a subgenomic replicon containing the JFH1 derived structural
genes replicated, without acquiring REMs, much more efficiently i Huh7 cells than
the Con1b replicon (Katoet al. (2003)). In vitro transcribed full-length RNA from
pJFH1 replicated very efficiently in Huh7 cells and also produced infectious virus, un-
like the replicons. The cell culture generated HCV was also infectious in chimpanzees
(Wakitaet al. (2005)). An intragenotypic recombinant containing the structural genes
plus part of NS2 from another genotype 2a isolate, pJ6CF, and the remaining genes
from the JFH1 subtype, replicated even more efficiently in Huh7-Lunet cells (subclone
of Huh7 cells) (Lindenbachet al. (2005); Pietschmannet al. (2006)). Transfection
of in vitro transcribed RNA from JFH1 or different intragenotypic pJ6CF/JFH1 chi-
maeras replicated very efficiently in Huh7 and Huh7.5.1 cells (highly permissive sub-
clone of Huh7 cells). Also, the secreted viral particles were infectious in cultured cells,
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chimaeric mice and chimpanzees and could be blocked by anti-CD81 and anti-E2 an-
tibodies (Lindenbachet al. (2005); Wakitaet al. (2005); Zhonget al. (2005)). This
system, for the first time, allowed thein vitro investigation of the whole viral lifecycle
of HCV. Since then, several intergenotypic recombinants, replacing the core-E1-E2-
p7-NS2 region with that of genotype 1-7, have been generated(Pietschmannet al.
(2006); Gottweinet al. (2007); Yiet al. (2007); Jensenet al. (2008); Scheelet al.
(2008); Gottweinet al. (2009)). However, as most of the nonstructural genes are
JFH1-derived, these recombinants most likely do not represnt the genotype specific
replication characteristics. Nevertheless, these recombinants provide an important tool
for the study of the entry process and allow the investigation of vaccines and entry
inhibitors for all 7 genotypes.
Another cell culture system has been developed using retroviral or lentiviral cores.
Retroviruses incorporate heterologous glycoproteins intotheir envelope when they bud
from cells. This mechanism was used to incorporate the envelope proteins E1 and
E2 into the envelopes of these very efficiently replicating vectors, creating so-called
HCV pseudoparticles (HCVpp) (Bartoschet al. (2003b)). These particles are highly
infectious and can mimic the HCV entry process, providing an important tool for the
study of the viral entry process. Several different entry receptors, such as CD81, were
identified using the HCVpp system, also see section 1.2.3 (Zhanget al. (2004)). The
advantage of the HCVpp system is that it can be used to investigate the HCV entry
process in many different cell lines, as it is independent ofreplication.
The developments of the HCVpp, replicon and infectious HCV cell ulture system
have allowed a great leap forward in HCV research. The study ofthe different parts of
the viral lifecycle, as well as the investigation of vaccines and efficacies of antivirals
are now possible. However, the major limitations are that the infectious cell culture
system is currently restricted to Huh7-derived cell lines and the JFH1 isolate. In order
to better represent and understand the huge diversity of HCV genotypes, subtypes and
quasispecies within a patient, the expansion of the infectious cell culture system to the
other genotypes is crucial.
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1.4.2 HCV animal models
The human is the only natural host of HCV, but HCV infected chimpanzees also de-
velop hepatitis, even though in a milder form. The chimpanzee is the only animal
model in which both, acute and chronic infection can be followed (Alteret al. (1978);
Hollingeret al. (1978); Taboret al. (1978); Shimizuet al. (1997); Yanagiet al. (1997,
1998); Dashet al. (2001); Nascimbeniet al. (2003)). However, chimpanzees are rare
animals and studies with chimpanzees are ethically problematic and expensive. There-
fore alternative animal models were searched. Other primates, such as cynomolgus
monkey, rhesus monkey, green monkey, Japanese monkey and doguera baboon and
woodchucks were inoculated with HCV, but none supported HCV replication (Abeet al.
(1993)).
Several different small animals have been developed as experimental HCV animal
models. Because HCV only replicates in very few specific cells,mice or rat mod-
els have to be engrafted with human liver cells. The first was the severe combined
immunodeficiency (SCID)-mouse. SCID-mice are animals that were treated with a
very high dose of irradiation. All the stem cells are therebydestroyed and the mice
are reconstituted with new bone marrow, excluding functional T and B lymphocytes.
Human liver cells infected with HCV can then be grafted under th kidney capsula
and are not rejected, as the mouse lacks functional T and B lymphocytes. These
immunodeficient mice with human liver transplants show detectable HCV viremia
up to 50 days post-transplantation (Galunet al. (1995)). The chimaeric human liver
uPA/SCID mouse model is presently the physiologically closest mall animal model
to human HCV infection. The Alb-uPA transgenic mouse overexpr sses the urokinase
plasminogen activator (uPA) transgene, which results in increased hepatocyte death.
The deceased hepatocytes can be replaced with new human hepatocytes, which estab-
lish themselves in the chimaeric mouse liver and can be infectedde novowith HCV-
positive human serum. HCV replication can be observed in the human hepatocyte
portion of the liver and is supported for months (Merceret al. (2001)).
Furthermore, a rat model has been developed, where human hepatocytes were en-
grafted into spleens of foetal rats before immune maturation, generating an immuno-
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competent animal model. The HCV-inoculated rats supported HCV replication, but
HCV replication rates were quite low (Wuet al. (2005)).
Another animal being investigated as a possible HCV model is the tupaia belangeri,
a tree shrew. Tupaias are non-primates permissive for HCV infection and can de-
velop chronic infection (Xieet al. (1998); Xuet al. (2007)). Tamarin, a new world
primate, cannot be infected with HCV, but with GBV-B, a flavivirus phylogenetically
closely related to HCV. Infected animals develop an acute infction, which can evolve
to chronicity similar to HCV infection, providing a model to study protective immunity
and evaluate antivirals (Bukhet al. (1999); Martinet al. (2003)).
The chimpanzee has played a pivotal role in the early days of HCV research and has
contributed substantially to the current understanding ofbasic and clinical aspects of
HCV and HCV infection. However, the considerable cost and ethical constraints have
limited the use of this animal model. To date the most useful anim l model is the
uPA/SCID mouse model, which has helped to understand viral entry, replication and
therapy. Difficulties associated with the transplantationof human hepatocytes into
the mice, which results in very low efficiencies when generating hese mice, make
them relatively expensive. The future development of animal odels will be towards
an immunocompetent small animal model that would allow the sudy of the immune




Acute hepatitis is defined as the presence of clinical signs or symptoms of hepatitis for
a period of 6 months or fewer after the presumed time of HCV exposure (Blackardet al.
(2008)). However, acute HCV infection is mostly asymptomatic, which makes di-
agnosis very difficult, meaning that cases are underreported (B rmanet al. (1979);
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Orlandet al. (2001)). Serum HCV RNA levels can be detected 1-3 weeks post-infect on
and after a 2-12 week long incubation period symptoms may appe r (Farciet al.
(1991)). If symptoms occur, they are generally very mild andfrequently mistaken
for the symptoms of a common cold; symptoms often reported include fatigue, ab-
dominal pain, nausea, vomiting, anorexia (decreased appetite), dyspepsia (indigestion)
and jaundice (Santantonioet al. (2003); Blackardet al. (2008)). After 4-12 weeks the
first signs of liver injury become apparent with an increase in ALT (Heathcoteet al.
(2003)). Seroconversion of anti-HCV antibody may become apparent 4-12 weeks post-
infection and is currently used for diagnosis of acute HCV infection together with de-
tection of HCV RNA (Mondelliet al. (2005); Pawlotsky (2002)). Further criteria for
diagnosing HCV are significantly elevated ALT levels (10-20 times above the upper
limit of normal), suspected HCV exposure or elevated levels of reactive proteins in
immunoblot assays and exclusion of all other possible causes for acute liver damage
(Mondelli et al. (2005)). The incubation time of 4-12 weeks before antibodies can
be detected is called “window period” and serological testing of donor blood will not
detect contaminated blood, therefore RT-PCR techniques to detect HCV RNA are used
as well.
Spontaneous resolution of acute hepatitis C
On average 26 % of all patients (range 20-67 %) are able to spontaneously resolve
an acute hepatitis and clear HCV from their system, which is mot likely to hap-
pen 3 months after the onset of disease and is more likely in femal s (Micallefet al.
(2006)). If the patient has not cleared the virus 6 months after onset of disease, it is
very likely a chronic disease will develop. The clinical course of the disease can be in-
fluenced by many different factors, such as HCV genotype, human leukocyte antigens
(HLAs), co-infection with HIV, gender, race and advanced age (Kenny-Walsh (1999);
Schnurigeret al. (2009)). For example, a clinical survey in a German prison has
shown that Caucasian men with an acute infection with genotype 3 were more likely to
clear the infection than those infected with genotype 1 (Lehmannet al. (2004)). Very
recent studies have reported that genetic variation in the IL-28B gene, which encodes
the type III IFN-λ3, is associated with spontaneous HCV clearance. It was demon-
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strated that a single C/C polymorphism 3 kb upstream of the IL-28B gene strongly en-
hanced spontaneous resolution in European and African individuals and was also asso-
ciated with better IFN/ribavirin treatment response. Thisled to the suggestion that the
gene product is likely to be involved in the innate immune contr l of HCV (Geet al.
(2009); Tanakaet al. (2009); Thomaset al. (2009); Suppiahet al. (2009)). Several
studies have reported that viral clearance is dependent on astrong and multispecific cel-
lular immune response (Diepoldert al. (1995); Gerlachet al. (1999); Gruneret al.
(2000); Thimmeet al. (2001); Grakouiet al. (2003); Lucaset al. (2007)), also see
section 1.6.2.
1.5.2 Chronic hepatitis
The majority of HCV infected individuals are not able to clearan acute infection and
will develop a chronic infection. The progression of chronic hepatitis is characterised
by persistence of HCV RNA in the serum. Serum ALT levels though,are only ele-
vated in two thirds of all patients (Zoulimet al. (2003)). Disease development differs
from individual to individual, but is usually asymptomaticinitially. However, over
the course of 20 to 30 years (range 5 to 50 years) the infectionmay develop to fibro-
sis, leading to cirrhosis and ultimately to HCC. HCC is a major healt issue in the
developed world and it is strongly associated with chronic hepatitis B and C, which
account for about 80 % of all HCC cases (Thomas & Zhu (2005)). Chronic infection
is characterised by inflammatory lesions in the liver and besides the progression to-
wards fibrosis, intrahepatic lipid accumulations, called steatosis, may occur as well
(Moradpour & Blum (2005)). Hepatic steatosis has been associated with genotype 3
and also with increased fibrosis progression (Rubbia-Brandtet al. (2000); Huiet al.
(2002); Casteraet al. (2004); Crosset al. (2009)). Other factors that can increase
the rate of progression towards fibrosis include alcohol intake (Jamalet al. (2005)),
coinfection with HBV and/or HIV, male sex, diabetes mellitus(DM) (El Seraget al.
(2004)), obesity (Chenet al. (2008)), advanced age at the time of infection and dura-
tion of infection (Niederauet al. (1998); Zoulimet al. (2003); Pradatet al. (2007)).
Some studies have associated genotype 1b with increased risk of HCC development
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(Silini et al. (1996); Brunoet al. (1997, 2007); Raimondiet al. (2009)), but these
findings have not been supported by others (Niederaut al. (1998); Serfatyet al.
(1998); Fattovichet al. (2001)). Very recent reports from Pakistan have suggested
that genotype 3a might be associated with an increasing incide e of HCC as well
(Khanet al. (2009)). Follow up of individuals who had received IFN therapy has
shown that successful clearance of chronic HCV infection reduc the incidence of
HCC and the overall liver-related mortality, demonstratinghe involvement of HCV in
this cancer (Kasaharaet al. (1998)).
The exact mechanisms underlying the development of HCC in chronic HCV infection
are still unclear (McGivern & Lemon (2009)). HCV is the only RNAvirus inducing
cancer with a predominantly cytoplasmic life cycle, suggesting an indirect role of HCV
in the development of hepatocarcinogenesis. Not only has HCVbeen shown to induce
chronic inflammation, steatosis, fibrosis and oxidative DNAdamage, but also direct
oncogenic effects and upregulation of mitogenesis have been reported for some HCV
proteins (Koike (2007)). Proteins with reported associations with hepatocyte transfor-
mation are core, E1/E2, NS2, NS3 protease, NS4A, NS4B and NS5A (Bartoschet al.
(2009)). For example, studies with transgenic mice have shown that core induces in-
tracellular oxidative stress in the liver in the absence of inflammation, indicating a pos-
sible role of core in the development of HCC in HCV infection (Moriya et al. (1998,
2001)). Elsewhere it was reported that core interacts with p53, a tumour suppressor
(Lu et al. (1999)).
1.5.3 HCV and extrahepatic manifestations
Several extrahepatic manifestations (EHMs) have been reported to occur during nat-
ural HCV infection. Up to 70 % of patients infected with HCV willdevelop at least
one EHM during the course of the disease (Cacoubet al. (1999)). Most often EHMs
observed in HCV patients involve joints, muscles and skin. Mixed cryoglobulinemia
(MC) is the most known and studied, though anti-nuclear antibodies and anti-smooth
muscle antibodies are observed as well. MC is characterisedby the deposition of cir-
culating immunocomplexes in small and medium-sized blood vessels, which leads to
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inflammatory destruction of blood vessels, also named systemic vasculitis. In indi-
viduals with HCV, MC can be found in 20-50 % of cases, dependingo the study
(Lunelet al. (1994); Wonget al. (1996); Pawlotskyet al. (1995)).
Another frequently reported disease associated with HCV infection is non-Hodgkin
lymphoma (NHL) (Dammaccoet al. (1998); Meleet al. (2003)). One possible ex-
planation for the underlying mechanism might be the long-term HCV infection, result-
ing in clonal B cell expansion of immunoglobulin (cryoglobulin)-secreting lympho-
cytes. Together with genetic and environmental factors this might result in mutations
within the oncogenes and therefore their activation, resulting in NHL (Galossiet al.
(2007)). Dermatological manifestations reported in associati n with HCV infection are
porphyria cutanea tarda and lichen planus (Fargionet al. (1992); Pilliet al. (2002)).
Several endocrinological manifestations have also been associated with HCV infec-
tion, including thyroid disease and DM (Huanget al. (1999); Masonet al. (1999);
Knobleret al. (2000)). DM has been recognised to influence the course of HCV
infection on the stage of insulin resistance (IR), a condition leading to type 2 DM
(Hui et al. (2003); Leandroet al. (2006)). HCV infected individuals may develop IR
independently of HCV, but several studies have supported thehypothesis that HCV
contributes to pathogenesis of IR. IR not only seems to accelerat the progression
of chronic hepatitis C, but has also been implicated in influencing the response to-
wards antiviral therapy (Negro (2006)). Finally, rheumatological manifestations, such
as rheumatoid arthritis and arthralgias (joint pain) are also commonly observed in the
course of chronic HCV infection (Riveraet al. (1999); Buskila (2009)).
1.6 Immune Response to HCV Infection
1.6.1 Adaptive immunity to hepatitis C virus
Studies of the host response to HCV infection have been hampered due to the often
asymptomatic disease progression of HCV during acute infection. These infections
often go unnoticed and the only immunocompetent animal model susceptible to HCV
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infection is the chimpanzee. As there are major differencesbetween HCV infection
in human and chimpanzees and because it is ethically and practically difficult to work
with chimpanzees, most studies on host’s immune responses rely on patient cohorts.
The humoral response to HCV infection
Early studies of the immune response in humans and chimpanzees have suggested
that antibody response alone was not sufficient to clear HCV infection in most cases.
Different studies have shown that a strong, multispecific and persistent cytotoxic T
lymphocyte response during the acute phase is crucial for clearing a HCV infection
(Lechneret al. (2000a,b); Thimme t al. (2002); Logvinoffet al. (2004)). The role
of antibodies in acute clearance of an infection is unclear.Studies in previously in-
fected and recovered chimpanzees have demonstrated a stronger T-cell response after
rechallenge with HCV, which helped to clear the infection, whereas there were con-
flicting results on whether there was an increased antibody response (Bassette al.
(2001); Majoret al. (2002)). A survey among IDUs in Australia even suggested that
HCV infection is more likely following prior infection and clearance, implying no in-
creased immunity against future infections (Aitkenet al. (2008)). Two other studies
have reported that neutralising antibodies are induced during the early phase of infec-
tion in individuals who control or resolve the viral infection (Lavilletteet al. (2005);
Pestkaet al. (2007)). In haemodialysis patients with nosocomial acquired HCV in-
fection, decreased viremia and HCV replication control was associated with a strong
response of neutralising antibodies, whereas individualswho were not able to clear the
infection lacked a neutralising response (Lavillettee al. (2005)). In a similar case,
pregnant women who acquired HCV in an accidental single-source outbreak were fol-
lowed up. Women who were able to clear the infection had a rapid induction of high-
titre and cross-neutralising antibodies in the acute phase, while those who developed
chronic infection, completely lacked or had a reduced capacity to neutralise the virus
during acute infection (Pestkaet al. (2007)). In summary these results suggest that a
strong, early and broad neutralising antibody response mayhelp to resolve HCV in the
acute phase of an infection, while a delayed antibody response may contribute to the
development of chronic infection.
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HCV has evolved many mechanisms to escape from the host immuneresponse, one
of them is viral escape from antibody-mediated neutralisation (Zeiselet al. (2008)).
This may occur through several mechanisms: (i) high variability of the HCV genome
and limited induction of cross-neutralising antibodies, (ii) the association of HCV with
serum factors such as VLDL and LDL, which might cover HCV epitoes, (iii) the in-
teraction of HCV glycoproteins with HDL, also possibly masking epitopes, (iv) the
covering of neutralising epitopes by glycosylation of certain amino acids on E1 and E2
and (v) the direct transfer of the virus from cell to cell (Zeis let al. (2008)). A very
recent clinical survey has investigated the induction of neutralising antibodies and vi-
ral escape from the neutralising responsein vivo in a cohort of young IDUs in China
(Dowdet al. (2009)). The survey found that during acute HCV infection older HCV
variants were neutralised by antibodies from the same individual before the neutral-
isation of newer HCV variants. This indicates that neutralising antibodies drive the
envelope sequence to change over time. The so-called antibody driven sequence evo-
lution might in some individuals determine the outcome of chronic infection. Another
escape mechanism has recently been described, whereby non-neutralising antibodies
bind to neutralising antibodies and disrupt their neutralisation of the virus. This mech-
anism might help the HCV virus to persist, even if plenty of neutralising antibodies are
present (Zhanget al. (2007, 2009)).
T cell responses to HCV infection
As mentioned above, T-cells play an important role in the immune response during
acute HCV infection. Most studies have been carried out in experimentally infected
chimpanzees or in individuals accidentally infected with acontaminated source, like
needle sticks. Many surveys, conducted in humans and chimpanzees, have shown that
the spontaneous clearance of the infection during acute phase is associated with a vig-
orous CD4+ and CD8+ T cell response, which targets multiple HCV regions and pro-
duces IFN-λ (Lechneret al. (2000a); Thimmeet al. (2002); Wedemeyeret al. (2002);
Bowen & Walker (2005)). One survey followed up 5 health care workers who were
exposed to HCV through accidental needle stick injuries (Wedemeyeret al. (2002)).
The only patient who cleared the acute HCV infection showed anearly, strong and
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sustained CD4+ and CD8+ T cell response. Another study, which followed individ-
uals who had spontaneously eradicated HCV infection, reportd that persistent CD4+
and CD8+ T cell responses targeting HCV epitopes last up to 35 years post-infection
(Wertheimeret al. (2003)). Additionally, it has been suggested that not only the num-
ber of active CD8+ cells, but also their breadth is important in spontaneous clearance
of HCV (Wertheimeret al. (2003)). A recent study confirmed these findings, by show-
ing that proliferating CTLs producing IFN-γ alone did not ensure recovery, but that the
presence or absence of CD4+ T cell help (HCV-specific interleukin-2 production) was
crucial for the priming of CTLs (Smyk-Pearsonet al. (2008)).
The onset and duration of the cellular immune response mightalso be crucial in the
outcome of chronic infection. This was demonstrated in a pros ective survey of 20 sub-
jects with acute infection, where the number of Th1 cytokine-producing CD4+ T cells
was higher in the first months in acute resolvers compared to those who failed to clear
the virus (Aberleet al. (2006)). Once established, cellular immunity appears to persist
for many years after clearance of infection (Wertheimeret al. (2003); Folgoriet al.
(2006); Changet al. (2001)).
Contrary to acute resolving HCV infections, persistent infections are characterised by
a weak and only monospecific CD4+ T cell response and even a strong CD8+ T cell
response in the acute phase of infection may not be able to prevent progression to-
wards chronicity (Coxet al. (2005b); Urbaniet al. (2006a)). Virus specific CD4+ and
CD8+ T cell responses are still detectable in the chronic phase, but the HCV specific
CD4+ and CD8+ T cells display defects in function and maturation (Wedemeyeret al.
(2002); Spangenberget al. (2005)). Urbaniet al. reported that the CD8+ T cell re-
sponse is generally weak and narrow, not only in chronicallyevolving, but also in self-
limited infections (Urbaniet al. (2006a)). In patients with chronic outcome, CD4+ T
cells were severely impaired as well, being weak and of narrow specificity. In resolvers
on the other hand, the CD4+ T cell dependent Th1 response, which is necessary for
CD8+ T cell activation, was found to be very strong and broad. After an initial stunned
phenotype, CD8+ T cells of resolvers were able to mature and becom active, whereas
they did not mature in patients with chronic outcome. This indicates that a functional
CD4+ T cell response, and its promotion of CD8+ T cell maturation, is crucial for
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resolving an infection (Urbaniet al. (2006a)).
Another possible mechanism involved in T cell failure of HCV-specific CD4+ and
CD8+ T cells in chronic infection is the downregulation of virus-specific T-cell re-
sponse by signalling through the programmed death 1 receptor (PD-1). PD-1 is an
inhibitory receptor on T cells and down-regulates their activ tion. It has been shown
to be markedly up-regulated on the surface of exhausted virus-specific CD8+ T cells
in mice and on HIV-specific CD8+ T cells in HIV-infected individuals näıve to anti-
HIV treatment (Barberet al. (2006); Dayet al. (2006)). Several recent studies have
reported elevated levels of PD-1 in HCV-specific CD8+ T cells with an exhausted
phenotype in patients with persistent HCV. Blocking of the PD-1/PD-L1 (PD-1 Lig-
and) interaction led to an enhanced proliferative phenotype, indicating a possible re-
lationship between PD-1 expression and T-cell exhaustion (Radziewiczet al. (2007);
Urbaniet al. (2006b); Bowenet al. (2008); Rutebemberwaet al. (2008)).
Furthermore, an increased frequency of CD4+ CD25+ FoxP3+ regulatory T cells (Treg)
has been observed in patients with chronic HCV infection (Sugimoto et al. (2003);
Cabreraet al. (2004); Boettleret al. (2005); Rushbrooket al. (2005)). Treg cells
have a suppressive function and are involved in the control of auto-immunity and
immune responses (Shevach (2009)). Boettleret al. have shown inin vitro deple-
tion studies that peptide specific proliferation and IFN-γ production of HCV-specific
CD8+ T cells were inhibited by Treg cells, that this inhibition was dose-dependent and
required a direct cell to cell contact (Boettleret al. (2005)). However, other studies
do not support these results. A recent study in chimpanzees found no difference in
Treg frequencies and the extent of their suppression between resolvers and those who
developed chronic infection. But they did report a differencbetween Tregs of HCV-
recovered and HCV-infected chimpanzees compared to naı̈ve chimpanzees, in that they
had an increased IL-2 responsiveness and lower T-cell receptor content, indicating a
history of in vivo proliferation (Manigoldet al. (2006)). Evidence against a role of
Tregs in promoting the development of chronic infection wasreported in another study
(Smyk-Pearsonet al. (2008)). In this prospective study of 27 acutely infected subjects
no significant difference in the proportion of Treg cells in the peripheral blood at base-
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line between resolvers and those who developed chronic infet on could be observed.
As in the chimpanzee studies, differences were observed compared to healthy control
groups; the frequency of Treg cells was higher than for the control group, but did not
vary over time. Thus, further studies are required to define the role of Tregs in the
outcome of HCV infection.
Yet another important mechanism of T cell response failure is viral escape from CD8+
T cells. Several studies have demonstrated that CTL exerts positive selection pres-
sure against the HCV quasispecies and that the outcome of the infection depends
on mutations within class I major histocompatibility complex (MHC) restricted epi-
topes (Changet al. (1997); Weineret al. (1995); Ericksonet al. (2001); Coxet al.
(2005a); Testeret al. (2005)). Findings from these studies revealed 2 important mech-
anisms of sequence evolution in chronic HCV infection: viralescape from CD8+ T
cells and optimisation of replicative fitness. Specific mutations within HLA class I
have been shown to be associated with persistence. These epitopes are targeted by
CD8+ T cells during acute immune selection pressure and the virus evades that pres-
sure by substituting amino acids in the targeted area (Timmet al. (2004); Rayet al.
(2005)). A clinical survey of an Irish cohort of women, accidentally infected with
HCV, showed that women with HLA class I alleles A3, B27 and Cw*01 were more
likely to spontaneously resolve the infection than women with an HLA class I allele
B8, suggesting that the host genetic background plays an important role in the outcome
of an infection (Neumann-Haefelinet al. (2006)).
Most likely, the clearance of HCV is a combined event of cellular and neutralising
immune response. In a rare study, both humoral and cellular immune responses were
analysed in a patient with chronic HCV infection (von Hahnet al. (2007)). The pa-
tient was followed up for 26 years and the development of autologous neutralising
antibodies, the HCV-glycoprotein-specific T-cell responseand their influence on viral
sequence evolution during chronic infection analysed. VonHahnet al. reported that
during chronic HCV infection the virus undergoes selected evolution under the pres-
sure of humoral and cellular immune response, leading to thecontinuous generation of
escape variants. These data underscore the above discussedfindings that impairment in
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both neutralising antibody response and cellular antiviral immunity lead to viral escape
from the host’s immune surveillance and the development of chronic infection.
1.6.2 Innate immunity to hepatitis C virus
HCV persists in more than 70 % of individuals, due to numerous very efficient mech-
anisms evolved by HCV to evade the host immune response. The cytokines type I
IFNs play an important role in innate immunity. HCV interferes with the IFN system
on many different levels: with the induction of IFN-β in infected cells, with IFN-α/β
signalling through the Jak-STAT pathway and with IFN induced proteins with antiviral
properties.
Induction of type I IFNs
More than 50 years ago Isaacs and Lindenmann discovered thatthe immune system
produced a substance in response to a viral infection that acted as an anti-viral agent,
the IFN (Isaac & Lindemann (1957)). Since then over 10 mammalian IFN species
and numerous subspecies have been identified (Pestka (2007)). Today IFNs are clas-
sified into three groups: type I, type II and type III IFNs. Type I IFNs include all
IFN-αs, IFN-β, IFN-ǫ, IFN-κ, IFN-ω and IFN-ν; IFN-γ is the only member of type II
IFNs and type III IFNs include IFN-λ2 (IL-28A), IFN-λ3 (IL-28B) and IFN-λ1 (IL29)
(Pestkaet al. (2004)). As discussed in section 1.5.1, mutations near the IL-28B gene
are associated with increased response rates to treatment with peg-IFN-α/ribavirin,
suggesting an important role of type III IFNs in the control of HCV (Geet al. (2009);
Tanakaet al. (2009); Thomaset al. (2009); Suppiahet al. (2009)). Upon infection
with a virus, the cell responds with the production of IFN-αs and IFN-β. As viruses
are composed of proteins and lipids mostly derived from the host, the cellular re-
ceptors have evolved to recognise the presence of viral nucleic acid. Two important
pathways have evolved to detect viral genomes and induce theproduction of type I
IFNs. Firstly, the TLR-dependent pathway detects many different pathogen-associated
molecular patterns (PAMPs), some of which are unmethylatedCpG DNA of bacte-
ria and viruses (TLR-9) (Baueret al. (2001)), dsRNA (TLR-3) (Alexopoulouet al.
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(2001)) and ss viral RNA (TLR-7,-8) (Dieboldet al. (2004); Heilet al. (2004)). The
cytosolic pathway on the other hand is triggered by viral RNA binding to the RNA he-
licases RIG-I and the melanoma differentiation antigen 5 (MDA5) (Yoneyamaet al.
(2004); Sumpteret al. (2005)). Unlike TLRs recognising bacterial components, which
are expressed on the cell surface, TLR-3, TLR-7 and TLR-9 are localised in intracel-
lular compartments, such as endosomes. TLR-3 signals througthe adaptor protein
TRIF, which results in translocation of IRF3 and NFκB to the nucleus and leads to
IFN-β production. TRL-7 and TLR-9 on the other hand signal through MyD88, which
leads to the translocation of IRF-7 and NFκB into the nucleus, resulting in IFN-α
production (Kawaiet al. (2004); Hoshinoet al. (2006)).
In the cytosolic pathway RIG-I and MDA5 recognise viral 5’triphosphate RNA and
dsRNA, which leads to a conformational change of these sensors (Schleeet al. (2009);
Schmidtet al. (2009)). This results in the binding of the downstream adaptor rotein
MAVS. The adaptor protein MAVS has been identified by 4 different groups at the
same time and is therefore also called IPS-1, cardif or VISA (Meylanet al. (2005);
Kawaiet al. (2005); Sethet al. (2005); Xuet al. (2005)). The signal is then propa-
gated through other mediators down to IRF3 and NFκB, which bind to the IFN-β pro-
moter and induce gene transcription. Secreted IFN-β is then bound by neighbouring
and the secreting cells, which induces the Jak-STAT pathwayleading to IRF7, IFN-αs
and IFN-stimulated genes (ISGs) gene transcription. This positive feed-back loop en-
sures a fast and strong induction of an antiviral state in theinfected and neighbouring
cells (Rehermann (2009)).
HCV interference with the innate immune response
As described above, infection with HCV activates the RIG-I andTLR-3 pathway,
which induces transcription of IFN-β. However, HCV has evolved mechanisms to
evade the action of IFN-β. The HCV NS3/4A protease has been reported to cleave
and inactivate MAVS (cardif, IPS-1 or VISA) thereby interfering with the RIG-I path-
way (Meylanet al. (2005)). It has also been shown that the NS3/4A protease blocks
the phosphorylation of IRF-3, a downstream protein of MAVS, thereby disrupting the
RIG-I pathway further down (Foyet al. (2003)). Treatment of cells with an active
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site protease inhibitor (PI) prevented this blockage and resto d intracellular antiviral
defence (Foyet al. (2005)). Moreover, it has been reported that the NS3/4A protease
also specifically breaks down TRIF, thus disrupting the TLR3 downstream signalling
and antiviral defence induction (Liet al. (2005b)). Targeting the NS3/4A protease
with antivirals will therefore not only prevent viral replication but also restore innate
immunity.
Induction of IFN stimulated genes by HCV
Interestingly, HCV still induces endogenous IFN transcription even though it blocks
several proteins of the IFN system, indicating the inhibition of the IFN pathway is in-
complete. Studies in chimpanzees have shown that an acute infectio leads to rapid
activation of the endogenous IFN system in the liver (Biggeret al. (2001)). Using
DNA microarray technology, the changes in liver gene expression were analysed in an
animal with an acute-resolving HCV infection. Upregulationf numerous ISGs ex-
pression levels were observed as early as 2 days post-infection, suggesting incomplete
inhibition of IFN-β induction. Follow-up of the IFN response in chimpanzees indi-
cated no fading away of IFN levels after the initial upregulation of IFNs as the virus
starts to persist (Biggeret al. (2004)). Also using DNA microarray analyses, gene
transcription regulation of chronically infected animalswere compared with that of
uninfected controls. Similarly to acute-resolving HCV infections, ISGs showed higher
transcriptional activity, indicating an ongoing IFN response towards HCV. Genotype-
associated differences were observed as well. A genotype 3 infected animal showed
upregulated expression in some genes potentially involvedin steatosis, but an overall
diminished ISG expression level when compared to genotype 1infections. Compar-
ing gene expression levels in humans lead to similar results. Chenet al. identified 18
genes whose expression profile was markedly different between all IFN/ribavirin treat-
ment non-responders and all responders (Chenet al. (2005)). Many of those genes
were IFN sensitive and the upregulation of a subset of 8 genesallowed a quite accurate
prediction of response to therapy. Interestingly, non-responders show an already high
expression level of ISGs before therapy and treatment with peg-IFN-α does not induce
expression of ISGs above pre-treatment levels (Sarasin-Filipow cz et al. (2008)). This
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phenotype of a preactivated IFN signalling pathway is more emphasised in patients
infected with genotype 1 and 4, compared with genotype 2 and 3, possibly explain-
ing the difference in response to therapy between these 2 groups. It was concluded
that the endogenous IFN system is not only ineffectively activ ted, but may also be in
an insensitive state that aggravates the response to therapy. Similar results have been
reported in another study, where the expression profile of liver mRNAs was analysed
using real-time quantitative PCR (RT-qPCR) (Asselahet al. (2008)). They demon-
strated that non-responders and patients who achieve a sustained virological response
have different liver gene expression profiles before treatmn and that the changes dur-
ing treatment were mostly associated with ISGs. Two gene signatures with predictive
response were identified in genes IF127 and CXCL9.
HCV interference with IFN signalling through the Jak-STAT p athway
Type I IFNs bind to IFN-α/β receptors (IFNAR), which are constituted of 2 subunits.
Each subunit binds a member of the Janus kinase (Jak) family;one to the tyrosine
kinase 2 (TYK2), the other to JAK1. Binding of type I IFNs to IFNAR leads to cross-
phosphorylation between those 2 kinases, initiating a downstream signalling cascade to
activate signal transducer and activator of transcription1 (STAT1), STAT2 and STAT3.
STAT1 and STAT2 then combine with a third transcription factor, IRF9, building the
IFN stimulated gene factor 3 (ISGF3), which binds to the IFN response elements and
initiates transcription of ISGs. Alternatively, gamma activated sequence (GAS) ele-
ments can be activated if STAT1 combines with STAT3. The STATs induced gene
expression leads to the transformation of the cell into an antiviral state (Darnellet al.
(1994); Darnell (1997)).
Suppressors of cytokine signalling (SOCS) are proteins thatinhibit, as the name im-
plies, the cytokine response through the Jak-STAT pathway (Krebs & Hilton (2001)).
SOCS1 and SOCS3 are induced by type I IFN (Song & Shuai (1998)). The impor-
tance of these negative regulators has been demonstrated inSOCS1-deficient mice,
which developed severe inflammatory disease due to IFN-γ hypersensitivity, but were
very resistant to viral infections, likely a result of increased type I IFN signalling
(Alexanderet al. (1999); Fenneret al. (2006)). Overexpressing the HCV core protein
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has been shown to inhibit IFN-α induced tyrosine phosphorylation and STAT1 activa-
tion in hepatic cells. This inhibition is most likely due to induction of SOCS3-mRNA
expression by core (Bodeet al. (2003)). Elsewhere it has been reported that core in-
duces upregulation of SOCS3 in HepG2 cells, which was associated with changes in
the glucose metabolism (Kawaguchiet al. (2004)). In addition, it has been shown that
the expression of HCV proteins in Huh7 cells leads to selectivSTAT1 degradation in
a proteasome-dependent way. As HCV core protein was found to bind STAT1, it was
suggested to be associated with the STAT1 degradation (Linet al. (2005b)). Another
group using HCV protein expression in Huh7 cells, reported that high-level expres-
sion of HCV core protein inhibited the IFN-α induced accumulation of STAT1 in the
nucleus (Melenet al. (2004)). STAT3 levels have also been shown to be reduced in
livers of HCV infected patients and Huh7 cells containing thefull-length HCV replicon
(Larreaet al. (2006)). It was concluded that HCV replication impairs the Jak-STAT
signalling pathway and might thereby improve viral replication and favour liver disease
progression.
The type I IFN induced antiviral state in a cell results in upregulation of many different
genes. One of them is PKR, which phosphorylates eIF2α when a cell is in an antiviral
state. This inhibits translation of most cellular and viralmRNAs, thereby prevent-
ing viral replication (Robertset al. (1976); Farrellet al. (1978)). The HCV protein
NS5A has been shown to prevent PKR activation in cell cultureby directly interact-
ing with the protein kinase catalytic domain. This presentsyet another mechanism
how HCV manages to avoid the antiviral effects of IFN (Galeet al. (1997)). A survey
among genotype 1b infected individuals has reported a correlation between mutations
within the ISDR of HCV NS5A, which is involved in PKR binding, and response
to IFN (Enomotoet al. (1996)). This observation was supported by another study
with genotype 1b infected individuals in Australia and a very recent one in Tunisia
(MacQuillanet al. (2004); Bouzgarrouet al. (2009)). However, similar correlations
were not observed in analogous studies carried out in Europeand the United States
(Zeuzemet al. (1997); Gerottoet al. (2000); Murphyet al. (2002)). A meta-analysis
in 2004 (Pascuet al. (2004)) and a more recent study (Murayamaet l. (2007b)) have
concluded that a correlation between the number of mutations within ISDR and the re-
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sponse rates to IFN-ribavirin combination therapy is dependent on genotype subtype
and not geographical region. In individuals infected with the J-type HCV 1b, ISDR
can serve as a predictable marker for response to IFN-ribavin combination therapy,
but not in individuals infected with other genotype 1b strains and other genotypes.
Another protein reported to interact with PKR is the HCV E2 envelope protein. HCV
E2 was demonstrated to bind PKR through a 12-amino acid sequence that resembles
the PKR auto-phosphorylation site and the eIF2α phosphorylation site, named the
PKR-eIF2α phosphorylation homology domain (PePHD) (Tayloret al. (1999)). E2
was shown to block PKR in transfected cells and yeast, promoting protein synthesis
and cell growth. The authors argue that together with the inhib tory effect of NS5A
on PKR, E2-PKR blocking may be a possible cause for the development of resistant
infections. The promoted protein synthesis, which allows the cell to grow again, may
explain HCV-associated HCC. The investigators compared the sequences of PePHD
domains of different genotypes and found that those of genotypes 1a and 1b were
more closely related to the sequence of PKR and eIF2α than those of genotypes 2a, 2b
and 3a. Genotype 1a and 1b show higher resistance to IFN treatment compared with
genotype 2a, 2b and 3a. This might explain the better response rates in individuals
infected with the latter genotypes. However, a clinical study comparing sequences of
this 12-amino acid motif between different genotypes and their response to IFN ther-
apy did not find a similar association, suggesting that otherfactors might influence the
response to IFN-α to a greater extent (Abidet al. (2000)).
HCV is very successful in establishing persistent infections. To achieve this, the virus
has evolved different mechanisms that interfere with the host innate immune system.
HCV not only interferes with the induction of IFN-β in infected cells, but also disrupts
IFN-α signalling through the Jak-STAT pathway and directly inhibits IFN induced
effector mechanisms, such as the PKR-mediated inhibition oftranslation. Together
with the above discussed abilities of the virus to evade the adaptive immune response,
disruption of the IFN response allows HCV to effectively persist in the host.
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1.7 Current Treatment Options
1.7.1 IFN-ribavirin combination treatment
Some individuals spontaneously cure a HCV infection, but themajority go on to de-
velop a chronic infection if no diagnosis is made during acute infection and treatment
initiated. If acute hepatitis C is diagnosed, the chances oftreatment response are quite
high, with treatment success rates being highest if treatment commences within 12
weeks of diagnosis (Jaeckelet al. (2001); Gerlachet al. (2003); Coreyet al. (2009)).
Chronic hepatitis C (CHC) on the other hand is resistant to treatm n in almost 50 %
of individuals. Initially therapy only consisted of IFN-α, which resulted in about 15-
20 % of individuals with chronic hepatitis achieving sustained virological response
(SVR) (Lin et al. (1995b); Poynardet al. (1996); Carithers & Emerson (1997)). SVR
is defined as the absence of any detectable HCV-RNA 6 months after end of treat-
ment. Treatment outcome was further improved with the introduction of the nucle-
oside analogue ribavirin and the pegylation of IFN-α (McHutchisonet al. (1998);
Poynardet al. (1998)). The addition of a polyethyleneglycol molecule to IFN in-
creases its half-life, thereby creating more favourable pharmacokinetics and allowing
a more comfortable once-weekly dosing.
The exact mechanism underlying HCV replication inhibition through ribavirin is un-
clear. Ribavirin is a guanosine nucleotide that is incorporated by the HCV polymerase
and can pair with cytosine or uracil. It has been shown for poliovirus that ribavirin can
induce lethal mutagenesis by increasing the viral error rate, leading to error catastro-
phe and repression of the viral fitness of the population (Crotty et al. (2000, 2001)).
A similar study on the HCV genome has shown that passaging the HCV replicon un-
der ribavirin leads to mutations within specific regions of the genome, supporting a
mechanism of error catastrophe induced by ribavirin (Contreras t al. (2002)). Fur-
thermore, it has been proposed that ribavirin incorporation by the HCV polymerase
blocks RNA elongation during RNA synthesis, directly inhibiting HCV RNA replica-
tion (Maaget al. (2001)). Ribavirin may also affect the immune response to HCV.
Activation of isolated T-cellsin vitro led to an increased type 1 and a suppressed type
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2 cytokine response upon ribavirin treatment (Tamet al. (1999)). The authors pro-
posed that the promotion of a type 1 cytokine-mediated immune response may be
in part responsible for the additive effect of ribavirin in the IFN-α/ribavirin combi-
nation treatment. Another possible effect of ribavirin might be the inhibition of the
inosine monophosphate dehydrogenase (IMPDH), which converts inosine monophos-
phate (IMP) to guanosine triphosphate (GTP). This leads to depletion of GTP and
reduced RNA synthesis (Lauet al. (2002)). Ribavirin is given twice daily, depending
on body weight.
The combination treatment of peg-IFN-α and ribavirin constitutes the standard of care
since 2001 and results in SVR rates of 46-55 % (Mannset al. (2001); Friedet al.
(2002); Hadziyanniset al. (2004)). To determine treatment duration, the HCV geno-
type and the initial response to therapy defined by HCV RNA virallo ds in serum at
baseline and after 4 and 12 weeks of therapy have to be considered. Treatment re-
sponses are categorised depending on the viral load after end of treatment, as outlined
in Table 1.1.
Table 1.1: Definition of treatment response.Adapted from Sarasin-Filipowiczet al.
(2008).
Rapid virological response (RVR) Negative HCV-RNA 4 weeks from treatment onset
Early virological response (EVR) > 2 log10 IU/ml reduction in HCV-RNA at week 12
Complete EVR (cEVR) Negative HCV-RNA 12 weeks from treatment onset
Primary non-responders (PNR) < 2 log10 IU/ml decrease in viral titre after 12 weeks
End of treatment response (EoTR) Undetectable serum HCV-RNA after end of treatment
End of treatment non-response (EoNR) Detectable serum HCV-RNA after end of treatment
Sustained virological response (SVR) No detectable HCV-RNA 6 months post-treatment
Relapse Detectable HCV-RNA after having achieved EoTR
Ideally a patient undergoing therapy achieves a response atthe end of the treatment
(EoTR) and maintains negative serum-HCV levels after the treatm nt has ended. How-
ever, not all patients who respond to therapy are able to achieve a SVR and HCV-RNA
is detectable again 6 months post-treatment; these patients are classified as relapsers.
When deciding on the duration of the therapy, the genotype plays an important role.
Patients infected with genotype 1 have been shown to benefit from a longer treatment
duration of 48 weeks (McHutchisonet al. (1998)). Individuals infected with geno-
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type 4 also benefit from a longer 48 week treatment, whereas genotype 2 and 3 in-
fected individuals show better response rates and 24 weeks of treatment are recom-
mended (Hasanet al. (2004); Friedet al. (2002); Hadziyanniset al. (2004)). How-
ever, side effects and the very high cost associated with IFN-α/ribavirin treatment has
led to recent suggestions that individuals showing RVR should nly be treated for
12-16 weeks, if infected with genotype 2 and 3, and 24 weeks ifinfected with geno-
type 1 (Mangiaet al. (2005); Mangia (2007)). Different clinical studies have shown
that about 50-60 % of individuals infected with genotype 1, 20 % infected with geno-
type 2 or 3 and 30-40 % infected with genotype 4 do not respond tthe current stan-
dard treatment (Mannset al. (2001); Friedet al. (2002); Hadziyanniset al. (2004);
Hasanet al. (2004); McHutchisonet al. (2009a)). In patients who do not achieve an
EVR after 12 weeks of treatment, therapy is discontinued. African-Americans and
individuals with steatosis generally achieve lower SVR rates (Reddyet al. (1999);
Muir et al. (2004); Poynardet al. (2003)). Other factors associated with lower SVR
rates are male gender and age (Hayashiet al. (1998)). Low pre-treatment serum HCV
RNA levels are associated with higher SVR rates (Martinot Peignouxet al. (1995)),
whereas high body fat mass (body mass index (BMI)> 30) (Hickmanet al. (2002);
McCullough (2003)) and high alcohol intake will reduce the efficacy of IFN-treatment
(Okazakiet al. (1994); Ohnishiet al. (1996)). The rate of fibrosis progression and
insulin resistance have also been associated with decreased SVR rates (Myerset al.
(2003); Nastaet al. (2008)). As discussed in section 1.6.1, different HLA typeshave
been associated with SVR rates as well.
Individuals with genotype 5 and 6 are generally underrepresented in clinical studies
and only very few data are available on their response to treatment. A recent study,
analysing retrospectively individuals who received IFN-α/ribavirin combination treat-
ment and were diagnosed with genotype 6, concluded that individuals infected with
genotype 6 should be treated with a full course of 48 weeks of treatment (Nguyenet al.
(2008)). No specific recommendations on dose and treatment dura ion are currently
available for genotype 5 infected individuals, as there is not sufficient data available.
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IFN-α/ribavirin combination treatment is frequently associated with severe side-effects
and 10-14 % of patients discontinue their therapy due to adverse vents (Mannset al.
(2001)). Side-effects often reported include influenza-like symptoms, such as fatigue,
headache, nausea, pyrexia (fever), rigors and myalgia (muscle pain); skin disorders,
such as pruritus (itch), alopecia (hair loss) and dermatitis; arthralgia (joint pain); diges-
tive dysfunction; neutropenia (abnormally low levels of neutrophils); thrombocytope-
nia (low levels of platelets in blood); thyroid dysfunctiona d depression (Friedet al.
(2002)). Addition of ribavirin in combination treatment can lead to extra side effects
such as haemolysis, resulting in anaemia in 30 % of patients.Surprisingly, a decline
in haemoglobin during the early phase of treatment has been found to be associated
with better treatment outcome in genotype 1 infected individuals (Sulkowskiet al.
(2009a)).
Risks and benefits of IFN-α/ribavirin combination treatment have to be evaluated for
each patient individually, as the course of infection can proceed more slowly in some
individuals and occurrence of side-effects may differ. Furthe more, treatment costs
can differ considerably as well. Treatment costs for individuals infected with geno-
type 1, with mild or moderate disease, and patients under theage of 40, is below
£20,000 per quality-adjusted life year (QALY). For genotype 1 infected individuals,
with cirrhosis, aged 50 and older, treatment costs can rise to over £60,000 per QALY
(Grishchenkoet al. (2009)).
Taking these factors into consideration, therapy has been recommended for individuals
with persistently elevated transaminase levels (ALT and ASP) (Martinot-Peignouxet al.
(2001); Persicoet al. (2000)), detectable serum HCV-RNA (sign of viral replication)
and progressed fibrosis (metavir fibrosis stage F≥ 2, where 4 is the maximum, as de-
termined by liver histology) (Wong & Koff (2000); Levinet al. (2006); Ghanyet al.
(2009)). However, more recent studies have shown that high-dose IFN-α/ribavirin
combination therapy is effective, safe and well tolerated in patients with normal ALT/
ASP levels as well (Zeuzemet al. (2004); Yuet al. (2006b)). This has led to the
suggestion that individuals with normal ATL/ASP levels might benefit from IFN-α/
ribavirin treatment as well and that liver biopsies should be taken to determine whether
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treatment should be initiated or not.
1.8 Antivirals
While the current standard treatment is reasonably effectivfor individuals infected
with genotype 2 and 3, there is still a high number of patientswi hout response and
others with reemerging HCV-RNA after end of treatment. Due to the partly very low
response rates and the frequently occurring side effects, the development of new, highly
specific small molecules targeting the HCV virus is highly desired. The so called
specifically targeted antiviral therapy for HCV (STAT-C) targets viral proteins, mostly
by small molecules. Highly active antiviral retrotherapy (HAART), using the com-
bined effect of several small molecule inhibitors to targetth virus, is already part of
the current standard treatment for HIV infection, but even though the causative agent
of hepatitis C has only been identified shortly after that of acquired immune deficiency
syndrome (AIDS), no specific antivirals for HCV are approved by the American Food
and Drug Administration (FDA) as to date (Dunning & Nelson (2009)). Of the 10 viral
HCV proteins, NS2, NS3/4A and NS5B have enzymatic functions and present possi-
ble targets for antiviral therapy. NS3/4A, a serine protease, lso plays a role in RNA
replication and assembly, as does the HCV polymerase NS5B. These 2 proteins have
therefore been 2 particularly promising targets in antiviral drug development, as their
inhibition prevents viral replication. Nevertheless, antiviral strategies targeting viral
entry, translation and protein-protein interactions are pursued as well. After showing
efficacy in cell culture and not inducing any severe cytotoxic effects in cell culture
and small animal models, the evaluation of antiviral drugs is carried out in 4 clinical
phases, which are explained in Table 1.2.
Table 1.2: Definition of clinical trial phases.Adapted from ClinTrials (2010).
Phase I Safety, dose range and side-effects evaluation in a small group (20-80 people)
Phase II Testing of efficacy and safety in a larger group (100-3 people)
Phase III Confirmation of efficacy, monitoring of side-effects and comparison to commonly
used treatments in large groups (1,000-3,000 people)
Phase IV Monitoring of drug risks and benefits post-marketing a d adjustment of optimal use
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1.8.1 NS3/4A protease inhibitors
The development of NS3/4A PIs was greatly spurred when the crystal structure of the
NS3 N-terminal protease domain and the full-length NS3 protein, complexed with a
NS4A peptide, was solved (Kimet al. (1996); Yaoet al. (1999)). The crystal struc-
ture revealed an unusually broad and shallow substrate binding site, which has compli-
cated the development of specifically binding small moleculs sing rational structure-
based drug design. However, it was observed that the carboxy-terminal NS3 residues
are located within the active site, presenting a “product inhibition” mechanism, where
cleaved substrate peptides occupy the active site. This finding has been very helpful for
drug design and peptidomimetic compounds dominate drug development against the
NS3/4A protease today (Steinkuhleret al. (1998)). The first of these peptidomimetic
compounds to enter clinical trials was the macrocyclic inhibitor BILN 2061 (cilupre-
vir). This small, orally available molecule inhibitor resulted in an impressive reduc-
tion of HCV RNA levels after only 2 days in genotype 1 infected inividuals. On
average patients showed a 2 to 3 log10 reduction in HCV RNA levels (copies/ml)
with some patients even reaching undetectable levels within 24-28 hours after admin-
istration (Lamarreet al. (2003)). Specifically developed for genotype 1 proteases,
BILN 2061 had a nearly 2 log10 weaker binding affinity for genotype 2 and 3 pro-
teases (Thibeaultet al. (2004)) and inin vivo studies BILN 2061 showed as expected
lower efficacy in patients infected with genotype 2 and 3 (Reiseret al. (2005)). Un-
fortunately, the development of BILN 2061 had to be halted dueto cardiotoxicity in
laboratory animals (Vanwolleghemet al. (2007)).
Because of the genetic variability of HCV proteins of different genotypes, the structure
of protease and polymerase enzymatic sites differs substantially and potentially limits
the effectiveness of certain classes of inhibitors (Holland-Staleyet al. (2002)). The
case of BILN 2061 demonstrated early on that it is crucial to investigate drug effica-
cies in all genotypes. Reduced effectiveness of antivirals on certain genotypes also
potentially facilitates the development of resistance mutations, section 1.8.4.
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Newer macrocyclic inhibitors currently in clinical trialsinclude ITMN-191 and TMC-
435 (Table 1.3). In phase Ib clinical trials, ITMN-191 was able to reduce HCV RNA
levels by about 3.5 log10 IU/ml after 14 days of treatment (Bradfordet al. (2008);
Forestieret al. (2008)). Biochemical inhibition studies have shown that ITMN-191
is about 10-fold more potent against proteases from genotype 4, 5 and 6 compared
to proteases from genotype 2a and 3a. However, the biochemical potency is still in
the nanomolar range for all genotypes and peg-IFN-α-2a showed an additive effect,
making it a very potent inhibitor (Seiwerte al. (2008)). In biochemical assays, TMC-
435 showed potent inhibition of HCV NS3/4A proteases from allgenotypes except
for genotype 3 proteases (Tsantrizos (2009)). In phase I andII clinical trials with
genotype 1 infected individuals, TCM-435 has demonstrated significant reductions in
HCV-RNA levels without any severe side-effects (Reesinket al. (2009)). TMC-435
is currently evaluated in phase IIa clinical trials in combinat on with peg-IFN-α and
ribavirin.
The currently most advanced PIs are 2 linear ketoamide peptidomimetic inhibitors,
VX-950 (telaprevir) and SCH 503034 (boceprevir). They have advanced into phase
IIb/III clinical trials. In monotherapy, VX-950 was able toreduce HCV RNA lev-
els 4.4 log10 IU/ml on average after 14 days of treatment and was well tolerated
(Reesinket al. (2006)). In 2 recent phase II clinical trials it could be demonstrated
that the addition of the STAT-C agent VX-950 to the current standard of care could in-
crease SVR rates, although discontinuation rates were higher due to VX-950 induced
side-effects (Hezodet al. (2009); McHutchisonet al. (2009b)). Tibotec conducted a
similar phase II study on previously untreated genotype 1 infected patients in Europe.
Up to 85 % of patients, taking 3 times daily VX-950 plus peg-IFN-α-2a and ribavirin,
achieved a SVR (Marcellinet al. (2009). Vertex is currently conducting a phase III
clinical trial that includes evaluation of 24-week and 48-week VX-950-based regi-
mens in genotype 1 treatment-naı̈ve HCV patients. An 8-12 week period of peg-IFN-
α/ribavirin/VX-950 triple-combination therapy is followed by 12-16 weeks of peg-
IFN-α/ribavirin dual-combination treatment and patients follow-up for 48 weeks.In
vitro studies have reported similar efficacies for VX-950 againstgenotype 1a, 1b and
2a (Paulsonet al. (2009)). In an ongoing phase IIa clinical trial, VX-950 has demon-
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strated substantial activity in genotype 2 infected patients, but only limited efficacy in
genotype 3 infected individuals (Fosteret al. (2009)). Highlighting again how influ-
ential the structural differences between the proteases ofthe different genotypes are
on drug efficacies and that it is important to take these into consideration during drug
design.
SCH 503034 (boceprevir), the other linear ketoamide peptidom metic, reduced repli-
con RNA levels over 4 log10 during continued exposure in cell lines (Malcolmet al.
(2006)). In a phase II clinical trial with genotype 1 infected individuals, addition of
SCH 503034 to the current standard care of treatment resultedin increased SVR rates
compared to the control group (Schering Plough (2009)). Schering-Plough is currently
running a phase III clinical trial testing SCH 503034/IFN/ribavirin combination ther-
apy on genotype 1 infected individuals, which is expected tobe completed in mid-
2010. BI 201335, the new PI from Boehringer Ingelheim, demonstrated a rapid and
potent antiviral activity in a very recent phase II clinicaltrial, where genotype 1 in-
fected patients were given BI 201335 in combination with the current standard care of
treatment (Sulkowskiet al. (2009b)).
As the NS3/4A protease also interferes with the IFN response, an inhibition of this
enzyme might potentially also rescue the endogenous IFN response. However, a recent
study showed that the concentration of the PI TMC-435 required for the rescue of
the virus-imposed inhibition of the IFN signalling, was significantly higher than that
necessary for the inhibition of viral replication (Lianget al. (2008)). Thus, PIs are




Table 1.3: HCV NS3 PIs and phase of clinical development.
Compound Phase of development Company
SCH 503034 (Boceprevir) Phase III Schering-Plough
VX-950 (Telaprevir) Phase III Vertex
BI 201335 Phase II Boehringer Ingelheim
BMS-650032 Phase II Bristol-Myers Squibb
ITMN-191 (RG7227/R05190591) Phase II1 Intermune/Roche
ITMN-121 Phase II Roche
MK-7009 Phase IIa Merck
TMC-435 Phase IIa Medivir/Tibotec
SCH 900518 (Narlaprevir) Phase II Schering-Plough
ABT-450 HCV Phase I Abbott and Enanta
ACH-1625 Phase I Achillion
BMS-791325 Phase I Bristol-Myers Squibb
BMS-824393 Phase I Bristol-Myers Squibb
PHX1766 Phase Ia Phenomix
VX-500 Phase Ib Vertex
VX-813 Phase I Vertex
VX-985 Phase I Vertex
AVL-181 Preclinical Avila Therapeutics
EA-058 Preclinical Abbott and Enanta
EA-063 Preclinical Abbott and Enanta
SCH 567312 Preclinical Schering-Plough
ACH-806/GS9132 Discontinued Gilead/Achillion
BILN 2061 Discontinued Boehringer Ingelheim
SCH6 Discontinued Schering-Plough
1Phase I in combination with the nucleoside analogue polymerase inhibitor RO5024048.
Information presented in this table has been gathered from public sources, accuracy is not guaranteed.
Sources include company websites and the following public websites:
http://www.hcvdrugs.com





1.8.2 NS5B polymerase inhibitors
The other important target in HCV specific antiviral drug development is the RdRp
NS5B. Similar to NS3 PI development, developing NS5B inhibitors has also been
greatly propelled forward by solving its 3-dimensional struc ure. Crystallographic
structure analysis has revealed a typical right-handed polymerase conformation with
palm, thumb and finger domains. The finger and thumb domains interact closely with
each other, providing a fully encircled active site (Lesburg et al. (1999)). More recent
structure analyses have disclosed that NS5B can exist in an ope r closed conforma-
tion (Biswalet al. (2005); Chinnaswamyet al. (2008)). It was proposed that during
de novoinitiation NS5B consists in a closed conformation, which isopened up during
elongation due to steric clashes induced by the growing polypeptide.
To date many small molecule inhibitors of NS5B have been ident fi d and some have
entered clinical trials (Table 1.4). They can be classified into 2 groups: nucleoside
analogs that bind to the active site and allosteric, non-nucleoside inhibitors (NNIs)
that bind sites at variable distances from the active site ofhe polymerase. Nucleoside
inhibitors bind to the active site and inhibit transcription initiation and elongation of
RNA synthesis, whereas NNIs binding to allosteric sites onlyseems to inhibit tran-
scription initiation by blocking the open conformation (Biswal et al. (2005)). Nucle-
oside inhibitors of HCV RdRp include 2’-C-methyl, 2’-O-methyl,and 4’-substituted
nucleoside analogs, working on a chain terminating mechanism (Carrollet al. (2003);
Klumppet al. (2006)). There are currently 3 nucleoside analogues in phase II devel-
opment; IDX-184, PSI-7977 and R7128.
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Table 1.4: HCV NS5B polymerase inhibitors and phase of clinical development.
Compound Phase of development Company
Nucleoside inhibitors
IDX-184 Phase II Idenix
PSI-7977 (Prodrug of PSI-7851) Phase IIa Pharmasset
R7128 (Prodrug of PSI-6130) Phase IIb Roche/Pharmasset





ABT-333 Phase II Abbott
ANA598 Phase II Anadys
GS 9190 Phase II Gilead
IDX-375 Phase II Idenix
PF-868554 (Filibuvir) Phase II Pfizer
VCH-759 Phase II Vertox/ViroChem
VCH-222 Phase Ib/IIa Vertox/ViroChem
A-837093 Phase I Abbott
ABT-072 Phase I Abbott
BI 207127 Phase I Boehringer Ingelheim
MK-3281 Phase I Merck
PF-4878691 Phase I Pfizer







JTK 003 Discontinued Akros Pharma
NM107/NM283 Discontinued Idenix Pharmaceuticals
R803 Discontinued Rigel Pharmaceuticals
XTL-2125 Discontinued XTL Pharmaceuticals
1In combination with the PI RO5190591/ITMN-191.
2Efficacious in the HCV-infected chimpanzee (Mollaet al. (2007)).
Information presented in this table has been gathered from public sources, accuracy is not guaranteed.
Sources include company websites and the following public websites:
http://www.hcvdrugs.com





Among the NNIs there are 7 inhibitors in phase II clinical trials now: ABT-333,
ANA598, GS 9190, IDX-375, PF-868554, VCH-222 and VCH-759. NS5B inhibitors
generally lower HCV RNA levels between 2 to 3 log10 IU/ml, slightly less than PIs
(Cretton-Scottet al. (2008); Lalezariet al. (2008); Cooperet al. (2009)). However,
in combination therapy with standard of care, R7128, a nucleosid analogue, was able
to lower HCV RNA levels up to 5 log10 IU/ml (Le Pogamet al. (2009)). As with
PIs, genotype associated differences in the enzyme structure an play a major role
in the susceptibility of polymerases to polymerase inhibitors. For example,in vitro
studies with ABT-333 have shown that it is a potent inhibitor of genotype 1b and 1a
polymerases, but nearly ineffective against genotype 2a, 2b, 3a and 4a polymerases,
demonstrating again the importance of genotype associateddiff rences in the enzyme
structure (Maringet al. (2009)).
1.8.3 Other HCV inhibitors
The exact role of the HCV NS3 helicase in the HCV viral life cycleis not clear yet, but
it is essential for viral replication and therefore anotherinteresting target for antivirals.
To date though, no specific small molecules that are free of cytotoxicity have been
identified. As the helicase is similar to human DEAD-box helicases it is difficult to find
compounds that discriminate between the two, leading to non-toxic drugs (Duet al.
(2002)). The NS2 protease is another possible target for STAT-C. A recent study has
reported that the cyclophilin inhibitor CysA acts on HCV replication through NS2. It
was the first anti-HCV drug shown to act through NS2, demonstrating possible role
of this protein as an antiviral target (Ciesekt al. (2009)).
Antiviral targeting is also possible against non-enzymatic proteins, as has been shown
with NS5A. Currently 3 anti-NS5A inhibitors are in phase II clinical trials (Table 1.5),
but the exact mechanism underlying their inhibition is unclear. In a proof-of-concept
study, a single dose of the NS5A inhibitor BMS-790052 was ableto r duce HCV RNA
levels 3.6 log10 IU/ml with no rebound during a 6 day follow-up period. BMS-790052
also proved highly effective not only against genotype 1a, 1b and 2a, but also against
genotype 3a, 4a and 5a in the replicon system. This high efficacy across genotypes
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clearly is an important advantage over other antivirals currently being evaluated, which
are mostly only effective in genotype 1 and 2 (Nettleset al. (2008)).
Another possible non-enzymatic target is the NS4B protein.Clemizole hydrochlo-
ride, a generic oral antihistamine, is the first molecule targeting NS4B being evaluated
in clinical trials. In in vitro studies it has demonstrated 50 % effective concentration
(EC50) values in the low micromolar range and is now being evaluated in a phase I
clinical trial (Einavet al. (2008)). Furthermore, p7, the putative ion channel, provides
another possible target. Finally, the envelope protein E2 has also been targeted, with
the entry inhibitors ITX-4520 and ITX-5061.
Table 1.5: Other HCV inhibitors and phase of clinical development.
Compound Phase of development Company
Entry inhibitors
ITX-5061 Phase IIa announced iTherX
ITX-4520 Phase I iTherX
SP-30 Preclinical/ Samaritan Pharmaceuticals
Phase I announced
NS4A inhibitors
ACH-1095 Preparing to enter Phase I Achillion
NS4B inhibitors
Clemizole hydrochloride Phase I Eiger BioPharmaceuticals
NS5A inhibitors
A-832 Phase II AstraZeneca
AZD-2836 (A-831) Phase II AstraZeneca
BMS-790052 Phase II Bristol-Myers Squibb
AZD-7295 (A-689) Phase I AstraZeneca
Information presented in this table has been gathered from public sources, accuracy is not guaranteed.
Sources include company websites and the following public websites:
http://www.hcvdrugs.com





1.8.4 Development of antiviral resistance
A major issue with STAT-C is the preexistence of drug-resistant genetic variants among
the hugely diverse pool of quasispecies and the short time frame within which new
drug-resistant genetic variants can be generated by the error-prone RdRp. The impact
of a drug-resistant variant depends on its replicative fitness and on the degree of drug
resistance it confers. Depending on the bio-availability and potency of a compound,
the drug-resistant variant will be able to evade the drug pressure, continue to replicate
and spread. Even though the replicon and full-length HCV system do not represent
the huge diversity of quasispecies within an infected individual, it was still possible to
select for resistance mutations developingi vitro under different protease and poly-
merase inhibitors. Importantly, some of these resistance mutations identifiedin vitro
have been observed in clinical trials and worryingly also intreatment näıve patients
(Sarrazinet al. (2007a); Bartelset al. (2008); Colsonet al. (2008)).
As all NS3/4A PIs bind to the active site of the protease, it isno surprise that the iden-
tified resistance mutations partly locate to the same position within the NS3 protease.
Resistance mutations at R155K/Q, A156T and D168V/A have been rported in BILN
2061 resistance development and confer 357-fold (A156T), 24-fold (R155Q) and 144-
fold (D168V) increases in the EC50 value of BILN 2061 (a macrocyclic inhibitor)
(Lu et al. (2004)). ITMN-191, another macrocyclic PI, also induced resistance mu-
tations at position D168A/V/E as well as A156S/V, F43S, Q41Rand S138T. Unlike
BILN 2061, where all mutations associated with decreased sensitivity located to the
NS3 protease, for ITMN-191 one mutation (S489L) was identified within the helicase
domain and one (V23A) within the NS4A cofactor (Seiwertt al. (2007b)). VX-950,
which is a linear ketoamide peptidomimetic, shows a different drug resistance profile.
The dominant resistance mutation under VX-950, A156S, still remains susceptible to
BILN 2061 and the dominant BILN 2061 resistance mutations, D168V/A, remain sus-
ceptible to VX-950, supporting combination treatments. However, the resistance muta-
tions A156V/T confer cross-resistance to both PIs, so do R155substitutions (Linet al.
(2005a)). The decreased susceptibility of these mutationswards PIs is possibly di-
minished by their impaired replicative fitness, which was shown to be the case in the
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replicon system (Linet al. (2005a)).
As discussed in section 1.8.2, polymerase inhibitors bind to ifferent sites in the en-
zyme leading to very different resistance profiles. While thenucleoside analogues bind
to the catalytic domain, the NNIs bind to sites with variabledistance to the active site.
The substantial differences in the resistance profiles could explain the relatively low
cross-resistance between polymerase inhibitors. As the NNIs bind outside of the cat-
alytic domain, functional constraints are lower and resistance mutations can arise more
easily than with nucleoside analogues. The 3-dimensional structure comprising the ac-
tive site is very important and one change of amino acid can led to a functionally
impaired polymerase. R1626 was one of the first nucleoside polymerase inhibitors
to enter clinical trials. In a phase Ib study, 14 days of treatment reduced the HCV
RNA levels up to 3.6 log10 IU/ml in the highest dosed arm. Importantly, no resis-
tance mutations were observed after 14 days of treatment with R1626, demonstrating
a clear advantage of nucleoside inhibitors over PIs and NNIs, where resistance can de-
velop within 2 weeks (Robertset al. (2006, 2008)). In comparison, viral resistant vari-
ants emerged in peg-IFN/VX-950 combination treatment within 14 days of treatment
(Reesinket al. (2006)). Similarly, in monotherapy with the NNI HCV-796, antivi-
ral resistance variants were selected within the first week of treatment (Villanoet al.
(2006)). Unfortunately, further studies with R1626 had cometo a halt, as dangerous
levels of neutropenia have been observed. However, R7128, another nucleoside ana-
logue, has also proven to have a high resistance barrier, with no resistance mutations
appearing after 4 weeks of therapy (Le Pogamet al. (2009)). Studies in the replicon
system have identified the NS5B polymerase amino acid substit tion S282T, which
confers a 3 to 4-fold decrease in susceptibility to R7128in vitro (Ali et al. (2008)).
However, a decrease in sensitivity was only observed when thS282T mutation was
present in a very high proportion of the quasispecies population in a patient (above
90 %) (Le Pogamet al. (2009)).
Many mutations conferring resistance to STAT-C agents alsosignificantly reduce vi-
ral fitness. This loss in viral replication competence can often be attributed to im-
paired enzymatic function. For example, A156T, which confers high-level resistance to
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many PIs, also greatly reduces the replication capacity of the virus (Linet al. (2005a);
Tonget al. (2006); Yiet al. (2006a); Cuberoet al. (2008)). However, not all resis-
tance mutations induce a loss in replication fitness, as shown in in vitro studies with
the replicon and the HCV cell culture system (Linet al. (2005a); Heet al. (2008)).
Results fromin vitro studies though, show some inconsistencies and do not always
coincide with clinical results (Le Pogamet al. (2009)). Studies with VX-950 have
shown that mutations conferring high level resistance wereassociated with lower lev-
els of viremia after the end of treatment, whereas resistantmutations conferring low
level resistance and having less impact on viral fitness weredominant. 3-7 months
after dosing, high level resistant variants had disappeared, th frequency of low level
resistant variants had decreased and wild type virus becamedo inant again. This
demonstrates the necessity of combination treatment of standard of care with STAT-C
to avoid the development of resistant mutations (Sarrazinet al. (2007a)). Importantly,
it has been shown that second-site compensatory mutations may partly rescue defects
in the viral fitness induced by a high level resistant mutation, enabling the high level
resistant variant to spread and dominate within a population (McCownet al. (2009)).
1.8.5 Prevention of antiviral resistance
As the development of resistance mutations in monotherapy with current drugs is al-
most certain, combination treatment with other STAT-C agents and/or IFN and rib-
avirin is inevitable. Ideally, drugs targeting different parts of the virus/viral lifecycle
are combined with each other and/or other agents targeting host proteins or supporting
the host immune system. Thereby the emergence of cross-resistance can be prevented.
This strategy is currently successfully used in HIV therapynd consists of at least 3 dif-
ferent drugs from at least 2 different “classes” of drugs. Typically therapies are based
on 2 nucleoside analogue reverse transcriptase inhibitors, plu either a PI or a non-
nucleoside reverse transcriptase inhibitor. Future HCV treatm nt regimes will most




In vitro studies have shown that compounds targeting different viral enzymes, such
as a PI and a polymerase inhibitor, generally do not select for cross-resistance mu-
tants and can be used in combination treatment. Nevertheless, it i possible to select
for cross-resistance mutations in combination therapy, ashas been shown in the repli-
con system. Culturing the subgenomic 1b replicon under the PIBILN 2061 and A-
782759, a polymerase inhibitor, selected not only for inhibitor specific, but also for
cross-resistance mutations. However, the replicons resistant to both compounds were
severely impaired in their replication kinetics and significantly lower in frequency,
demonstrating again the inverse relationship between impaired viral fitness and drug
susceptibility. Nevertheless, the inhibitors showed a synergistic effect and could re-
duce cellular replicon RNA levels over 7 log10 (Mo et al. (2005); Koevet al. (2007)).
Combinations of BILN 2061 or SCH 503034 with NNIs (A848837 and A837093) also
showed synergistic effects and were able to cure the replicon from the cells after long
term treatment, whereas monotherapy led to the developmentof resistance mutations
(Koevet al. (2006)). These studies provide encouraging results for future STAT-C
inhibitor combination therapy. Besides protease and polymerase inhibitor combina-
tions, it might also be possible to combine different NNIs, athey show lower cross-
resistance as discussed above. However, nucleoside polymerase inhibitors are likely to
play an important role in future combination treatments as they have a high barrier for
resistance development.
Because resistance mutations against STAT-C agents developso quickly, peg-IFN and
probably also ribavirin, will remain part of combination therapy for the near future.
Current clinical trials usually consist of a 8-12 week triplecombination therapy of
a STAT-C agent plus peg-IFN and ribavirin, which is followedby 12 weeks of peg-
IFN/ribavirin combination treatment. With this treatmentregime, an initial rapid de-
cline of viral load is achieved by the STAT-C agent and peg-IFN/ribavirin. The stan-
dard care of treatment (peg-IFN/ribavirin) is then continued to suppress any viral re-
bound. The ultimate goal though, is to develop STAT-C agent combinations that will
allow a rapid clearing of the virus and achieve a sustained virological response with-
out the need of peg-IFN and ribavirin. A step towards this goal has been taken by
Roche, who have recently completed a phase I clinical trial evluating the efficacy and
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safety of combination treatment with a HCV nucleoside analogue polymerase inhibitor
(RO5024048) and an HCV PI (RO5190591/ITMN-191).
1.8.6 Targeting host enzymes
Compared to STAT-C antivirals, targeting host enzymes essential for viral replication
provides the advantage of an intrinsically much higher barrier to resistance, as the virus
is not directly targeted. The first molecules identified in this class were the cyclophilin
inhibitors (Table 1.6). As described in section 1.2, cyclophilin B (CypB) enhances
the RNA binding activity of the RdRp NS5B and can be inhibited by CysA. DEBIO-
025, a CysA analogue, has advanced to phase II clinical trials, where it significantly
reduced RNA levels in combination with peg-IFN-α-2a (Flisiaket al. (2009)). Even
though DEBIO-025 targets a cellular protein, it has been report d to exert selective
pressure on the HCV genome, which led to the emergence of resistance mutations in
the replicon system (Robidaet al. (2007)).
Another interesting target is the cellular micro-RNA miR-122. miR-122 has been
shown to interact directly with the 5’UTR, thereby facilitatng the replication of RNA
(Joplinget al. (2005)). Therapies are currently being developed trying tosequester
miR-122 using nucleic acid technology. A very recent study with SPC3649, a nucleic
acid homologue to miR-122, has reported promising results inchimpanzees. Animals
treated with SPC3649 showed a long lasting suppression of viral RNA without HCV
rebound and no evidence of viral resistance or side-effects. As both binding sites of
miR-122 are conserved in all HCV genotypes and subtypes, it is likely that this kind
of treatment will be genotype-independent (Lanfordet al. (2010)). Moreover, other
possible targets include the 4 cellular receptors necessary for viral attachment and en-
try (Plosset al. (2009)) or the geranylgeranylation of host proteins required for RNA
replication (Yeet al. (2003); Kapadia & Chisari (2005)). The important issue with
targeting host cell proteins though is cellular toxicity ofc mpounds, which has to be
carefully considered when administering these drugs in longterm. Furthermore, several
phase I and II clinical trials are currently evaluating the eff ctiveness of immunodula-
tors, TLR agonists (selectively stimulate IFN production), A3AR agonists (tumour
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growth inhibitors), caspase and pancaspase inhibitors (anti-apoptotic), thiazolides (in-
terfere with virus maturation) and anti-inflammatory agents.
Table 1.6: HCV inhibitors targeting host enzymes and phase of development.
Compound Phase of development Company
Cyclophilin inhibitors
DEBIO 025 Phase II (IIb announced) Debiopharm
NIM811 Phase II Novartis
SCY-635 Phase Ib Scynexis
microRNA inhibitors
SPC3649 Phase I Santaris Pharma
Information presented in this table has been gathered from public sources, accuracy is not guaranteed.
Sources include company websites and the following public websites:
http://www.hcvdrugs.com
http://www.hivandhepatitis.com/hivhcv co inf articles.html
http://www.hcvadvocate.org/hepatitis/hepC/HCVDrugs.html
http://clinicaltrials.gov
Even though major achievements have been accomplished in the development of spe-
cific antiviral drugs targeting HCV in the last decade, still no STAT-C drug has been
approved. This is mostly due to the highly replicative nature of HCV infection and
the error-prone RdRp NS5B, which provide an enormous challengeto drug develop-
ment. In the near future, peg-IFN will therefore most likelyremain part of the standard
care of treatment. Hopefully though, multiple, direct-acting STAT-C agents that can be
used in combination to achieve a sufficiently high resistance barrier, will soon become





2.1 Sources of HCV Clones
pJFH1 and pJFH1-GND (AB047639) used in recombination construction were pro-
vided by T. Wakita (Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan)
(Wakitaet al. (2005)) and pFK JFH1/J6/C-846dg (Jc1) by R. Bartenschlager (Depart-
ment of Molecular Virology, University of Heidelberg, Heidlberg, Germany) (Pietsch-
mannet al. (2006)). pJ6CF (AF177036) and pH77* (differs from pH77 (AF011751) at
M1205T) were provided by J. Bukh (NIH, Hepatitis Viruses Section, National Institute
of Health, Bethesda, Maryland) (Yanagiet al. (1997, 1999)) and pHCV3a-Gla (p3a)
by E.A. McCruden (Division of Virology, Institute of Biomedical and Life Sciences,
University of Glasgow, Glasgow, UK) (Shawet al. (2003)). HC-J4 (p1b, D10750)
was described by Okamoto (Okamotoet al. (1992)). ED43* (p4a), differs from ED43
(Y11604) in 4 amino acids (T1048A, T1064I, I1160T, R1176A); EUH1480* (p5a) dif-
fers from EUH1480 (Y13184) by 9 amino acids (L1045V, F1061V,I1072T, L1081V,
K1117T, G1118R, R1122P, I1694V, T1695I) and EUHK2* (p6a) differs from EUHK2
(Y12083) in 6 amino acids (I1196V, K1094R, F1087S, D1065A, V1070L, P1085A).
Plasmids p4a, p5a and p6a were provided by Richard Elliot (Centre for Biomolecular
Sciences, University of St Andrews, St Andrews, UK). Differences between clones
and prototype sequences within the analysed NS3/4A region,were present in received
clones and likely arose during cloning. Huh7, Huh7.5 and polycl nal sheep anti-NS5A
serum were a gift from M. Harris (Institute of Molecular and Cellular Biology, Uni-
versity of Leeds, UK). Sequences of HCV isolates used for sequence diversity analysis
were retrieved from the HCV sequence database (Kuikenet al. (2005)) and the NCBI
GenBank. 570 NS3 and NS4A sequences of genotype 1a; 459 NS3 sequenc s of
genotype 1b; 242 NS3 and 180 NS4A sequences of genotype 3a; 39NS sequences of





Huh7 are human cells established from hepatoma tissue takenfrom a Japanese patient
with well-differentiated hepatocellular carcinoma. Theyhave a very low expression
of the exogenous dsRNA sensor Toll-like receptor 3 and show anenhanced permis-
siveness for the replication of HCV RNA (Lohmannet al. (1999); Nakabayashiet al.
(1982); Liet al. (2005a)). The Huh7.5 cell line is a highly permissive subclone from
the Huh7 cell line, with a defect in RIG-I signalling (Blighte al. (2002); Sumpteret al.
(2005)).
Huh7 and Huh7.5 cells were maintained in Dulbecco’s ModifiedEagle Medium (DME-
M, Invitrogen) supplemented with 4.5 g/l glucose, 2 mM L-glutamine, 10 % heat-inact-
ivated fetal calf serum (FCS, Harlan Sera-Lab), MEM non-essential amino acids (Invit-
rogen), 20 mM hepes (4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid) (Sigma),
100 U/ml penicillin and 100µg/ml streptomycin (Invitrogen) and incubated at 37°C,
5 % CO2 and 100 % relative humidity.
2.2.2 Harvesting and reseeding of cells
Adherent cells at 70-80 % confluency were removed from the flasks by trypsinisation.
Following the removal of growth medium and washing of the cells with phosphate
buffer saline (PBS), trypsin-ethylenediaminetetraaceticacid (EDTA) (0.05 % trypsin,
0.53 mM EDTA, Invitrogen) was added and left at 37°C until cels detached. An equal
volume of media was added to deactivate the trypsin. The cells w re then concentrated
at the bottom of an universal tube by centrifugation at 6,200× g for 5 minutes. Super-
natant was taken off, cells resupended in fresh medium and reseed d into a fresh tissue
culture flask at a ratio of 1:3.
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2.2.3 Freezing and thawing of cells
Cells were frozen if they were healthy and had not been passaged more than 2-3 times.
It was crucial that cells had not been grown to more than 70-80% confluency, as
they lose their susceptibility to HCV. After washing and trypsinisation, cells were pel-
leted, resuspended in 10 ml fresh medium and counted using a haemocytometer. Once
counted, cells were pelleted again and resuspended in freezing media at a concentra-
tion of 2-5× 106 cells per ml. Freezing media consisted of 10 % dimethyl sulfoxide
(DMSO) in 10 % FCS-DMEM. 1 ml of this cell suspension was then slowly frozen
in 1.5 ml Nunc cryovials within a freezing box containing isopr panol, at -80°C. The
slow freezing of the cells is crucial to allow water to escapefrom the cells, preventing
the damaging of cells. Isopropanol reduces the cooling to approximately 1°C/minute.
The following day cells were transferred to liquid nitrogen, storing them below -130°C
and thereby preventing the formation of damaging ice crystals.
Cells were thawed up again in a 37°C water bath. It was crucial to keep the cells on
dry ice while transporting and then thawing them as quickly as possible. Before the
cryovials were incubated at 37°C, their cap was loosened slightly to allow gases that
might have built up to escape. Cells in freezing media were then diluted in 10 ml fresh
media and pelleted at 6,200× g for 5 minutes. After pouring off the supernatant, the
pellet was resuspended in fresh media and cells were seeded into a fresh T25 flask.
The next day they were transferred to a T80 flask.
2.3 Extraction of Viral RNA
2.3.1 RNA extraction from patient plasma
HCV RNA was isolated form patient plasma using the QIAGEN RNeasykit according
to the manufacturer’s guidelines. 150µl patient plasma was mixed with 350µl RLT
buffer containing 1 %β-mercaptoethanol. To this 500µl 70 % ethanol was added,
mixed by pippeting, then transferred to an RNeasy mini spin column. The column
in a collection tube was subjected to 15 seconds centrifugation at 8,000× g. The
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flow through was disposed of and the RNA bound to the silica membrane was washed
by adding 700µl RW1 buffer to the membrane and centrifuging at 8,000× g for 15
seconds. Two further washes were carried out with 500µl RPE buffer, centrifuging at
8,000× g for 15 seconds, then for 2 minutes. The column was transferred to a new
collection tube and spun for one minute at 8,000× g to dry the column and remove
excess ethanol which would affect the purity of the RNA. The column was then placed
into an Eppendorf tube, 30µl RNase free water added to the membrane and incubated
for one minute. To elute the RNA, the column was spun at 8,000× g for one minute.
The elution was repeated using the 30µl eluate. Purified samples were stored at -80°C.
2.3.2 RNA extraction from virally infected cells
To extract RNA from virally infected cells, cells were detached from tissue culture
wells by trypsination and pelleted by centrifugation at 6,200× g for 5 minutes. About
1× 106 infected cells were lysed using 350µl RLT buffer containing 1 %β-mercapto-
ethanol. The cell lysate was directly pipetted onto a QIAshedder spin column placed
in a 2 ml collection tube and centrifuged for 2 minutes at fullspeed. One volume of
70 % ethanol was added to the homogenised lysate and mixed well by pipetting. Up to
700µl of the sample was transferred to an RNeasy mini spin column and purification
proceeded as described above.
2.3.3 RNA extraction from cell culture supernatant
Alternatively, the QIAamp viral RNA kit from QIAGEN was used to extract viral RNA
from cell culture supernatant. 140µl cell culture supernatant was added to 560µl
AVL buffer containing carrier RNA at a concentration of 1µg/µl. The carrier RNA
helps the binding of viral nucleic acid to the QIAamp mini membrane and reduces
the chance of degradation of the viral RNA by RNases, which might have escaped
degradation by AVL. After pulse-vortexing for 15 seconds, the sample was incubated
at room temperature for 10 minutes. The tube was briefly centrifuged to remove drops
from inside the lid before 560µl ethanol (96-100 %) was added. The sample was again
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mixed by pulse-vortexing for 15 seconds and the tube briefly cntrifuged, before 630µl
of the sample was applied to a QIAamp mini column. The column was centrifuged at
8,000× g for one minute then placed into a new collection tube. The rest of the sample
was applied to the QIAamp mini column and the spin step repeatd. The column was
then washed by applying 500µl of AW1 buffer to the centre of the column, followed
by centrifugation at 8,000× g for one minute. A second wash step was performed by
adding 500µl AW2 buffer to the column and centrifugation at full speed for2 minutes.
The QIAamp mini column was placed into a new collection tube and centrifuged at full
speed for one minute to remove residual buffers. To elute theRNA, the column was
placed into a clean Eppendorf tube and 40µl AVE buffer added. Following incubation
for one minute, the column was centrifuged at 8,000× g for one minute. To increase
the concentration of the viral RNA, the eluate was passed through the column a second
time. Purified samples were stored at -80°C.
2.4 First-strand cDNA Synthesis by Reverse Transcrip-
tion
Reverse transcription was performed in a 20µl reaction volume which contained the
following: 500 ng total or 5µl viral RNA and DNase/RNase-free water to a final vol-
ume of 8µl. The mixture was heated for 10 minutes at 70°C and then chilled on ice
for 5 minutes. The tubes were kept on ice and 4µl of 25 mM MgCl
2
, 2µl reverse
transcription 10X buffer, 2µl of 10 mM dNTPs, 0.5µl recombinant RNasin ribonu-
clease inhibitor, 2.8µl of 0.1 mM random primers and 15 Units (U) of AMV reverse
transcriptase were added. The reaction mixture was first incubated for 10 minutes at
room temperature, then for 50 minutes at 42°C. To inactivate the reverse transcriptase,




2.5 Plasmid Dilution Series
To test primers and optimise the PCR reaction, plasmid dilution series were used. Pa-
rameters varied for optimisation included annealing temperature, MgCl
2
and DMSO
concentrations and elongation time. Plasmid pH77* (genotype 1a) and pHCV3a-Gla
(genotype 3a) were diluted in tris-sodium chloride-EDTA (TNE) buffer, containing
250 pg/ml herring DNA. Final dilutions contained 4.4× 109 DNA molecules perµl
for dilution 1, then 10-fold dilutions were prepared down to4.4 molecules of DNA per
µl in dilution 10.
2.6 Polymerase Chain Reaction
Polymerase chain reaction (PCR) was performed to amplify nucleic acids for down-
stream applications. All PCR and RT-PCR reactions were performed using a TECHNE
Flexigene thermocycler. Depending on the downstream application, 3 different ther-
mostable polymerases were used. Fragments used for cloningwere amplified using
the high-fidelity VentR® polymerase (New England BioLabs (NEB)). All primers were
made up to a concentration of 10 OD/ml (OD, optical density),sequences are shown in
Appendix A. PCR reactions were set up in a 50µl reaction volume. Reagents used for
the Vent PCR are listed in Table 2.1 and the thermal cycling carried out in Table 2.2.
Table 2.1: Reagents used for Vent PCR.
Reagent Quantity
10X ThermoPol reaction buffer 5µl
10 mM dNTPs 1µl
Sense primer (10 OD/ml) 0.5µl
Anti-sense primer (10 OD/ml) 0.5µl
Template DNA 5µl
VentR DNA polymerase (2 U/µl) 0.5µl
DNase/RNase-free water to 50µl
Table 2.2: Vent PCR protocol.
# Cycles Temperature Time
1 95°C 2 minutes
35 95°C 30 seconds
55°C 30 seconds
72°C 90 seconds
1 72°C 5 minutes
The 10X reaction buffer contained: 20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM KCl,
2 mM MgSO
4
and 0.1 % Triton X-100 at pH 8.8. A non-template (deionized (d) H2O)
control was used in every PCR run to test possible contaminatio of the reagents. PCR
68
Materials and Methods
products were analysed by agarose gel electrophoresis (0.7-2 % agarose gel, depending
on the size of the product).
Fragments which could not be amplified successfully with VentR polymerase were
amplified using the high-fidelity KOD polymerase (Novagen).PCR reactions were set
up in a 50µl reaction volume. Reagents used in the KOD PCR are listed in Table 2.3
and the thermal cycling carried out in Table 2.4.
Table 2.3: Reagents used for KOD PCR.
Reagent Quantity




2 mM dNTPs 5µl
Sense primer (10 OD/ml) 1.5µl
Anti-sense primer (10 OD/ml) 1.5µl
Template DNA 5µl
KOD Hot Start polymerase (1 U/µl) 1 µl
DNase/RNase-free water to 50µl
Table 2.4: KOD PCR protocol.
# Cycles Temperature Time
1 95°C 2 minutes
35 95°C 20 seconds
55°C 10 seconds
72°C 10 seconds/kb
kb, kilo base pair
The enzyme buffer contained: 50 mM tris-HCl, 1 mM DTT, 0.1 mM EDTA, 50 % glyc-
erol, 0.001 % Nonidet P-40 and 0.001% Tween-20 at pH 8.
For diagnostic PCR and for sequencing of the amplified fragments standard GoTaq
DNA polymerase (Promega) was used. PCR reactions were set up in a 30µl reaction
volume. Reagents used in the GoTaq PCR are listed in Table 2.5 and the thermal
cycling carried out in Table 2.6.
Table 2.5: Reagents used for GoTaq PCR.
Reagent Quantity
5X GoTaq Mix (7.5 mM MgCl
2
) 6µl
10 mM dNTPs 0.6µl
Sense primer (10 OD/ml) 0.3µl
Anti-sense primer (10 OD/ml) 0.3µl
Template DNA 3µl
GoTaq DNA polymerase (5 U/µl) 0.2µl
DNase/RNase-free water to 30µl
Table 2.6: GoTaq PCR protocol.
# Cycles Temperature Time
1 95°C 2 minutes
35 95°C 30 seconds
55°C 30 seconds
72°C 90 seconds
1 72°C 5 minutes
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2.7 One Step RT-PCR and Amplification of Viral RNA
The reverse transcriptase-polymerase chain reaction (RT-PCR) followed by a second
round, nested, PCR reaction was used to amplify the N-terminal protease of the NS3
gene and the NS4A gene of HCV subtypes 1a, 1b, 3a, 4a and 6a, fromclinical strains.
For the RT-PCR step, the Access Reverse Transcriptase PCR kit (Promega) or the
SuperScriptTM III One-Step RT-PCR System with Platinum®Taq DNA polymerase was
used. The Promega Access kit PCR reactions were set up in a 50µl reaction volume.
Reagents used in the Access RT-PCR are listed in Table 2.7 and the thermal cycling
carried out in Table 2.8.
Table 2.7: Reagents used for Access RT-PCR.
Reagent Quantity




10 mM dNTPs 1µl
Sense primer (10 OD/ml) 1µl
Anti-sense primer (10 OD/ml) 1µl
Extracted viral RNA 10µl
AMV RT polymerase (5 U/µl) 1 µl
Tfl DNA polymerase (5 U/µl) 1 µl
DNase/RNase-free water to 50µl
Table 2.8: Access RT-PCR protocol.
# Cycles Temperature Time
RT step 48°C 45 minutes
1 94°C 2 minutes
35 94°C 36 seconds
55°C 30 seconds
68°C 2 minutes
1 68°C 5 minutes
For the second step PCR reaction, the first round PCR product wasamplified using
primers that anneal inside the primary reaction, performing nested PCR.
Alternatively, the SuperScriptTM III One-Step RT-PCR System with Platinum® Taq
DNA polymerase (SC) was used. The outer primers were used to initiate the RT step
to generate a cDNA and the following first round PCR product. SCRT-PCR reactions
were set up in a 25µl reaction volume. Reagents used in the SC RT-PCR are listed
in Table 2.9 and the thermal cycling carried out in Table 2.10. The 2X reaction buffer
contained: 0.4 mM of each dNTP and 3.2 mM MgSO
4
.
If the RT-PCR amplification was not successful, a second round, nested PCR was
performed using primers that anneal inside the first amplificat on product. For this,
oligonucleotide primers flanking the NS3 protease gene or the NS4A gene were de-
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Table 2.9: Reagents used for SC RT-PCR.
Reagent Quantity
2X Reaction buffer 12.5µl
Sense primer (10 OD/ml) 0.25µl
Anti-sense primer (10 OD/ml) 0.25µl
Extracted viral RNA 5µl
SuperscriptTM III RT/Platinum®Taq mix 1µl
DNase/RNase-free water to 25µl
Table 2.10:SC RT-PCR protocol.
# Cycles Temperature Time
RT step 43°C 60 minutes
20 53°C 1 minute
55°C 1 minute
1 70°C 15 minutes
1 94°C 2 minutes
35 94°C 30 seconds
54°C 30 seconds
68°C 90 seconds
1 68°C 5 minutes
signed (Table A.1, A.2 and A.4, Appendix A). Second round primers were designed to
introduce restriction sites to the NS3 fragment or NS4A for future cloning purposes.
NotI was added to the 5’NS3 sense primer andSpeI to the 3’NS3 anti-sense primer.
Alternatively, aBstBI restriction site was added to the 5’NS3 sense primer and aBglII
site to the 3’NS3 anti-sense primer (Table A.5, Appendix A).SapI restriction site
was added to the 5’NS4A sense primer and aMluI site to the 5’NS4A anti-sense primer
(Table A.6, Appendix A). Second round PCR was performed as describ d above. To
test whether HCV RNA isolation was successful, primers which cover the core re-
gion were used as a control (Table A.7, Appendix A). PCR products were used for
sequencing without any further purification.
2.8 Agarose Gel Electrophoresis
Analysis of DNA and RNA was performed by agarose gel electrophoresis. Depending
on the size of the DNA or RNA 0.7-2 % agarose gels were prepared using 1X tris-
acetate-EDTA (TAE) buffer with 0.5µl ethidium bromide (EtBr). Samples were mixed
with 10X loading buffer and loaded into the wells of the agarose gel. To separate
different fragments of the nucleic acid, an electric current of 150 V was applied for
30-60 minutes, depending on the size of the fragments. As a size marker a DNA ladder
of 10 kb or 1,000 bp (base pair) was used. Nucleic acid fragments were visualised
using an ultraviolet (UV) transilluminator. EtBr intercalates into the DNA and exhibits
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fluorescence under UV light, thereby allowing the visualisation of the DNA/RNA.
2.9 Sequencing
Sequencing of PCR products and purified plasmids was performed using the ABI
BigDye terminator technology. To sequence the NS3 protease regions, primers an-
nealing outside the NS3 protease gene region where designed, which can be found in
Table A.11 and A.13, Appendix A. The primers used for sequencing of NS4A and
the rest of the HCV genome can be found in Table A.9, A.10 and A.12, Appendix A.
The sequencing reactions were set up in a 20µl reaction volume. Reagents used in the
sequencing reaction are listed in Table 2.11 and the sequencing protocol carried out in
Table 2.12.
Table 2.11:Reagents used for sequencing.
Reagent Quantity
PCR product 1-4µl
or plasmid DNA 300-500µg
BIG Dye 1µl
Primer (10 OD/ml) 1µl
dH2O to 20µl
Table 2.12:Sequencing reaction protocol.
# Cycles Temperature Time
25 95°C 30 seconds
50°C 20 seconds
60°C 4 minutes
1 68°C 5 minutes
Sequencing reactions were sent to the departmental sequencing fa ility and results
were returned in the AB1 file (Chromas) and SEQ file format. Sequence analysis was
performed using the Simmonics2005v1.8 software.
2.10 Restriction Digest
Digestion reactions were set up as follows: 1-10µg DNA, 5µl 10X restriction enzyme
buffer 1, 2, 3 or 4 (NEB), 0.5µl 100X bovine serum albumin (BSA), 0.3-1µl restric-
tion enzyme (1 U/µg DNA) and nuclease-free water to a final volume of 50µl. The





To prevent recircularisation of digested vectors in ligation reaction, the 5’ phosphate of
the vector was removed using Antarctic Phosphatase (AP) (Invitrogen). Phosphatase-
treated vectors lacking the 5’ phosphoryl termini requiredby the ligase, cannot self-
ligate and vector background is thereby reduced. Dephosphorylati n reactions were
set up as follows: 1-10µg DNA, 5µl 10X restriction enzyme buffer 1, 2, 3, 4 (NEB)
or 10X AP reaction buffer (NEB), 0.3-2µl AP (1 U/µg DNA) and DNase/RNase-free
water to a final volume of 50µl. The reaction mixture was incubated for 30 minutes at
37°C and the enzyme heat inactivated through incubation for5 minutes at 65°C.
2.12 Purification of PCR Products
To purify single banded, digested PCR products up to 10 kb, theQIAquick PCR pu-
rification kit was used. In brief, 5 volumes of buffer PB were added to one volume of
the digestion reaction and mixed by pippeting. To bind, the DNA sample was applied
to the QIAquick column and the column was centrifuged for oneminute at 17,900×
g. Flow-through was discarded and 750µl of buffer PE was added followed by one
minute centrifugation at 17,900× g. To remove any residual ethanol, an additional
centrifugation step of one minute at 17,900 x g was performed. After adding 30µl elu-
tion buffer (EB, 10 mM Tris-HCl at pH 8.5), the column was incubated for one minute,
before DNA was eluted by centrifugation at 17,900× g for one minute. Samples were
stored at -20°C for further experiments.
2.13 Gel Purification
Digested plasmids or amplified PCR products with multiple bands were separated by
gel electrophoresis and DNA visualised under long wavelength UV light. The appro-
priate band on the gel was excised using a sterile blade, weighed and purified using the
QIAGEN gel extraction kit for fragments of up to 10 kb. Three volumes of buffer QG
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were added and the sample incubated at 50°C until completelydissolved. One volume
of isopropanol was added and the sample mixed before it was applied to a QIAquick
column and centrifuged for one minute at 17,900× g. The low pH conditions allowed
the DNA to bind to the silica membrane. Flow-through was discarded and the column
washed with 500µl QG buffer to remove any traces of agarose. A further wash step
was carried out by applying 750µl buffer PE and centrifuging for one minute at 17,900
× g. To ensure complete removal of residual ethanol, the QIAquick column was cen-
trifuged for an additional minute at 17,900× g. DNA was then eluted under basic and
low-salt conditions. To increase the yield of DNA, 30µl of EB was added to the centre
of the column and incubated for one minute, before it was centrifuged for one minute
at 17,900× g to elute the sample.
For fragments larger than 10 kb the QIAEX II gel extraction kit was used. The ap-
propriate band on the gel was excised using a sterile blade, weighed and 3 volumes
of buffer QX1 and 2 volumes of H2O added. For every 10µg DNA, 30µl QIAEX II
resins were added, mixed by flicking the tube and incubating for 10 minute at 50°C
to solubilise the agarose and bind the DNA. To keep the QIAEX II in suspension, the
mixture was mixed by flicking and inverting the tube every 2 minutes. The sample
was centrifuged at 17,900 x g for 30 seconds, the supernatanttaken off and the pel-
let washed with 500µl buffer QX1. Two further washes were carried out with 500µl
buffer PE. All wash steps consisted of resuspension of the sample in the wash buffer
and centrifugation at 17,900 x g for 30 seconds. The pellet was air-dried for 15 to 30
minutes or until it became white. To elute the DNA, 20µl buffer EB was added and
the pellet resuspended by flicking and inverting the tube. After 10 minutes incubation
at 50°C the solution was centrifuged at 17,900× g for 30 seconds. The supernatant
containing the DNA was taken off and transferred to a clean microcentrifuge tube. To




2.14 DNA Precipitation and Purification
To precipitate and purify DNA a phenol/chloroform extraction, followed by ethanol
precipitation was used. Samples smaller than 200µl were diluted in water to a final
volume of 200µl and an equal volume of phenol:chloroform:isoamyl-alcohol:25:24:1
added. Following vortexing for 30 seconds, samples were centrifuged at 17,900× g
for 5 minutes. The upper aqueous phase containing the DNA wasremoved and trans-
ferred to a new microcentrifuge tube. 200µl chloroform was added and the mixture
vortexed for 30 seconds. After centrifugation at 17,900× g for 5 minutes, the upper
aqueous phase containing the DNA was transferred to a new microcentrifuge tube and
DNA precipitated by adding 1µl glycogen, 0.1 volume of 5 M NaCl and 2 volumes of
ethanol (96-100 %). Following incubation on ice for 30 minutes, the precipitated DNA
was pelleted by centrifugation at 17,900× g for 30 minutes at 4°C. Supernatant was
carefully removed and the pellet washed by resuspension in 400µl 70 % ethanol and
centrifugation at 17,900× g for 15 minutes at 4°C. Supernatant was carefully removed
and the pellet redissolved in DNase/RNase-free water.
2.15 Bacterial Techniques
2.15.1 Bacterial cultures
Different strains ofE.coli were used. Transformed bacteria were grown on Luria-
Bertani (LB) plates with 1.5 % agarose or in LB medium, supplemented with appro-
priate antibiotics (100µg/ml ampicillin or 50µg/ml kanamycin). LB agar was poured
into Petri dishes with a diameter of 10 cm. Bacteria were plated on the LB agar sur-
face using a glass spreader and incubated inverted at 30°C for approximately 16 hours.
All incubations for bacteria were carried out at 30°C to reduce spontaneous mutations
within the plasmid. Single colonies were then picked to inoculate 5 ml of LB broth,
which was incubated at 30°C for approximately 16 hours with constant shaking at 200
rounds per minute (rpm) in an orbital shaker. 500µl of the cell culture was mixed with
500µl glycerol to generate a glycerol stock of the correspondingcolony for longterm
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storage at -20°C. The remaining culture was used for plasmid extraction using mini or
maxiprep kits, see section 2.15.3 and 2.15.4. All bacterialp ocedures were performed
under a flame ensuring aseptic conditions.
2.15.2 Transformation of chemically competent cells
Transformation of NEB 5-α E.Coli (subcloning efficiency). NEB 5-α E.Coli were
used for the transformation of intact plasmids dissolved inH2O or EB. 1-10 ng of
plasmid DNA was used to transform the bacterial cells according to the protocol pro-
vided by the supplier of the competent cells (NEB). In brief, half a vial (25µl) of com-
petent cells was thawed on ice, plasmid DNA added, mixed gently a d incubated on ice
for 30 minutes. Cells were then heat shocked at 42°C for 30 seconds and 250µl pre-
warmed super-optimal broth with catabolite repression (SOC) medium added. Vials
were incubated at 37°C for one hour with constant shaking at 200 rpm in an orbital
shaker. 50-100µl of the transformed bacteria were then plated on LB agar plates con-
taining the appropriate antibiotic and incubated overnight at 30°C.
Transformation of NEB 10-β competent E.Coli (high efficiency). Alternatively,
highly efficient NEB 10-β competentE.Coli were used for the transformation of liga-
tion products. The same protocol was followed as described aove for the NEB 5-α.
After the heat shock 500µl instead of 250µl SOC medium was added to the cells.
Transformation of TOP10 One Shot® chemically competentE.Coli (high efficiency).
For TOPO cloning reactions, see section 2.16.1, TOP10 One Shot® c emically com-
petentE.Coli (Invitrogen) were used for the transformation of ligation products. The
same protocol was followed as described above for NEB 5-α cells.
Transformation of XL1-Blue supercompetent cells. Plasmids modified by site di-
rected mutagenesis were transformed into XL1-Blue supercompetent cells (Strata-
gene). Protocol see section 2.16.3.
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2.15.3 Small scale plasmid DNA preparation (mini prep)
To isolate small amounts of plasmid DNA for diagnostic purposes (sequencing and
restriction digestions) the QIAprep spin miniprep kit was used. 5 ml of LB medium
supplemented with 100µg/ml ampicillin or 50µg/ml kanamycin was inoculated with
a single bacterial colony picked from an LB agar plate. Liquid cultures were incubated
overnight at 30°C and continuously shaken at 200 rpm. Bacteriwere then pelleted
by centrifuging at 6,200× g for 3 minutes. Pelleted bacterial cells were resuspended
in 250µl buffer P1 and transferred to a microcentrifuge tube. 250µl lysis buffer P2
was added and gently mixed by inverting the tube 4-6 times. Following the addition
of 350µl buffer N3 the tube was again mixed gently, then centrifugedat 17,900× g
for 10 minutes. The supernatant was transferred to a QIAprepspin column and the
column centrifuged for one minute at 17,900 x g to allow the DNA to bind to the
silica-gel membrane. The column was washed by adding 500µl buffer PB followed
by centrifugation at 17,900× g for one minute. A further wash step was carried out
by adding 750µl buffer PE and centrifuging at 17,900× g for one minute. To remove
residual wash buffer, the column was centrifuged for an additional minute. To elute
DNA, 50µl buffer EB was added, the column allowed to stand for one minute and
centrifuged at 17,900× g for one minute. The quality and purity of plasmid DNA
was assessed by spectrophotometry and test digests, followed by gel electrophoresis
on a 1.5 % agarose gel. Alternatively, enzymes were heat inacivated (65°C for 20
minutes) and plasmid DNA subjected to further treatments. Depending on the amount
of plasmid DNA, reaction mixtures were scaled up. Plasmid DNA was stored at -20°C.
2.15.4 Large scale plasmid DNA preparation (maxi prep)
For the extraction of large amounts of high quality plasmid DNA the QIAGEN plas-
mid maxi kit was used. 5 ml of LB medium containing the appropriate antibiotic,
100µg/ml ampicillin or 50µg/ml kanamycin, were inoculated with a single bacterial
colony picked from a LB agar plate. The starter culture was incubated for 8 hours at
30°C in an orbital shaker at 200 rpm. 500µl of the starter culture was used to inoc-
ulate 250 ml LB medium supplemented with the appropriate antibiotic and incubated
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for another 12-16 hours at 30°C and continuously shaken at 200 rpm. Bacteria were
pelleted by centrifugation at 6,000× g for 15 minutes at 4°C. Following the removal
of LB medium, pelleted bacterial cells were resuspended in 10 ml buffer P1. 10 ml
of buffer P2 was added, thoroughly mixed and lysis allowed toproceed for no more
than 5 minutes. After adding 10 ml of chilled buffer P3 to the lysate, the mixture was
thoroughly mixed, then immediately poured into the barrel of a QIAfilter cartridge and
incubated at room temperature for 10 minutes. The cell lysate w s then filtered into a
QIAGEN-tip previously equilibrated with 10 ml buffer QBT andallowed to enter the
resin by gravity. The QIAGEN-tip was washed twice with 30 ml buffer QC and DNA
eluted with 15 ml buffer QF. DNA was precipitated by the addition of 10.5 ml iso-
propanol and pelleted by centrifugation at 5,000× g for 60 minutes at 4°C. The pellet
containing the DNA was washed with 5 ml 70 % ethanol and centrifuged at 5,000× g
for 60 minutes. The supernatant was carefully decanted and the pellet air-dried for ap-
proximately 10 minutes before it was resuspended in 300µl DNase/RNase-free water
and stored at -20°C.
2.16 Molecular Cloning
2.16.1 TOPO cloning
For amplification, further cloning and to check insert sequence, NS3 fragments am-
plified by PCR were cloned into pCR®-blunt II-TOPO vector. The plasmid vector is
supplied linearised with Vaccinia virus DNA topoisomeraseI covalently bound to the
3’end of each DNA strand. Blunt-end PCR products can directly be inserted and no
DNA ligase is necessary. DNA fragments were amplified using primers described in
Appendix A and Vent Polymerase, giving 95 % blunt-ended PCR products. TOPO
cloning was performed according to the manufacturer’s usermanual. The cloning
reaction contained the following: 4µl PCR product, 1µl salt solution and 1µl TOPO-
vector. The reaction mixture was gently mixed, then incubated for 30 minutes at room
temperature. 2µl of the TOPO cloning reaction was used to transform TOP10 One
Shot® competentE.coli as described in section 2.15.2. Transformed bacteria were
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spread on a plate containing 50µg/ml kanamycin and incubated over night at 30°C.
The next day colonies were picked, grown up and plasmids isolated as described in
section 2.15.3. The quality and purity of plasmid DNA was asses ed by spectropho-
tometry and test digests followed by gel electrophoresis ona 1.5 % agarose gel. Insert
integrity was analysed by sequencing using M13 forward and M13 reverse primers (se-
quences can be found in Table A.11, Appendix A). Alternatively, a TOPO vector con-
taining a 100 bp insert was digested with restriction enzymes targeting the restriction
sites of the multiple cloning site and dephosphorylated. The linearised and dephospho-
rylated vector was purified from the insert and enzymes by gelpurification and used in
ligation reactions with inserts digested with the same restriction enzymes.
2.16.2 Colony PCR
To quickly identify colonies containing the correct insert, colony PCR was performed.
Primers annealing within the insert of interest were used for a ne-step PCR. The
PCR mixture was prepared and added to the PCR tubes. Using a pipette t individual
colonies were picked, a fresh LB agar plate touched and the rest immersed in the PCR
mix. The PCR reaction was performed as described in section 2.6. PCR products were
analysed on an agarose gel and sequenced.
2.16.3 Site directed mutagenesis
To introduce specific mutations into a desired plasmid, the QuickChange® site directed
mutagenesis kit (Stratagene) (QC) was used. The high fidelityPfuTurboDNA poly-
merase** and 2 primers containing the desired mutation/s are used to amplify a mu-
tated plasmid from supercoiled dsDNA. The parental plasmidis then digested with the
endonucleaseDpnI, which specifically targets methylated and hemimethylatedDNA.
The mutated, nicked and non-methylated DNA remains intact and c n be transformed




Primer design. For each desired mutation 2 primers annealing to the same sequence
on opposite strands and containing the same desired mutation were designed using
Simmonics2005v1.8 software and NetPrimer (PREMIER Biosoft International). A
maximum of 4 mutations per primer were introduced. A list of all primers used to
introduce mutations can be found in Table A.8, Appendix A. Prime s were designed to
be between 25 and 45 bp in length and to have a melting temperatur (Tm) above 78°C.
The desired mutation was designed to be in the middle of the primer. The minimum of
the GC content was 40 % and the termini contained desirably one or two G or C bases.
Mutant strand synthesis reaction. The reaction was set up in thin-walled tubes to
allow ideal contact with the temperature cycler’s heat block. The mutagenesis PCR
reactions were set up in a 25µl reaction volume. Reagents used in the QC PCR are
listed in Table 2.13 and the thermal cycling carried out in Table 2.14.
Table 2.13:Reagents used for QC PCR.
Reagent Quantity
10X Reaction buffer 2.5µl
Plasmid DNA 15 ng
Sense primer (5 OD/ml) 0.4µl
Anti-sense primer (5 OD/ml) 0.4µl
10 mM dNTP mix 0.5µl
DNase/RNase-free water to 25µl
PfuTurboDNA polymerase (2.5 U/µl) 0.5µl
Table 2.14:QC PCR protocol.
# Cycles Temperature Time
1 95°C 30 seconds
18 95°C 30 seconds
55°C 1 minute
68°C 1 minute/kb1
1 Total length of plasmid
Following temperature cycling the reaction mixture was placed on ice for 2 minutes.
To digest the parental supercoiled (non-mutated) dsDNA, 0.5µl Dpn I was added and
the reaction incubated at 37°C for one hour.
Transformation of XL1-Blue supercompetent cells. 25µl of XL1-Blue cells were
thawed on ice and 1µl of the Dpn I treated DNA added and gently mixed. Following
30 minutes incubation on ice, the cells were heat pulsed for 45 seconds at 42°C and
placed back on ice for 2 minutes. 500µl pre-warmed SOC medium was added and
the vial incubated at 37°C for one hour and constantly shakent 200 rpm in an orbital
shaker. 50-100µl of the transformed bacteria were plated on LB agar plates containing
the appropriate antibiotic and incubated overnight at 30°C.Individual colonies were
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picked, grown up in LB and plasmid DNA isolated as described in section 2.15.3.
More than 95 % of all colonies analysed contained the desiredmutation.
2.16.4 Construction of pJFH1 and Jc1-based intra- and intergeno-
typic recombinants
Nucleotide positions used for numbering are referred to accrding to their position in
the H77 reference strain, AF009606. pJFH1 contains the full-length HCV genome of
genotype 2a isolated from an Japanese patient with fulminant hepatitis (Wakitaet al.
(2005)). pJFH1-GND is the replication deficient negative contr l, encoding a GDD
to GND mutation in the NS5B RdRp polymerase (Katoe al. (2003)). Jc1 (pFK-
JFH1/J6/C-846 dg) is a recombinant containing the structural genes and part of NS2
from the genotype 2a isolate pJ6CF, and the remaining non-structural genes from the
genotype 2a isolate JFH1 with the cross-over point within NS2 (Pietschmannet al.
(2006)). The general cloning protocol consisted of digestion of the insert and the vector
with equivalent restriction enzymes. If the 2 restriction enzymes did not exhibit at least
75 % activity in the same buffer, sequential digests were performed. After the first
digest, DNA was precipitated with ethanol, redissolved in EB and the second digest
set up. To prevent self ligation of cut vector, the vector wasdephosphorylated using
AP. Digested insert and vector were purified by PCR and gel extraction purification
as described in section 2.12 and 2.13. Both insert and linearised vector were run on a
agarose gel to verify their size. Subsequently, a ligation reaction using a 1:10 molar
ratio of vector to insert DNA was set up. The ligation reaction had a final volume of
10µl and contained 300 ng DNA, 1µl 10X ligase buffer, 0.5µl T4 DNA ligase and
dH2O to a final volume of 10µl. To calculate the amounts of insert and vector required
for each reaction equation 2.1 was used
mv × lv
lv
× 0.1 = mi (2.1)
wheremv is the vector mass (ng),mi the insert mass (ng),lv the vector length (kb)
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andli the insert length (kb). The reactions were incubated overnight at 4°C, followed
by incubation for further 4-5 hours at 16°C. To estimate the ext nt of vector religation
and as a negative control, cut vector without insert was subjected to the same ligation
reaction. 2µl of the ligation reaction was then used to transform highly effici nt NEB
10-β competentE.Coli as described in section 2.15.2.
Replacement of the NS3 protease gene in pJFH1 using naturally occurring re-
striction sites (Fnxn). The NS3 protease gene was amplified by PCR from plasmid or
cDNA generated from patient plasma using corresponding genotype specific primers
containing the desired restriction sites. Primer sequences can be found in Table A.1
and A.2, Appendix A; primers -IS containNotI and -IA SpeI. For the amplification
of the protease the naturally occurring restriction sitesNotI (nt position 2945) and
SpeI (nt position 4094) were used. The 1149 bp long fragment includes the N-terminal
475 bp of NS2, the entire NS3 protease and the C-terminal 131 bpof the NS3 helicase.
PCR products were digested usingNotI and SpeI in a double digest in NEB buffer
2. Digested inserts were run on a gel to confirm their size, cleaned up and ligated
into pJFH1. pJFH1 was likewise digested withNotI andSpeI, dephosphorylated and
cleaned up.
Replacement of the NS3 protease gene using genetically engineered restriction
sites (Fx/Jx). To construct F1a, F1b, F2a, F3a, F4a, F5a and F6a aBstBI restric-
tion enzyme site was generated at the junction of NS2 and NS3 of the pJFH1 plasmid
and aBglII restriction enzyme site at the junction of the NS3 protease nd NS3 heli-
case domain. To reduce the possibility of PCR errors, the NS3 gene was subcloned
into Zero Blunt® TOPO using the naturally occurring restriction sitesNotI and SpeI.
QuickChange® site directed mutagenesis, see section 2.16.3, was used to introduce 2
silent point mutations to generate aBglII (C3398T and C3401G) and one to create a
BstBI site (G3993A). The entire length of the subcloned fragmentwas sequenced to
verify each of the introduced base changes and to make sure nofurther base changes
were introduced. The NS3 protease region was amplified from pH77* (genotype 1a)
with primer 1aBstBI and 1aBglII, introducing aBstBI and aBglII restriction site. The
same strategy was used to amplify the NS3 protease from genotype 1b-6a prototype
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plasmids using the corresponding genotype specific primers. P imers were designed
to include JFH1 (type 2a) sequence for the NS2 and NS3 helicasregion and the cor-
responding intra- or intergenotypic sequence for the NS3 protease region (nt position
3420-3963). Their sequence can be found in Table A.5, Appendix A. PCR products
were digested withBstBI and BglII, gel purified and ligated into pJFH1. pJFH1 has
similarly been digested withBstBI andBglII, dephosphorylated using AP and gel pu-
rified. Each introduced NS3 protease gene was verified by DNA sequence analysis. To
generate the corresponding Jc1-based recombinants (Jx), pJFH1-based recombinant
plasmids (Fx) were digested withNotI andSfiI, gel purified and ligated into Jc1 which
had likewise been digested withNotI andSfiI and dephosphorylated.
Replacement of the NS3 protease and NS4A cofactor gene usinggenetically engi-
neered restriction sites (Fxx/Jxx).To generate F1a1a, F1b1b, F2a2a, F3a3a, F4a4a,
F5a5a and F6a6a, 2 new restriction sites were introduced into pJFH1. To reduce the
possibility of PCR errors, a 4381 bp long JFH1 fragment including the NS4A cofactor
was subcloned into Zero Blunt® TOPO using the naturally occurring restriction sites
NsiI (nt position 5286) andXbaI (nt position 9667). ABlpI restriction site was gener-
ated by introducing one silent point mutation (C5297G) at theNS3 helicase and NS4A
junction and aMluI site at the NS4A and NS4B junction by introducing 4 point mu-
tations (T5478A, T5480G, A5481C, G5483T), were one was non-sile t. The NS4A
region was amplified from pH77* (genotype 1a) with primer 1aSapI and 1aMluI, in-
troducing aSapI (5’-end) and aMluI (3’-end) restriction site. The same strategy was
used to amplify NS4A from genotype 1b-6a prototype plasmidsusing the correspond-
ing genotype specific primers. Primers were designed to include JFH1 sequence up to
the start of the NS4A gene (nt position 5313) and from the end of the NS4A gene (nt
position 5474) to the restriction site. Primer sequences can be found in Table A.6, Ap-
pendix A. Products were digested withSapI andMluI, gel purified and ligated into the
TOPO vector containing the JFH1 insert digested withBlpI andMluI and dephospho-
rylated. A5478 was mutated back to T by site directed mutagenesis to recreate native
JFH1 amino acid sequence (Ala to Thr) outside of the NS4A region. To generate Fxx
and Jxx, TOPO vector including the modified insert was digested withNotI andSfiI,




Construction of adapted genomes.RNA was extracted from infectious supernatant
using the QIAmp viral RNA mini kit. If no infectious supernatan was generated,
RNA was alternatively extracted from cell pellets using QIAGEN shredder columns
followed by a QIAGEN RNeasy kit and a PCR product generated using Superscript III
RT-PCR. The primers JFH-s and JFH-as were used to amplify a 1.2 kb long fragment
encompassing the HCV NS3 protease, JFH-5230 and JFH-5536 fora 300 bp long frag-
ment encompassing the NS4A cofactor. Their sequences can befound in Table A.12
and A.13, Appendix A. The PCR-product was then subjected to bulk sequence deter-
mination or clonal sequence analysis. To generate J2a2a-C3538G (J2a2a-T1066S), J3a3a-
6-A3364G,A3478G,A4005T(J3a3a-6-Q1008,N1046S,T1222S), J5a5a-C3416G,T3968C,A4081T(J5a5a-Q1247L),
J6a6a-A3458G,G3459T(J6a6a-V1040L) and Jxx plus resistance mutation, the fragment en-
compassing the HCV NS3 protease was digested withSpeI andNotI and cloned into
the corresponding Jxx recombinant plasmids. To generate J33a- -C5328G,T5329C(J3a3a-
3-L1663A), J3a3a-8-C5328G,T5329C(J3a3a-8-L1663A) and Jxx plus resistance mutations, point
mutations were introduced by site directed mutagenesis andcloning. Modified frag-
ments were verified by sequencing.
2.17 RNA Transcription
Plasmid templates were linearised byXbaI (for pJFH1 and pJFH1 recombinants) or
MluI (for Jc1 and Jc1 recombinants) digestion at 37°C for 4 hours. After blunting
with Mung Bean Nuclease (NEB) at 30°C for 30 minutes, DNA was cleaned by phe-
nol/chloroform extraction followed by ethanol precipitaton. RNA was synthesised
from 1µg DNA template using the T7 RNA polymerase (Promega), incubating the
reaction mixture at 37°C for one hour. Following treatment with RNase-free DNase
for 15 minutes at 37°C, to remove template DNA, RNA was cleaned up using the
RNeasy kit. RNA concentrations and the integrity of the RNA wereanalysed by non-
denaturing agarose gel electrophoresis. RNA concentrations were determined using
spectrophotometry and 10µg aliquots were stored at -80°C until use.
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2.18 RNA Transfection into Huh7 and Huh7.5 Cells
RNA was transfected into Huh7 or Huh7.5 cells by electroporati n. Huh7/Huh7.5 cells
were washed with PBS and detached with trypsin. Cells were pellted by centrifuga-
tion (6,200× g for 7 minutes at 4°C), then resuspended in 10 ml chilled diethylpyrocar-
bonate (DEPC)-treated PBS and counted with a hemocytometer. Counted cells were
washed 3 times with 10 ml chilled DEPC-treated PBS (6,200× g for 7 minutes at 4°C),
then chilled on ice for at least 5 minutes. 10µg of RNA was mixed with 5× 106 cells
suspended in 400µl of chilled DEPC-treated PBS and transferred to an electroporation
cuvette (0.4 cm gap width, Bio-Rad). Electroporation consisted of one square wave
pulse for 25 ms of current delivered by the Bio-Rad Gene Pulser Xc ll electroporation
device, set at 150 V. Transfected cells were immediately resuspended in 4.5 ml 50:50
mix of conditioned and fresh complete growth medium (containing 10 % FCS), then
transferred into T25 flasks containing 10 ml complete growthmedium or seeded into
24-well plates containing coverslips for NS5A immunostaining. Cells were incubated
in the Cat III lab at 37°C, 5 % CO2 and 10 % relative humidity. Reaching 70-80 % con-
fluency (every 3-4 days) cells were passaged by trypsinationnd reseeding with a 1:3
to 1:4 split ratio into fresh culture vessels or 24-well plates for NS5A immunostaining.
Virus containing supernatant was collected, cleared of cell debris by centrifugation at
6,200× g for 4 minutes and stored at 4°C overnight or at -80°C for longterm. For su-
pernatant infectivity assays, collected supernatants were additionally filtered through a
0.2µm filter.
2.19 Immunostaining
Viral replication was assessed by anti-NS5A immunostaining. Polyclonal antibodies
have been raised in sheep against the non-structural protein NS5A. This was carried
out by M. Harris in Leeds. The polyclonal sheep anti-NS5A serum was used to de-
tect NS5A protein in Huh7 and Huh7.5 cells. Electroporated clls or split cells during
passaging experiments were seeded into 24-well plates containing cover slips and im-
munostained for NS5A when they were subconfluent. Followingfixation of cells in
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4 % paraformaldehyde for 20 minutes, plates were decontaminated on the surface with
5 % trigene and taken out of the Cat III lab. Subsequently, cells were washed 3 times
with PBS by adding 1 ml of PBS to each well and shaken for 5 minutes. C lls were then
permeabilised by adding 0.8 ml 0.01 % Triton-X 100 in PBS per well and incubated for
7 minutes. Following 2 further washes with PBS, cells were incubated with sheep anti-
NS5A serum diluted 1:5,000 in 400µl 10 % FCS PBS per well for one hour. After
cells were washed 2 times with PBS, bound NS5A-specific antibody was detected by
one hour incubation with Alexa Fluor 488 donkey anti-sheep IgG (Invitrogen), diluted
1:1,000 in 400µl 10 % FCS PBS per well. Cells were further washed once with PBS
and once with dH2O before NS5A-positive cells were detected using a fluorescence
microscope (Zeiss Axioskop 2 plus). For visualisation, coverslips were removed from
plates and mounted onto glasslides using 5µl Mowiol mounting medium. To deter-
mine percentage of positive cells and titres, 3 images per coverslip were taken from 2
coverslips per sample and the percentage of HCV-positive cells was determined using
the AxioVision 4.8 software. Low titre samples were measured by counting foci form-
ing units per millilitre (FFU/ml) or well, which can be single cells stained for NS5A
or groups of stained cells. Alternatively, the percentage of HCV-positive cells of the
total number of cells was determined, where 0 % is no cells infected and 100 % all
cells infected. Jc1 served as a positive and JFH1-GND as a negativ control. Staining
of 96-well plates was carried out similarly, with 100µl wash volumes and a volume of
50µl for antibody dilutions.
2.20 Determination of 50 % Tissue Culture Infectious
Dose in HCV Culture
Näıve Huh7.5 cells were seeded in 96-well plates the previous day at a concentration of
6 × 103 cells per well. The sample was serially diluted in complete growth media and
inoculated onto the cells at 10-fold dilutions with 6 replicates at each dilution. After
3 days incubation, cells were stained for NS5A as described in section 2.19. Viral
titres were determined by calculating tissue culture infectious dose at which 50 % of
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the wells were positive for viral antigen (TCID50). Wells were scored positive if at
least one positive cell was detected. TCID50 was calculated according to the method
of Reed and Muench (Reed & Muench (1938)).
2.21 Drug Inhibition Studies
Susceptibility towards the PIs BILN 2061 and VX-950.The HCV-specific PI BILN
2061 was resuspended at 5 mM in DMSO and VX-950 at 20 mM in DMSO.Näıve
Huh7.5 cells were seeded in 96-well plates the previous day at concentration of 6×
103 cells per well. The next day cells were infected for 8 hours with the correspond-
ing infectious supernatant at a multiplicity of infection (MOI) of 0.015, washed with
PBS and the media replaced with complete growth medium containi g 0.1 % DMSO,
as a carrier control, with or without the PI. Concentrations icreased from 0.1 nM
to 10,000 nM in 10-fold increments. After 3 days incubation,cultures were stained
for NS5A as described in section 2.19. Each concentration was assayed in triplicate.
Percentage of inhibition in supernatant infectivity was calculated from reduction in
FFU/ml after antiviral addition compared to FFU/ml in viruscontrol without antiviral
addition.
Alternatively, 10µg synthetic RNA was electroporated into Huh7.5 cells as described
in section 2.18, and seeded into 24-well plates containing cover slips. The next day
media was replaced with complete growth medium containing 0.1 % DMSO with or
without increasing concentrations of the PI. After 3 days incubation, cultures were
stained for NS5A as described in section 2.19. Antiviral efficacy was measured as
inhibition of RNA replication by staining for NS5A and determining the percentage
of HCV-positive cells. Each concentration was assayed in triplicate. For J2a2a 1µg
instead of 10µg was used to achieve an infection frequency of around 40 %. For J6a6a
cells were first passaged for 24 days to allow 40 % of the culture o be infected be-
fore the PI was added. Dose-response curves were fitted to a standard 4 parameter




y = yo +
a




wherey is the percent activity/inhibition;x the corresponding PI concentration;yo
percent activity/inhibition at the bottom of the fitted curve;a the test substance activity,
b the slope of the fitted curve andxo the calculated relative IC50 value. The IC50 is
defined as the concentration giving a response half way between the fitted top and
bottom of the curve.
2.22 In Vitro Selection of PI Resistant Recombinant
Viruses
Synthetic RNA of the recombinant viruses J1b1b, J2a2a-T1066S, J3a3a, J4a4a-19, J5a5a-
-Q1247Land J6a6a were electroporated into Huh7.5 cells as described in s ction 2.18 and
seeded into 12-well plates. Three (J1b1b and J4a4a-19) or 4 (J2a2a-T1066S, J3a3a and
J5a5a-Q1247L) days post-electroporation the PI was added and the cells serially passaged
under increasing PI concentrations. J6a6a was first passaged for 35 days before antivi-
ral addition. Alternatively, J6a6a-V1040L was used for selection experiments. During the
course of selection, infected cells were split when 70-80 % confluency was reached.
Fresh medium and PI were added every 3 or 4 days, regardless ofwhether the cell cul-
ture was split or not. Whenever the cell culture was split, cell p llets were collected,
total cellular RNA extracted and subjected to RT-PCR. To determine the frequency of
PI resistance mutations, 1.2 kb long RT-PCR products containi g the NS3 protease of
HCV RNA were ligated into the TOPO cloning vector, individual bcterial colonies
subjected to colony PCR and sequenced. Each passaging experiment was carried out
in duplicate and with a no antiviral control parallel passage.
A list of all primers can be found in Appendix A.
Common solutions and buffers are described in Appendix B.
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Chapter 3
Variability of the HCV NS3 Protease
and NS4A Cofactor Gene in Genotype
1a and 3a
3.1 Introduction
The ssRNA genome of HCV displays a high genetic diversity. Thisdiversity is due
to the error prone RdRp, the lack of a 5’-3’exonuclease to repaithe induced errors
and the rapid replication rate of HCV. An estimated 1012 virions are produced per day
in an infected individual (Neumannet al. (1998)). Along the genome, HCV displays
different degrees of genetic variability. The 5’UTR, 3’UTR and core show the highest
degree of sequence conservation across genotypes, whereasthe non-structural genes
NS2, NS3, NS5A and NS5B are relatively variable. The envelope proteins E1 and E2,
together with NS4 and the C-terminus of NS5A, display a high degre of inter- and
intragenotypic diversity (Pawlotsky (2006)). The differenc in sequence variability
within the different genome regions reflects the functionalconstraints of some proteins
(e.g., NS5B) and the immune pressure acting on others (e.g., E2). The intergenotypic
variability of the HCV genome has important implications in treatment efficacies. As
discussed in section 1.7.1, patients infected with genotype 1 and 4 respond more poorly
to IFN-α/ribavirin combination treatment than patients infected with genotype 2 and 3.
Genotype specific differences in efficacies have also been found to have implications in
treatment with STAT-C antivirals. For example, genotype 1 infected patients showed
higher response rates to the PI BILN 2061 than did genotype 2 and 3 i fected indi-
viduals (Lamarreet al. (2003); Reiseret al. (2005)). The considerable intragenotypic
genetic diversity of HCV is likely to further influence treatment response rates within
a genotype. To obtain the highest degree of treatment response rates within each indi-
vidual, an understanding of the intragenotypic diversity is crucial. A detailed map of
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not only inter- but also intragenotypic variability will help the targeted development of
new STAT-C compounds, which ideally should be equally effectiv in all individuals.
While the genetic diversity of HCV has been largely explored inthe envelope and
core domain, the NS3 protease region has not been investigated to the same extent.
Even though the NS3 protease domain is considered one of the less variable proteins,
different studies have reported variability in the nucleotide and amino acid sequence
(Holland-Staleyet al. (2002); Lodriniet al. (2003); Valletet al. (2005); Pawlotsky
(2006); Winterset al. (2006); Akhavanet al. (2009)). Holland-Staleyet al. reported
significant variability at both the nucleotide and amino acid sequence, with 11 % amino
acid variability in genotype 1a and 9.9 % in genotype 1b variants. The analysis was
further extended by Valletet al., who analysed the natural polymorphism on the quasis-
pecies level. They showed that the substitution rates were evenly distributed through-
out the NS3 protease gene and that the proportion of synonymous substitutions was
significantly higher than that of non-synonymous substitutions (Valletet al. (2005)).
This indicates that mutations within the NS3 protease gene rgion are predominantly
due to random genetic drift rather than positive selection pressure. Another study
(Lodrini et al. (2003)) reported that the domains involved in the protease enzymatic
function were highly conserved within genotype 1a and 1b variants, but showed some
variability in genotype 3 variants.
Together these studies suggest that the NS3 protease gene isflexible enough to tol-
erate substitutions despite the various functional and structu al constraints. NS4A
has been shown to be highly diverse, with only 50-60 % amino acid sequence simi-
larity within the antigenic region (amino acid 21-39) between genotypes 1, 2 and 3
(Simmondset al. (1993)). Elsewhere it was reported that the N-terminal predict
membrane segment (amino acid 1-20) and the C-terminal acidicdomain (amino acid
40-54) are highly conserved across genotypes (Brasset al. (2008)). Although data is
available on NS4A variability, it has not been systematically nalysed for intrageno-
typic variability.
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To analyse the natural genetic diversity within the NS3 protease and NS4A gene re-
gion, a nested PCR method was developed in this study. Primersreading into the
NS3 protease and NS4A gene were used to directly amplify the NS3 protease and
NS4A genes from clinical isolates and subjected to bulk sequencing. NS3 protease and
NS4A sequences were aligned and a consensus sequence generated using the Simmon-
ics2005v1.8 software. Nucleotide and amino acid sequence divergence were calcu-
lated with Simmonics and synonymous and non-synonymous nucleotide substitutions
relative to the consensus sequence identified. Finally, molecular modelling was used
to estimate the potential effect of genetic variability on enzyme structure.
3.2 Results
3.2.1 Patients
For the study of the NS3 protease gene diversity, the plasma of 29 genotype 1a infected
patients (3 women and 26 men) with a mean age of 43 years and of 32 genotype 3a
infected patients (7 women and 25 men) with a mean age of 39 years were analysed.
For the NS4A gene, plasma was analysed from 28 genotype 1a infected patients (9
women and 19 men) with a mean age of 41 and of 31 genotype 3a infected patients (5
women and 26 men) with a mean age of 39 years. The overall mean age was 40 years
with a range from 19-64 years.
3.2.2 Development of nested PCR reaction
The NS3 protease gene and the NS4A cofactor gene were amplified from plasma from
patients infected with genotype 1a or 3a. Primers flanking the NS3 protease and the
NS4A cofactor gene region were designed to include specific restriction sites for fur-
ther cloning purposes. Primers-1a/3a-NS3-OS and -OA were used for the RT-PCR
step, while primers NS3-1a/3a-IS and -IA were used for the second round nested PCR.
Second round -IS primers included aNotI restriction site, -IA aSpeI restriction site.
NS3-1a/3a-OMS, -MS, -MA and -OMA align in the middle of the protease gene and
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were used for sequencing. Sequences of primers can be found in Table A.1 and A.2,
Appendix A. To optimise PCR reactions, DMSO and MgCl2 concentrations were ad-
justed and primer sets optimised using serial dilutions of plasmids pH77* for genotype
1a and pHCV3a-Gla for genotype 3a primers. DMSO enhances the specificity of an
assay by lowering the effectiveTm of the primers through reduction of complex sec-
ondary structures. Lowering the MgCl2 concentration can further raise the specificity
of the PCR reaction, as the Mg2+-ion binds tightly to the phospate sugar backbone
of nucleotides and nucleic acids, thereby lowering theTm of the primer/template com-
plex. Adjusting the annealing temperature also influences th specificity of the PCR
reaction. The higher the annealing temperature, the betterthe specificity, but yield
might be reduced. Table 3.1 gives an overview of the investigated parameter combi-
nations. Amplification of the NS3 protease and the NS4A gene from patient plasma
resulted in a single band PCR product, which was subjected to sequencing. Figure 3.1
shows the PCR product from patients plasma infected with genotype 3a, which results
in a 823 bp fragment for the NS3 protease gene and a 644 bp product f r NS4A. PCR
amplification was successful in 40-70 % of reactions. The same PCR products were
generated for genotype 1a.
3.2.3 Investigation of nucleotide and amino acid sequence diver-
gence within the NS3 protease and NS4A gene region
NS3 protease amino acids were numbered from 1 (1027 absolutenumbering) to 181
(1207) and standard 3 letter code used. Amino acid numberingfor NS4A was from 1
(1658 absolute numbering) to 54 (1711) with lower case 4 (e.g., Ile254) to distinguish
NS4A numbering from NS3 protease numbering. The entire NS3 protease sequence
of 543 nucleotides, encoding 181 amino acids and the entire NS4A cofactor sequence
of 162 nucleotides, encoding 54 amino acids were aligned. Intotal 29 NS3 protease
variants from genotype 1a and 32 variants from genotype 3a, as well as 28 NS4A
isolates of genotype 1a and 31 variants of genotype 3a were analysed.
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Table 3.1: PCR parameter optimisation.To optimise the PCR reaction, the DMSO
concentration, the MgCl2 concentration and the annealing temperature were adjusted.
Final settings used are in bold.
Agent Variation
DMSO 1.0 % 1.5 % 2.0 % 2.5 % 5.0 % 7.5 % 10.0 %
MgCl2 1.0 mM 1.5 mM 2.0 mM 2.5 mM 3.0 mM 3.5 mM
Temperature 50°C 52°C 52.5°C 53°C 55°C 57.5°C 60°C
Figure 3.1: Amplification of the NS3 protease and NS4A gene of genotype 3a using
nested PCR.Primers flanking the NS3 protease and NS4A gene region were designed
to introduce restriction sites on both ends for future cloning purposes. Amplification
of the NS3 protease gene of genotype 3a resulted in a 823 bp product, left-hand side.
Amplification of the NS4A gene of genotype 3a resulted in a 644 bp product, right-hand
side. MW, molecular weight marker.
A consensus sequence was generated for the NS3 protease and NS4A gene, respec-
tively, by incorporating all the sequences belonging to thesame genotype. Figure 3.2
shows the amino acid alignment of genotype 1a NS3 protease sequ nces to the 1a con-
sensus sequence and Fig. 3.3 that of genotype 3a NS3 proteasesequ nces to the 3a
consensus sequence. The NS4A amino acid alignment of genotype 1a and 3a vari-
ants to their respective consensus sequence is depicted in Fig. 3.4. The subtype 1a
consensus sequence differed from that of the 1a prototype strain H (NCBI accession
number M62321) at 2 positions (Ile48Phe and Ser91Ala) within t e NS3 protease; the
subtype 3a consensus sequence differed to that of the prototype s rain pHCV3a-Gla at
3 positions (Ile48Val, Thr91Ala and Thr179Ala) within the NS3 protease. Ten spo-
radic amino acid changes were found in the NS3 protease sequences of genotype 1a
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variants, 15 in that of genotype 3a variants. A mean nucleotid and amino acid se-
quence divergence between the variants of the same genotypewas calculated using the
Simmonics2005v1.8 software. Analysis of the genotype 1a NS3 protease sequences
showed a mean sequence divergence of 7.6 % on the nucleotide level, and 2.5 % on
the amino acid level between the 29 analysed variants. Out of181 amino acids, sub-
stitutions were identified at 25 positions (13.8 %). Between the 32 genotype 3a NS3
protease sequences a mean sequence divergence of 6.9 % on thenucleotide level and
2.7 % on the amino acid level was calculated. Out of 181 amino acids, substitutions
were identified at 29 positions (16 %). No insertions or deletions were detected.
The consensus sequence of the genotype 1a NS4A variants differe to the HCV H
strain prototype sequence at one amino acid position (Val29Ile4); the consensus se-
quence of genotype 3a NS4A was identical to the prototype pHCV3a-Gla amino acid
sequence. Five sporadic amino acid substitutions were found in genotype 1a variants
and all 6 substitutions identified in genotype 3a variants were sporadic. Within the
NS4A gene a mean sequence divergence of 7.4 % on the nucleotide level and 3.7 %
on the amino acid level between the 28 analysed genotype 1a variants was identified.
For genotype 3a NS4A genes the calculated mean sequence divergenc was 5.3 % on
the nucleotide level and 0.7 % on the amino acid level betweenth 31 analysed vari-
ants. Overall 8 out of 54 (14.8 %) amino acids within genotype1a variants and 6 out
of 54 (11 %) within genotype 3a variants were substituted compared to the consensus
sequence. Table 3.2 summarises the genetic variability within the NS3 protease and
NS4A nucleotide and amino acid sequence in genotype 1a and 3avariants.
Types of amino acid substitutions
The amino acid sequences of clinical variants were comparedto the consensus amino
acid sequence and amino acid substitutions relative to the consensus sequence iden-
tified. In Fig 3.2 and 3.3, conservative as well as non-conservative amino acid sub-
stitutions away from the consensus sequence, together withthe functional domains of
the NS3 protease are indicated. The most frequent non-conservativ amino acid sub-
stitutions were represented by non-polar to polar substitutions, followed by a change
from amino acids with a neutral side chain to amino acids witha charged side chain,
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e.g., the non-polar amino acid Ala was often replaced by the polar amino acid Thr. A
common change from an amino acid with a neutral side chain to oe with a positively
charged side chain was a Gln to Lys substitution. Table 3.3 gives an overview of all the
physico-chemical types of substitutions in the NS3 protease sequences of genotype 1a
and 3a variants.
None of the genotype 1a or 3a variants showed any substitutions in the catalytic triad,
constituted of His57, Asp81 and Ser139. No variant was identfi d that contained any
of the described resistance mutations for PIs at position 36, 41, 43, 54, 109, 155,
156, 168 and 170 (Tonget al. (2006); Bartelset al. (2008); Cuberoet al. (2008);
Kuntzenet al. (2008); Heet al. (2008)). Furthermore, no variant had an amino acid
substitution within the zinc binding site Cys97, Cys99, Cys145and His149, the S1
substrate binding pocket Ile/Leu132, Leu135, Phe154 and Ala157 or the S2 substrate
binding pocket Arg155, Arg123, Arg/Lys161, Arg/Gln165 andAsp/Gln168. Gly137,
which is part of the oxyanion hole, was not substituted either. Val29 and Ile/Leu64,
which are involved in the contact with the NS4A amino acid Ile254, are substituted in
several genotype 1a variants but in no genotype 3a variants.One genotype 1a variant
and 9 genotype 3a variants had an Ala to Thr change at position7 within the NS4A
binding site, which is highly conserved among the remainingresidues (amino acid
1-22). Apart from highly polymorphic sites at position 40 and 174 in genotype 1a
and position 7, 98 and 176 in genotype 3a, amino acid substitutions were evenly dis-
tributed throughout the protease gene. The diversity of theNS3 protease gene was
further evaluated by determination of the type of nucleotide substitution. The propor-
tion of nucleotide sites with substitutions were divided into synonymous (no amino
acid change) and non-synonymous (resulting in amino acid change). Within genotype
1a variants the proportion of synonymous nucleotide substitutions was 25.1 %, that
of non-synonymous substitutions 1.3 %. For genotype 3a variants the proportion of
synonymous nucleotide substitution was 22.2 % and 1.3 % for non-synonymous sub-
stitutions. In both cases the proportion of synonymous substit tions is significantly
higher than the proportion of non-synonymous substitutions, suggesting that the sub-
stitutions away from the consensus sequence arose due to rand m genetic drift rather
than positive selection pressure.
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Most amino acid substitutions away from the consensus sequence in NS4A were con-
servative, with only one non-conservative amino acid substitution within a genotype 3a
variant and a polymorphic site at position 46 including non-c servative amino acid
changes within the genotype 1a variants (Fig. 3.4). The overall diversity of NS4A
within a genotype is rather low when compared to the high heterogeneity between
genotypes within the antigenic region (Simmondset al. (1993)). The proportion of
synonymous nucleotide changes was significantly higher than t e proportion of non-
synonymous substitutions within genotype 1a variants (23.5 % versus 2.1 %) as well
as in genotype 3a variants (20.9 % versus 0.4 %). This suggests a natural sequence di-
vergence arisen through random genetic drift as described aove for the NS3 protease
gene.
Table 3.2: Nucleotide and amino acid sequence divergence within the NS3protease
and NS4A gene.The nucleotide (nt) and amino acid (aa) sequence divergencebetween
the NS3 protease sequences from different clinical variantswas analysed using p-value
calculations and are shown in column 2 and 3. 29 genotype 1a and32 genotype 3a
sequences were analysed. Likewise the nt and aa sequence divergenc between the
NS4A sequences of 28 genotype 1a and 31 genotype 3a variants were analysed. The
proportion of synonymous nt substitutions and non-synonymus nt substitutions are
shown in the forth and fifth column.
Gene nt sequence aa sequence Synonymous nt Non-synonymous
divergence divergence substitutions nt substitutions
1a NS3 protease 7.6 % 2.5 % 25.1 % 1.3 %
3a NS3 protease 6.9 % 2.7 % 22.1 % 1.3 %
1a NS4A 7.4 % 3.7 % 23.5 % 2.1 %
3a NS4A 5.3 % 0.7 % 20.9 % 0.4 %
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Figure 3.2: Amino acid alignment of full-length NS3 protease sequences (residues
1 (1027) to 181 (1207)), from 29 variants of genotype 1a to theconsensus sequence.
Amino acid residues are indicated by standard single-letter codes. The consensus se-
quence is listed on the top line and points indicate residuesid ntical to the consensus
sequence. Colour code: Red: catalytic triad His57, Asp81 andSer139; Dark blue:
zinc binding residues Cys97, Cys99, Cys145 and His149; Light blue: NS4A bind-
ing site; Purple: S1 binding pocket Ile132, Leu135, Phe154 and Ala157; Green: S2
binding pocket Arg123, Arg155, Arg161, Lys165 and Asp168; Black: conservative
substitutions; Orange: non-conservative substitutions.
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Figure 3.3: Amino acid alignment of full-length NS3 protease sequences (residues
1 (1027) to 181 (1207)), from 32 variants of genotype 3a to theconsensus sequence.
Amino acid residues are indicated by standard single-letter codes. The consensus se-
quence is listed on the top line and points indicate residuesid ntical to the consensus
sequence. Colour code: Red: catalytic triad His57, Asp81 andSer139; Dark blue:
zinc binding residues Cys97, Cys99, Cys145 and His149; Light blue: NS4A binding
site; Purple: S1 binding pocket Leu132, Leu135, Phe154 and Ala157; Green: S2
binding pocket Thr123, Arg155, Arg161, Lys165 and Gln168; Black: conservative
substitutions; Orange: non-conservative substitutions.
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Figure 3.4: Amino acid alignment of full-length NS4A sequences (residues 1 (1658)
to 54 (1711)), from 28 genotype 1a variants (a) and 31 genotype 3a variants (b) to
their consensus sequence.Amino acid residues are indicated by standard single-letter
codes. The consensus sequence is listed on the top line and points indicate residues
identical to the consensus sequence. Blue: N-terminal membrane segment (highly con-
served); Red: amino acids essential for cofactor activity;Pink: kink segment; Green:




























Table 3.3: Physico-chemical types of substitutions in the NS3 proteasof genotype 1a and 3a variants aligned to their consensus
sequence. Amino acid residues are indicated by standard single-letter code. Substitutions away from the consensus sequence were
sorted according to their physico-chemical properties andlisted if they occurred in at least 2 variants.
Type of substitutions 1a NS3 protease 3a NS3 protease 1a NS4A 3a NS4A
Hydrophobic to hydrophobic V29A, G31A, V33I, V48I, A67V, I29V4, I37V4
A40G, I64L, P67A, V107I, I170V
V71I, A87V
Polar neutral to polar neutral Q89N, H110Q, N174S N176S
Polar basic to polar basic R24K, R62K K34R4, R41K4
Polar acidic to polar acidic D110E
Hydrophobic to neutral polar A7T, P67S, P86S, A7T, A39T, A91T
A87S, A91T, A147S A165S/T, A179T
Polar neutral to non-polar hydrophobic S122G
Polar basic to polar neutral R46Q4
Polar neutral to polar charged N27D, Q33H, Q80K
Hydrophobic to polar charged
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3.2.4 3-Dimensional (3D) modelling of amino acid substitutions
To estimate the influence of the identified conservative and non-conservative amino
acid substitutions on the structure or function of the NS3 protease, they were mod-
elled onto the 3D structure of the genotype 1a NS3 protease from the HCV H strain
(Kim et al. (1996)). Using the UCSF Chimera software, functional domainsd
amino acid positions where substitutions were identified, were outlined. Figure 3.5
shows the 3D structure of the HCV H strain protease complexed with the NS4A pep-
tide and polymorphic sites identified within genotype 1a variants highlighted. Figure
3.6 shows the equivalent for genotype 3a variants. As the 3D model of genotype 1a pro-
tease was used, amino acid residues do not always correspondto the type 3a residues.
However, spatial arrangement will be similar. Most of the non-c nservative amino acid
substitutions within the genotype 1a variants mapped to surface loops of the protease
and pointed away from the remaining protein residues. However, Ser122 is located
between Asp168 and Arg155, which are part of the S2 substratebinding pocket and
involved in the binding of the PI BILN 2061 (Courcambecket al. (2006)). Two vari-
ants have a Gly122 substitution, a change from a polar amino acid with a hydroxyl
group to a non-polar smaller amino acid without a hydroxyl group. Gly122, without a
hydroxyl group, might possibly interact differently with Arg155 and Asp168, having
an influence on the structure of the S2 binding pocket.
The majority of non-conservative amino acid substitutionswithin the genotype 3a vari-
ants also map to surface loops, except for Ala166, which points towards Arg123 of the
S2 substrate binding pocket. Three genotype 3a variants have a Ser166 and 2 have
a Thr166 substitution, 2 amino acids which are polar and bulkier than the non-polar
amino acid Ala, possibly pushing Arg123 out of his position and ffecting the S2 sub-
strate binding pocket. Two further polymorphic residues are Thr47 and Ala151. Both
are located on interiorβ-strands. At position 47, 3 variants have a Thr to Ala substi-
tution and at position 151, one variant has an Ala to Thr substit tion. A change from
a bulkier and polar amino acid, such as Thr, to a smaller and no-hydrophobic amino
acid, such as Ala, possibly has an influence on the 3D structure of the protein.
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Overall, the amino acid substitutions within the genotype 1a and 3a variants are either
conservative, which can be found onβ-strands,α-helices and loop regions, or non-
conservative, which mostly locate to the surface loops where they do not influence the
structure of the protease. Furthermore, all sites of substit tion are located away from
the active site and other functional domains, except for a few substitutions possibly
affecting the S2 substrate binding pocket. Modelling the positions of substitutions
onto the 3D structure of the NS3 protease allows speculations about their possible
influence on protein structure and function. The observed natural sequence diversity
most likely arose through random genetic drift rather than positive selection pressure,
as non-conservative amino acid changes locate mostly to thesurface area where they
are less likely to have an influence on the functional domains.
3.2.5 Summary of results
In summary, these results show that the NS3 protease of genotype 1a and 3a is suf-
ficiently flexible to tolerate substitutions, despite the functional constraints provided
mainly by the catalytic domain, but also its substrate binding pockets and the cofac-
tor binding site as well as the zinc binding site. In concordance with the functional
constraints, polymorphic sites are mainly found away from the functionally impor-
tant domains. Substitutions away from the consensus sequence are evenly distributed
throughout the gene and synonymous nucleotide substitutions are far more common
than non-synonymous substitutions, supporting a mechanism of natural genetic poly-
morphism induced through random genetic drift. The NS4A gene tolerates substitu-
tions within the cofactor activity region and the kink segment, but is more conserved
within the functionally constraint N-terminal membrane segment. Even though NS4A
is highly diverse between genotypes, it is fairly conservedwithin genotypes.
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Figure 3.5: 3D analysis of sequence diversity in genotype 1a variants.Amino acid
positions where substitutions away from the consensus sequence have been identified,
were mapped onto the crystal structure of the genotype 1a HCV H strain NS3 protease.
The NS3 protease domain (white) is shown complexed with a synthetic NS4A cofactor
peptide (orange). Colour code: Light blue: sites of conservative amino acid substitu-
tions; Yellow: sites of non-conservative amino acid substitutions; Red: catalytic triad
His57, Asp81 and Ser139; Dark blue: zinc binding residues Cys97, Cys99, Cys145
and His149; Purple: S1 binding pocket Ile132, Leu135, Phe154 and Ala157; Green:
S2 binding pocket Arg123, Arg155, Arg161, Lys165 and Asp168.
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Figure 3.6: 3D analysis of sequence diversity in genotype 3a variants.Amino acid
positions where substitutions away from the consensus sequence have been identified,
were mapped onto the crystal structure of the genotype 1a HCV H strain NS3 pro-
tease. As the genotype 1a protease is used as a model, amino acids depicted corre-
spond to genotype 1a residues. The NS3 protease domain (white)is shown complexed
with a synthetic NS4A cofactor peptide (orange). Colour code: Light blue: sites of
conservative amino acid substitutions; Yellow: sites of non-c servative amino acid
substitutions; Red: catalytic triad His57, Asp81 and Ser139; Dark blue: zinc binding
residues Cys97, Cys99, Cys145 and His149; Purple: S1 binding pocket Leu132 (Ile in
the model), Leu135, Phe154 and Ala157; Green: S2 binding pocket Thr123 (Arg in the
model), Arg155, Arg161, Lys165 and Gln168 (Asp in the model).
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3.3 Discussion
The HCV RNA genome displays high genetic diversity, which is not evenly distributed
throughout the genome (Chooet al. (1991)). The NS3 protease has previously been
identified as one of the less variable gene regions of the HCV genom (Pawlotsky
(2006)). Due to its role as a target for specifically targetedantiviral therapy a detailed
understanding of the NS3 protease diversity is crucial. As discussed in section 1.8.1
intergenotypic diversity plays a major role in the efficacies of protease and polymerase
inhibitors. The intragenotypic diversity most likely willhave further influence on how
patients within the same genotype respond to treatment and adetailed understanding is
important to facilitate drug development. The aim of the results presented in this chap-
ter was to investigate the genetic diversity of the HCV NS3 protease and its cofactor
NS4A in the absence of any specific antiviral pressure and to possibly identify pre-
existing resistance mutations. The NS3 protease diversityhas been studied previously
by different groups (Holland-Staleyet al. (2002); Lodriniet al. (2003); Valletet al.
(2005); Pawlotsky (2006); Winterset al. (2006); Akhavanet al. (2009)). This study
will add to the current knowledge of NS3 protease sequence diversity, especially for
genotype 3a, which has not been studied extensively. The work focused on genotype
1a and 3a, as these are the predominant genotypes in NorthernEurope and are less well
described than genotype 1b, on which research mostly focuses.
Even though the NS3 protease is one of the less diverse genes in the HCV genome, vari-
ability was found among the studied HCV variants on the nucleotid (7.6 % sequence
divergence between variants of genotype 1a and 6.9 % for genotype 3a) and amino
acid level (2.5 % for genotype 1a and 2.7 % for genotype 3a). The genetic diversity
between genotype 1a variants and genotype 3a variants was found t be fairly simi-
lar with amino acid sequence divergences of 2.5 % and 2.7 %, respectively. However,
within the NS4A cofactor amino acid sequence, divergence was found to be higher in
genotype 1a variants compared to genotype 3a variants (3.7 %versus 0.7 %). A previ-
ous study (Lodriniet al. (2003)) has reported a slightly higher value for genotype 1a
variants, with 4.5 % nucleotide and 4 % amino acid sequence divergence and a lower
value for genotype 3a variants, with a nucleotide sequence divergence of 3.7 % and
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an amino acid sequence divergence of 1.6 %. Even though the results presented here
could not identify a significant difference between genotype 1a and 3a NS3 protease
diversity, a difference was found within the NS4A gene. A lower amino acid sequence
diversity was found within genotype 3a variants, as reported by Lodrini et al. for the
NS3 protease. However, the overall diversity is low within both genotypes and sample
sets differ in number, making a comparison difficult. Furthemore, Lodriniet al. do
not distinguish between subtypes in the genotype 3 group.
Holland-Staleyet al. have reported slightly higher values for NS3 protease divers ty,
with a nucleotide sequence divergence of 30.2 % and an amino ac d sequence diver-
gence of 11 % for genotype 1a variants (Holland-Staleyet al. (2002)). Significantly
higher values were reported by Valletet al., who found an amino acid sequence diver-
gence of 22.1 % (nucleotide sequence divergence 41.2 %) within genotype 1a variants
(Vallet et al. (2005)). Whereas the 2 first studies also directly sequenced the predomi-
nant variant in each plasma sample, as in this study, Valletet al. sequenced a mean of
17 variants per clinical isolate. Clonal analysis allows thedetection of the depth of the
quasispecies and will include the possibly highly variablesequences of less dominant
viral variants, increasing the overall genetic diversity detected. The higher diversity in
the Vallet and Holland-Staley study might also be attributed to the age of the analysed
patients. The mean age of patient in these 2 studies was 50 and52 years, whereas pa-
tients in this study were on average 10 years younger, with a mean age of 40 years. It is
possible that the patients studied here had a shorter time ofinfection, which might in-
fluence the degree of genomic diversity (Casinoet al. (1999); Farciet al. (2000)). As
discussed in section 1.6.1, viral proteins are under the pressu of the immune system
and will evade it through mutational escape, generating a diverse pool of viral variants
over time. Positive selection pressure though, is limited by the functional constraints
of the protease.
Like most RNA viruses, HCV has a high mutation rate and if it is random, theoreti-
cally each site will contain an equal number of mutations. However, this is not the case
as e.g., has been shown for E1 HVR1 and also NS3 (Holland-Staley et al. (2002);
Peninet al. (2001)). As demonstrated by these studies, substitutions are random, al-
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though some regions of the genome are more permissive to mutations than others be-
cause proteins like the NS3 protease are functionally constrai ed. Kimet al. have
reported that the NS4A binding domain within the N-terminalregion of the NS3 pro-
tease is flexible (Kimet al. (1996)). They demonstrated that the binding of NS4A
induces a structural rearrangement of the NS3 protease catalytic domain towards a
more favorable conformation. This suggests that some mutations are possible within
this region. The NS4A binding domain of the NS3 protease was fairly conserved
within the genotype 1a and 3a variants analysed, with only one polymorphic site at
position 7. Ala7 is the dominant amino acid, although Thr is tolerated as well. Only
one nucleotide substitution is necessary to change from Alato Thr, making this sub-
stitution fairly accessible. Ala7 is part of a hydrophobic pocket formed by the NS3
protease residues Ala5, Ala7, Val33, Ile/Val35, Leu44, Val107, Ala111 and the NS4A
residue Leu314. This interaction is part of the extensive hydrophobic interaction be-
tween NS4A and NS3 (Kimet al. (1996)). Although Thr has a hydrophilic hydroxyl
group, it might still replace Ala with its hydrophobic methyl group. The methyl group
is likely to be positioned within the hydrophobic pocket andthe hydroxyl group away
from it. It is important that the hydrophobic pocket maintais ts hydrophobic charac-
ter to not disrupt the interaction between NS3 and NS4A. The addition of a hydroxyl
group though, might affect the 3D conformation. Other residues of the hydrophobic
pocket with polymorphism are Val33 and Val107. Two genotype1a variants show a
Ile33 substitution and 2 genotype 3a variants a Ile107 substit tion. Both substitutions
keep the hydrophobic character and are unlikely to have a major effect on the protease
structure or function.
Ile254 and Gly274 of NS4A are highly conserved across genotypes and together with
Val234, Ile/Leu294 and Leu314 they make significant contact with the NS3 protease
(Ile/Leu294; first amino acid is the one occurring in genotype 1a, the second the one
occurring in genotype 3a) (Kimet al. (1996)). The 4 NS3 protease residues Pro88,
Ile64, Val29 and Val/Leu36 are involved in the contact with NS4A Ile254 (Fig. 3.7).
All 4 positions are conserved within genotype 1a and genotype 3a variants except for
6 genotype 1a variants that have a conservative amino acid substitution (2x Leu64, 1x
Met64 and 3x Ala29). These substitutions away from the consensus sequence are un-
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Figure 3.7: NS3/4A interaction.The highly conserved Ile254 of NS4A (red, ball and
stick) interacts with the 4 hydrophobic NS3 residues Pro88, Ile64, Val29 and Val36
(yellow spheres). The NS3 protease is depicted in white asβ-sheets andα-helices
and the NS4A peptide in orange. Conservative substitutions away from the consensus
sequence are tolerated as long as the hydrophobic characteris maintained.
likely to have an effect on the interaction between NS3 and NS4A, as they all are non-
polar neutral to nonpolar neutral changes and amino acids are about the same size as
well. However, it demonstrates that it is important to keep the hydrophobic character.
Analysis of all variants revealed mostly synonymous nucleotid substitutions within
genotype 1a and 3a variants. About 20-25 % of all nucleotide positions had synony-
mous substitutions and only about 1-2 % were non-synonymousand resulted in amino
acid changes. The same was true for NS4A. The far greater proporti n of synony-
mous versus non-synonymous nucleotide substitutions indicates that the natural se-
quence divergence is a product of random genetic drift and not ue to positive selection
pressure. Functional constraints within the NS3/4A protease make mutations within
the catalytic, substrate binding and zinc domains highly unlikely as shown by others
(Holland-Staleyet al. (2002); Valletet al. (2005)). None of the variants analysed had
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a mutation within the catalytic domain comprised of the 3 amino acids His57, Asp81
and Ser139. However, mutations within the catalytic domainhave been described
by others. One study e.g., found 2 sporadic mutations affecting the catalytic Ser129
(Ser139Pro) and Asp81 (Asp81Gly) (Valletet al. (2005)). These changes most likely
are lethal as they present non-conservative amino acid changes and variants would cir-
culate in very low numbers, which could only be picked up by clonal analysis. As
no clonal analysis was performed in this study, it was unlikely to detect any variants
with lethal mutations. Gly137, together with Ser139, creates an oxyanion hole. This
helps to stabilise the transition state during the hydrolysis of peptides, thereby lowering
the activation energy. This favoured energetic state is important for efficient catalysis
(Kim et al. (1996)). Expectantly, residue Gly137 and Ser139 were conserved across
all variants analysed.
NS3 has a very flat substrate binding site and requires peptide-binding spanning the
S6 to S4’ binding site. The Schechter and Berger nomenclaturedescribes the subsites
of a protease (Schechter & Berger (1967)). The amino acid resiu of a polypeptide
binding to the active site of the protease are called P (for peptid ) and the subsites on
the protease they are binding to are called S (for subsites).Depending on the size of
the peptide, substrate residues around the cleavage site can be numbered up to P8. The
subsites on the protease are accordingly numbered, e.g., S3, S2, S1, S1’, S2’, S3’ etc.,
where S1 and S1’ are located adjacent to the scissile bond. The S1 substrate binding
pocket of the NS3 protease is lined by the hydrophobic amino acids Ile132, Leu135,
Phe154, and Ala157. Arg155, Arg/Thr123, Arg161, Lys165, and Asp/Gln168, which
are mainly charged residues, line the S2-S6 binding pocket (Kim et al. (1996)). None
of the variants analysed showed any substitutions at the S1 or S2 substrate binding
pocket, which is consistent with findings by others (Valletet al. (2005)). This suggests
that the integrity of the substrate binding pockets is important, and that preserving
polarity and hydrophobicity alone are not sufficient.
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The NS3 protease contains a zinc ion that is tetrahedrally coordinated by the 4 residues
Cys97, Cys99, Cys145, and His149 and a water molecule (Kimet al. (1996)). The 3
Cys residues are particularly crucial for protease activity. Mutational studies showed
that replacement of any of these with an Ala led to significantly reduced protease ac-
tivity (Hijikata et al. (1993)). Substituting His149 to Ala had a less dramatic effect,
which is consistent with the indirect interaction of His149with the zinc ion. As the
zinc ion is located 20̊A away from the catalytic site, it has been suggested to play a
structural role (Kimet al. (1996)). Folding analysis inE.coli have revealed that the
NS3 protease does not fold properly in the absence of zinc, supporting this hypothesis
(De Francescoet al. (1996)). Consistent with this crucial role of zinc and its coordi-
nation, no mutation within the zinc binding site was found inany variant.
None of the variants contained any of the reported resistance mutations for PIs at po-
sition 36, 41, 43, 54, 109, 155, 156, 168 and 170 (Tonget al. (2006); Bartelset al.
(2008); Cuberoet al. (2008); Kuntzenet al. (2008); Heet al. (2008)). As described
in section 1.8.4, viral variants containing resistance mutations are often impaired in
their replication kinetics and will not be the main strain circulating in a pool of quasis-
pecies. As no clonal analysis was performed in this study, itwas unlikely to detect any
variants with PI resistance mutations.
Outside the NS3 protease active site and substrate binding pockets, polymorphisms
have been identified at several positions. Conservative amino acid substitutions were
found on interior and surfaceβ-strands, as well as surface loops and generally only 2-3
variants differed in their sequence from the consensus sequence, suggesting that these
substitutions are sporadic. Most conservative substitutions nvolved changes from one
hydrophobic to another hydrophobic amino acid. Within genotype 1a variants polar
neutral to polar neutral substitutions were observed several times as well. A highly
polymorphic site is amino acid position 40, which lies on a surface loop and faces
away from the protease, allowing amino acids of different size to replace each other.
Furthermore, only one nucleotide change is necessary for a Th to Ala change, whereas
2 nucleotide changes are necessary for a change to Gly. This explains the Thr/Ala
polymorphism within genotype 1a variants and why there is only e variant with a
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Gly. Why no polymorphism was found at this site within genotype 3a is unclear. The
genotype 1a polymorphic site 174 is part of a surfaceα-helix, allowing certain flex-
ibility of the amino acid. However, Asn174 points towards Gln80 on the opponent
loop. This restricts the size of amino acid 174, explaining the conservative Asn174Ser
polymorphism. Both amino acids are polar and are about the samsize. Also, only
one nucleotide change is necessary to change form Asn to Ser.Int estingly, the op-
ponent amino acid Gln80 can be substituted with Lys, a non-conservative change from
a polar neutral to a polar positive amino acid. An Asn174Ser change though, was not
associated with a Gln80Lys change. As no data is available onthe fitness of the indi-
vidual variants, it cannot be estimated whether a specific combination of amino acids
at position 174 and 80 are favourable.
Within genotype 3a variants, highly polymorphic sites werefound at position 7, 98 and
176. Ala7 is part of the NS4A binding domain and has been discussed above. Thr98 is
part of a surface loop pointing away from the protease allowing flexibility with amino
acid substitution. A simple adenosine to guanosine nucleotid substitution results in
a change of Thr to Ala, explaining the Thr to Ala polymorphism. Asn176 is part of a
surfaceα-helix facing away from the protease, suggesting that a certain flexibility of
the amino acid residue at this position will be allowed. As the Asn176Ser substitution
is a conservative amino acid change, it is unlikely to have a major impact on protease
structure and function.
The most common non-conservative amino acid changes involved substitutions of a
hydrophobic amino acid with a neutral polar one, followed bysubstitutions of neutral
side chains with charged side chains. In general non-conservative amino acid substitu-
tions away from the consensus sequence mapped to surface loops. Within genotype 1a
variants though, 2 variants had a Ser122Gly change. Ser122 is located on a loop, but
points towards Asp168 and Arg155, which are part of the S2 binding pocket. Both are
involved in the resistance mechanism against the PI BILN 2061(Courcambecket al.
(2006)). Arg155, together with Ala156, directly binds to the inhibitor, whereas Arg168
indirectly affects inhibitor binding. The hydroxyl group of Ser122 could possibly build
a hydrogen bond with the guanidinium group of Arg155. The non-p lar amino acid
Gly does not have a hydroxyl group to build a hydrogen bond. This disrupted interac-
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tion might have an influence on the 3D structure and affect substrate binding as well
as inhibitor binding. More detailed structural modelling though is necessary to get
conclusive prediction on this amino acid polymorphism.
Within genotype 3a variants, the polymorphic site Ala166 islocated on aβ-strand and
points towards Thr123, which is part of the S2 binding pocket. S r166 was found in 3
genotype 3a variants and Thr166 in 2 variants. Ala is a small hydrophobic amino acid,
whereas Ser and Thr are both polar and bulkier. Substitutionof Ala with Ser/Thr is
therefore likely to push away the opponent Thr123 and changethe S2 binding pocket
environment. As the binding of PIs is influenced by the 3D structure of the binding
site, the efficacy of some PIs might be reduced in variants containi g Ser166/Thr166.
Thr47 and Ala151 are 2 further polymorphic sites located on inter orβ-strands. Thr47
points towards Asp110, which is also polymorphic (Asp110Glu). Ala47 was found in
3 genotype 3a variants. Substitution of Thr47 with a larger amino acid would displace
Asp110 and modulate the 3D structure. However, Ala is smaller than Thr and it is un-
clear what kind of effect a substitution would have. Val151 and Thr151 were found in
one genotype 3a variant each. Ala151 points towards Arg118 on the opponentβ-strand
and a replacement with the slightly bulkier amino acids Val and Thr might displace
Arg118 and have an effect on the 3D structure and the functional domains.
The genetic diversity of NS4A was slightly higher within genotype 1a variants com-
pared to genotype 3a variants. Like NS3 protease sequence diversity, NS4A nucleotide
sequence diversity was mostly synonymous. Around 23 % of nucleotide positions
within genotype 1a variants had synonymous substitutions and 21 % within genotype
3a variants. The proportion of non-synonymous substitutions away from the consensus
sequence was higher in genotype 1a variants compared to genotyp 3a variants (2.1 %
versus 0.4 %), but overall low and most likely due to genetic dr ft. The N-terminal
membrane segment, which is highly conserved across genotypes, is also highly con-
served within genotype 1a and 3a variants (Brasset al. (2008)). Only 3 variants of
genotype 3a had a substitution away from the consensus sequences, which were con-
servative and sporadic and unlikely to affect the membrane topology of NS4A. Some
variability was found within the region essential for cofactor activity. As discussed
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above, Val234, Ile254, Gly274 and Ile294 are crucial for the interaction with the NS3
protease and expectantly only conservative amino acid substitutions were observed.
Whereas an Ile294Val polymorphism was found in genotype 1a variants, genotype 3a
variants were highly conserved in this area. Ile254 interacting with the NS3 hydropho-
bic pocket is conserved within both genotypes. Some diversity was also found within
the kink region and the C-terminal domain, but except for an Arg46Gln substitution, all
amino acid substitutions were conservative. These resultsggest that the NS4A gene
is highly conserved within a genotype, but flexible enough toall w some mutations,
especially within the genotype 1a kink and C-terminal region.
3.4 Conclusion
This study describes the polymorphisms within the NS3 protease and NS4A cofactor
gene of genotype 1a and 3a clinical variants. It shows that the NS3/4A protease is flex-
ible enough to tolerate substitutions despite the different fu ctional constraints. Even
though no mutations were found within the catalytic site, thS1 and S2 binding pocket
or the zinc binding domain, natural polymorphism observed outside of the functional
domains of the NS3 protease could potentially have an effecton linical resistance to
HCV PIs. Amino acid substitutions from smaller to bulkier andfrom neutral to charged
residues or vice versa influence the interaction between individual amino acids and po-
tentially alter the 3D structure of the protease, thereby affecting functional sites. 3D
modelling was used to estimate which non-conservative substit tions would influence
the 3D structure of the NS3 protease and have an effect on the functional domains. As
discussed in section 1.8, PIs show different efficacies for di ferent genotypes. Because
of the genetic variability of HCV proteins encoded by different genotypes, the molec-
ular structure of protease and polymerase enzymatic sites diff rs and potentially limits
the effectiveness of certain classes of inhibitors (Holland-Staleyet al. (2002)). The
case of BILN 2061 demonstrated very early on that structural differences within geno-
types have a big impact on drug efficacies. The intragenotypic diversity potentially has
a similar influence on protease efficacies in individuals infected with the same geno-
type. As shown in chapter 4 and 5, NS3 proteases from clinicalvariants of the same
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genotype subtype behave differently in intergenotypic 2a recombinants. Differences in
their susceptibility to the PI BILN 2061 could be demonstrated as well.
The information provided here will be very valuable for the design of new PIs. Con-
sidering sites of potentially influential polymorphism, inh bitors could be designed to
target sites which are conserved across and within genotypes and subtypes. This will
enable the development of inhibitors that are more likely tobe effective in all geno-
types and subtypes. Furthermore, individuals with known amino acid polymorphism at
target sites could be excluded from treatments with potentially ineffective drugs, sav-
ing them from antivirals with often severe side effects. However, clonal analysis will




Construction of Intra- and
Intergenotypic Recombinants
4.1 Introduction
Research into antiviral drugs and vaccines has been hamperedby the lack of a full vi-
ral life cycle cell culture system. Only recently a full-length HCV cell culture system
in which infectious virus can be generated in Huh7 cells fromtransfection of com-
plete HCV genomic RNA sequences has been described (Lindenbach et l. (2005);
Wakitaet al. (2005)). JFH1 was isolated from a patient with fulminant hepatitis C and
a subgenomic replicon containing the JFH1 derived non-structu al genes replicated
very efficiently in Huh7 cells (Katoet al. (2003)). Surprisingly,in vitro transcribed
full-length RNA from pJFH1 replicated very efficiently in Huh7 cells as well and the
cell culture generated HCV was also infectious in chimpanzees (Wakitaet al. (2005)).
It was the first full-length HCV RNA to replicate efficiently in cell culture and proved
to be an important milestone in HCV research. The big advantage of full-length virus
replication is that it also produces infectious virus, unlike the replicons, thereby pro-
viding insight into the whole viral lifecycle. For the first time this allowed the analysis
of viral proteins in the context of the entire viral lifecycle. Unfortunately, as to date,
the genotype 2a isolate JFH1 has remained the only isolate toefficiently replicate in
cell culture. However, the JFH1-system has been expanded toother genotypes by re-
placing parts of the JFH1 genes with those of other genotypes. Viable JFH1-based
intergenotypic recombinants containing genotype specificstructural proteins (core, E1
and E2), p7 and NS2 have been developed for all 7 genotypes (Pitschmannet al.
(2006); Gottweinet al. (2007); Yiet al. (2007); Jensenet al. (2008); Scheelet al.
(2008); Gottweinet al. (2009)), which allow the study of vaccines and entry inhibitors
for all genotypes. However, full-length HCV cell culture systems allowing the study
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of the NS3 protease are currently only available for genotype 2a (JFH1 and J6CF)
(Lindenbachet al. (2005); Wakitaet al. (2005); Murayamaet al. (2007a)) and 1a
(H77), which needs adaptive mutations to replicate efficiently (Yi et al. (2006b)). The
limited number of replication competent full-length reference sequences limits the as-
sessment of how genetic variation between the different genotypes and within subtypes
influences susceptibility to antiviral therapy and development of resistance.
The use of chimaeric replicon vectors, where protease genesof different genotypes
were inserted into the genotype 1a/1b/2a standard replicons, has been demonstrated in
several reports (Binderet al. (2007); Qiet al. (2009)). These intergenotypic replicons
have greatly expanded the ability of tools to assess geneticvariation within genotypes,
subtypes and quasispecies. Before, replication competent replicons were restricted to
laboratory optimised strains which did not represent the immense genetic diversity of
HCV. Furthermore, they demonstrated that the NS3 protease isfunctional in a hetero-
logous background. However, replacing the helicase as wellgr atly reduced replicon
fitness, indicating that the helicase is highly specific in recognising and interacting
with other parts of the RNA complex (Qiet al. (2009)). Other approaches involve
the release of reporter molecules upon NS3/4A cleavage (Ludmereret al. (2008)).
However, none of these methods release infectious virus that would allow the whole
replication cycle of HCV to be analysed.
The aim of the current study was to develop effective cell culture systems for the 6
major genotypes of HCV. This will allow the comparison of the susceptibility of each to
different PIs, such as BILN 2061 (chapter 5). Furthermore, through passaging in sub-
inhibitory concentrations of the drug, the ability and mechanism of antiviral resistance
development between genotypes can be compared (chapter 6).
Recently, the full-length replication competent clone Jc1 (pFK JFH1/J6/C-846) has
been developed. This clone comprises the J6CF core, the envelope and the p7 coding
sequences and a portion of the NS2 gene, with the remainder ofthe polyprotein de-
rived from JFH1 (Lindenbachet al. (2005); Pietschmannet al. (2006)). It replicates
autonomously and yields high infectious titres in the Huh7.5 cells. It was therefore cho-
sen as a backbone for the construction of the intra- and intergenotypic recombinants in
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the current study. Intra- and intergenotypic recombinantswere first constructed within
the JFH1 backbone and then cloned into the Jc1 backbone. In aniniti l approach, natu-
rally occurring restriction sites outside the NS3 proteasewere used for the construction
of recombinants. As this approach was not successful, specific restriction sites at the
exact boundaries of the NS3 protease were designed. This wasonly partly successful,
which led to the strategy of including the NS4A cofactor in the recombinant construc-
tion. Homologous NS4A allowed the rescue of replication defective intergenotypic
recombinants for most variants. The development of these replication competent in-
tergenotypic recombinants will improve the ability to predict clinical doses, efficacies
and development of drug resistance mutations to different PIs in a diverse range of
HCV variants circulating worldwide.
4.2 Results
4.2.1 Design and construction of intra- and intergenotypic recom-
binants containing heterologous NS3 protease
Using naturally occurring restriction sites
To establish full-length cell culture systems allowing theanalysis and characterisa-
tion of the NS3 protease gene of all 6 major genotypes, intergenotypic recombinants
based on the genotype 2a clones JFH1 and Jc1 were constructed. Int rgenotypic re-
combinants containing the NS3 protease gene of heterologous enotypes were created
through ligation of protease domain sequences from different g notypes into the Jc1
and JFH1 backbone sequence (Fig. 4.1). JFH1 contains 2 naturally occurring unique
restriction sites,NotI within NS2 andSpeI within the NS3 helicase. Primers flanked
with these restriction sites were used to amplify the corresponding fragment from geno-
type 1a (pH77*) and 3a (pHCV3a-Gla) prototype plasmids or patient plasma. The
1149 bp fragment was digested in a double digest, cleaned andclo ed into the like-
wise digested JFH1 backbone. The resulting intergenotypicrecombinants contain the
full-length NS3 protease plus the 3’ 464 nucleotides of NS2 as well as the 5’ 142 nu-
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cleotides of the NS3 helicase and were named Fnxn, where x stands for the genotype
the NS2-3 fragment is derived from (Fig. 4.2). RNA transcribed from the recombi-
nant plasmids and the replication defective pJFH1-GND as well as Jc1 and JFH1 was
electroporated into the HCV permissive Huh7 cells and virus replication assessed by
NS5A immunostaining (Fig. 4.3). Initially Huh7 cells were used for assessment of
viral replication, but they were replaced with the far more permissive Huh7 subclone
Huh7.5, which has a defect in RIG-I signalling (Blightet al. (2002); Sumpteret al.
(2005)). HCV variants replicate to higher levels in these cells. To create the corre-
sponding Jc1 based recombinants (Jnxn), theSpeI restriction site in the plasmid back-
bone of Jc1 first had to be mutated, to render theSp I restriction site within the NS3
helicase unique. This was done by PCR using primers includingpoint mutations and
religation of the modified insert back into Jc1.
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Figure 4.1: Genome map of JFH1 and Jc1. Genome map of JFH1 and Jc1 used in
recombinant construction. The structural genes are depictd in grey; non-structural
genes in white. The intragenotypic recombinant Jc1 containsthe non-structural genes
and part of NS2 of the genotype 2a isolate J6CF (dark grey) and the remaining non-
structural genes from JFH1.
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Figure 4.2: Fnxn and Jnxn recombinants. Genome map of cDNA clones: JFH1 back-
bone, light grey and white; Jc1 backbone, dark grey and white. Th fragment between
the restriction sites NotI and SpeI was replaced with the corresponding intergenotypic
gene (replaced region, coloured).
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Figure 4.3: Anti-NS5A immunostaining. RNA transcripts from JFH1, Jc1, JFH1/Jc1
recombinants (here J2a) or the replication defective JFH1-GND were electroporated
into Huh7 or Huh7.5 cells (here Huh7.5) and replication was asessed by immunos-
taining against the HCV non-structural protein NS5A. Cells werecounterstained with
the nucleic acid probe 4’,6’-diamidino-2-phenylindole hydrochloride (DAPI) (blue)
and sheep anti-NS5A serum (green).a 20X magnification;b 100X magnification.
Replication assessment in Huh7 cells
JHF1 and Jc1 replicated in Huh7 cells with infectivity titres of 5× 103 FFU/ml and 2.9
× 104 FFU/ml, respectively. In contrast, Huh7 cells transfectedwith RNA transcripts
from pJ6CF, the replication defective pJFH1-GND and mock transfected cells were
negative for anti-NS5A staining. For all further experiments carried out in this study,
Jc1 was used as a positive and JFH1-GND as a negative control,respectively.
The JFH1 recombinants Fn1an and Fn3an were severely impaired or defective in their
replication kinetics and transfected cells were negative for NS5A. Even though Jc1
replicates to higher levels in Huh7 cells than JFH1, using Jc1 as a backbone to create
the intergenotypic recombinants Jn1an and Jn3an did not result in improved replication
kinetics. Cells transfected with Jn1an and Jn3an RNA were NS5A negative as well.
Replication assessment in Huh7.5 cells
Alternatively, the replication kinetics of parental and recombinant variants were as-
sessed in Huh7.5 cells. 24 hours post-electroporation about 80 % of all cells trans-
fected with JFH1 and Jc1 RNA were positive for NS5A, indicating replication (Fig.
4.4). In contrast, JFH-GND replication was not detected. Whereas Jc1 continues to
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infect 70-80 % of all cells, JFH1 infectivity is slightly reduced during passaging. In
all graphs of HCV RNA passaging in cell culture, data points areplotted with lines
connecting them for better visualisation. During the course of the experiment the cell
cultures were continuously split and variants have to spread b tween cells to not be di-
luted out. Serial dilutions of cell culture supernatants were used to infect naı̈ve Huh7.5
cells and to determine the tissue culture infective dose (TCID50). The TCID50 for Jc1
(104.5 TCID50/ml) was expectantly higher than that of JFH1 (103.6 TCID50/ml). Due to
the better replication kinetics and higher infectivity of Jc1, it was used for further re-
combinant construction. Neither of the 4 recombinants (Fn1an, Jn1an, Fn3an or Fn3an)
replicated in the Huh7.5 cell culture to detectable levels.
Days post-electroporation

































Figure 4.4: Replication kinetics of JFH1, JFH-GND and Jc1 full-length RNA tran-
scripts in Huh7.5 cells. 10µg of RNA was electroporated into Huh7.5 cells and cells
incubated for 24 hours. The cells were then stained for NS5A or alte n tively pas-
saged and assessed for NS5A positive cells every 3 to 4 days. The y-axis records the
percentage of HCV NS5A-positive cells as scored by fluorescence microscopy.
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Introducing artificial restriction sites
The defective replication kinetics of the Fnxn and Jnxn recombinants might be due to
the partial inclusion of gene segments from NS2 and the NS3 helicas . This creates
intergenotypic NS2 and NS3 helicase proteins. The considerabl differences between
genotypes possibly disrupt the correct folding of these proteins and affect their func-
tion. The cloning strategy was therefore changed to only swap the protease domain and
leave the entire NS2 and NS3 helicase of backbone identity. To generate recombinants
containing only the NS3 protease gene of heterologous genotypes, 2 unique restriction
sites, aBstBI site at the 5’end and aBglII site at the 3’end of the NS3 protease were
introduced, creating Jc1-BB. The unique restriction sites were identified using Vector
NTI scan. Jc1-BB containing the introduced restriction sites showed similar replica-
tion kinetics to the parental strain Jc1 (Fig. 4.5). Protease genes from genotypes 1a
(H77*), 1b (HC-J4), 2a (J6CF), 3a (HCV3a-Gla), 4a (ED43*), 5a (EUH1480*) and 6a
(EUHK2*) were amplified by PCR and cloned into Jc1-BB. The primers were designed
to include JFH1 sequence up to the start of the NS3 protease gene (nt position 3420)
and the corresponding genotype sequence to the 3’end of the NS3 protease (nt position
3963). From the 3’end of the protease to the restriction site, the primer sequence was
designed to include JFH1 sequence again. Because p4a (ED43*)contained a naturally
occurringBglII restriction site within the protease domain, this restriction site first had
to be mutated by site directed mutagenesis. Recombinants conaining heterologous
proteases were termed Jx, where x identifies the genotype of th protease domain (Fig.
4.6).
RNA transcribed from the recombinant plasmids and the replication defective pJFH1-
GND as well as Jc1 was electroporated into the highly permissive Huh7.5 cells and
virus replication assessed by NS5A immunostaining. BesidesJ2a, which showed sim-
ilar replication kinetics to that of the parental strain Jc1, only J5a replicated to de-
tectable levels and it took 25 days to spread to 80 % of the cellculture (Fig. 4.7). As
the cell culture was split through the course of the experiment, the virus would have had
to spread to neighbouring cells to achieve this infection frequency during passaging,
indicating that the J5a recombinant is able to spread between c lls.
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Figure 4.5: Replication kinetics of Jc1, Jc1-BB and JFH-GND full-length RNA
transcripts in Huh7.5 cells. 10µg of RNA was electroporated into Huh7.5 cells and
cells incubated for 24 hours. The cells were then stained for NS5A or alternatively
passaged and assessed for NS5A positive cells every 3 to 4 days.
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Figure 4.6: Genome map of Jx recombinants.Genome map of cDNA clones (pJ6CF,
dark grey; pJFH1, white). The NS3 protease gene of Jc1 was replacd with the cor-
responding intra- or intergenotypic gene (replaced region, coloured) using the geneti-
cally engineered restriction sites BstBI and BglII.
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Figure 4.7: Jx recombinants and their viability in Huh7.5 cells.RNA transcripts
from J1a, J1b, J2a, J3a, J4a, J5a and J6a were electroporated into Huh7.5 cells and
replication was assessed by immunostaining against NS5A. Transc ipts from the J1a,
J1b, J3a, J4a and J6a clones showed no detectable replication(all values lying on the
x-axis line).
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4.2.2 Design and construction of intra- and intergenotypic recom-
binants containing heterologous NS3 protease and NS4A
Since the NS4A cofactor is an indispensable part of the NS3 protease function and
highly variable in sequence between genotypes, it was investigated whether inclusion
of the homologous NS4A gene in the intra- and intergenotypicrecombinants improved
their replication ability (Bartenschlagert al. (1995); Faillaet al. (1995); Tanjiet al.
(1995)). Two unique restriction sites were introduced at the 5’end (BlpI) and at the
3’end (MluI) of NS4A and the corresponding NS4A genes from genotypes 1a, 1b,
2a (pJ6CF), 3a, 4a, 5a and 6a were amplified by PCR using primers with SapI and
MluI restriction sites. Introducing aBlpI restriction site into pJFH1 results in one
non-synonymous nt change on the 3’end of the restriction site. Due to that an alter-
native restriction site, with compatible ends but different recognition sequence was
introduced to the 5’end of the inserted fragment.SapI produces NNN..3’ overhangs
and the recognition sequence is entirely located on the 5’site of the cutting site. This
allowed the design of a recognition site forSapI that changed the vector sequence back
to that of JFH1 once the insert was religated into the vector.The obvious disadvantage
of this approach is that the restriction site is destroyed anfragments cannot be cut
out anymore with the same restriction enzymes. The primers we designed to include
JFH1 sequence up to the start of the NS4A gene (nt 5313), then the corresponding
genotype sequence to the 3’end of NS4A (nt 5474) and JFH1 sequence again to the
restriction site. As the introduction of theMluI restriction site was not synonymous
and no alternative compatible restriction enzymes could befound, it was reversed to
the JFH1 amino acid sequence after NS4A gene insertion by site directed mutagene-
sis. The entire mutagenesis reaction was carried out on fragments subcloned into the
TOPO vector. JFH1 fragments including the intra- or intergenotypic NS4A gene were
then recloned into JFH1 and Jc1, respectively. The corresponding intra- and intergeno-
typic recombinants containing the NS3 protease and NS4A gene s quence of hetero-
or homologous genotypes in the JFH1 background were termed Fxx, where xx stands
for the corresponding genotype in the protease and NS4A regions, respectively (Fig.
4.8). Recombinants with Jc1 as a background were named Jxx (Fig. 4.9).
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Figure 4.8: Genome map of Fxx recombinants. Genome map of cDNA clones
(pJFH1, light grey and white). The NS3 protease gene of JFH1 was replaced with the
corresponding intergenotypic gene (replaced region, coloured) using the genetically
engineered restriction sites BstBI and BglII. The NS4A gene of JFH1 was replaced
with the corresponding intergenotypic gene using the genetically engineered restric-
tion sites BlpI and MluI.
Comparing Fxx and Jxx replication kinetics in Huh7 cells
Initially recombinant replication was assessed in Huh7 cells. Because the replicative
fitness of Fxx and Jxx were too low to determine percentage positive NS5A cells, foci
forming units (FFU) per well were determined. Recombinants were passaged in Huh7
cells and seeded into 24-well plates for anti-NS5A staining. Jc1 and JFH1 RNA tran-
scripts replicated in 60-70 % of all cells and were omitted inthe comparison of Fxx
with Jxx recombinants (Fig. 4.10). F1a1a and J1a1a replication levels were below the
detection limit and no NS5A positive cells were detected during the passaging exper-
iment. Both, F3a3a and J3a3a replicated to detectable levelswithin Huh7 cells (Fig.
4.10). As expected from the better replication kinetics of Jc1, the Jc1 recombinant
J3a3a replicated to higher levels than the JFH1 based recombinant F3a3a. After peak-
ing on day 7, FFU/well levels start to decrease for both recombinants. Because the Jc1
based recombinant replicated more efficiently, for the following experiments only Jxx
recombinants were assessed.
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Figure 4.9: Genome map of Jxx recombinants.Genome map of cDNA clones (pJ6CF,
dark grey; pJFH1, white). The NS3 protease gene of Jc1 was replacd with the cor-
responding intra- or intergenotypic gene (replaced region, coloured) using the geneti-
cally engineered restriction sites BstBI and BglII. The NS4Agene of Jc1 was replaced
with the corresponding intra- or intergenotypic gene using the genetically engineered
restriction sites BlpI/SapI and MluI.
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Figure 4.10: Recombinants F1a1a, J1a1a, F3a3a and J3a3a and their viability
in Huh7 cells. RNA transcripts from F1a1a, J1a1a, F3a3a, J3a3a and JFH1-GND
were electroporated into Huh7 cells and replication was assesed by immunostaining
against NS5A. They-axis records the number of foci forming units (FFU) per well in
24-well plates. Transcripts from the F1a1a, J1a1a and JFH1-GND clones showed no
detectable replication (all values lying on thex-axis line).
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Comparing replication kinetics of Jxx recombinants in Huh7.5 cells
As the replication kinetics of the J3a3a recombinant was very low in the Huh7 cells,
all remaining experiments were carried out with Huh7.5 cells. Replication competent
recombinants could be created with genotype 1b, 2a, 3a, 5a and 6 (Fig. 4.11, 4.12
and 4.13). Four days after transfection, J1b1b was detectedin 50 % of the cell culture,
but was then cleared from the cell culture likely reflecting ainability to infect Huh7.5
cellsde novobeyond the transfection stage (Fig. 4.11 top). In marked contrast, J2a2a
and J5a5a replication was detected in almost all cells 2 daysafter transfection, compa-
rable to Jc1 (Fig. 4.12). The immediate spread of these recombinants and Jc1 was ac-
companied by increased cell death, followed by proliferation of HCV-NS5A negative
Huh7.5 cells as described in previous studies (Zhonget al. (2006); Gottweinet al.
(2007); Mateuet al. (2008); Scheelet al. (2008)). However, both start to re-spread in
the cell culture after this initial decrease in infected cell fr quency, indicating sequence
changes that reduce the cytopathic effect of the virus and promote its survival in cell
culture. Theses changes were termed as “attenuating”, to make clear the difference
with conventional “adaptive” mutations that enhance replication ability.
Replicating J3a3a and J6a6a viruses were found in 80 % of the cell culture after an
eclipse phase of 6 and 33 days, respectively (Fig. 4.13). Compared to other Jxx re-
combinants, where the percentage of NS5A positive cells wasreduced again after an
eclipse phase, J3a3a still infected 80 % of the cell culture 70 days post-electroporation,
indicating continuous spread to uninfected cells. Supernatant infectivity was measured
at the peak of the infection by determining TCID50s (Table 4.1). The highest infectivity
titre was measured for J2a2a with a TCID50/ml of 104.2. The TCID50 measurement for
J1b1b was below detection limit (TCID50/ml <10), indicating that this recombinant
does not secrete any infectious virus into the supernatant or only at levels below the
detection limit. J1a1a and J4a4a were not viable or their replication was not efficient
enough to be detected with our assay. However, replacement of the NS3 protease gene
in J4a4a with that of patient-derived protease genes generated the replication com-
petent recombinants J4a4a-7, -8, -19, also see section 4.2.3 (Fig. 4.11 bottom and
4.17 bottom). J4a4a-7 and J4a4a-19 showed a similar replication profile to J1b1b,
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with NS5A-positive cells initially detected in 50 % of the cell culture but then cleared
out as the culture was passaged. As with J1b1b, no detectableinfectious virus was
secreted into the supernatant (TCID50/ml <10). J1a1a and J4a4a both differ to the pro-
totype sequence H77 and ED43 by one (H77-Met1205Thr) and 4 (ED 3-Thr1048Ala,
Thr1064Ile, Ile1160Thr and Arg1176Ala) amino acids, respectiv ly, in the protease
gene, whereas both are identical to H77 and ED43, respectively, n the NS4A gene
(Table C.2 and C.4, Appendix C). Which amino acid polymorphism potentially in-
fluences the impaired replication kinetics of J1a1a and J4a4a is discussed in section
4.3.
Table 4.1: Supernatant infectivity titres determined by TCID50 assay.
Viral variant Days post-electroporation TCID50/ml
JFH1 5 103.6
Jc1 5 104.5
JFH1-GND 5 < 10
J1a1a 5 < 10
J1b1b 5 < 10
J2a2a 5 104.2
J3a3a 15 103.4
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Figure 4.11: Recombinants J1b1b and J4a4a and their viability in Huh7.5 cells.
Results from 2 independent experiments are presented (JxxA, J xB). RNA transcripts
from J1b1b (top) and J4a4a-19 (bottom) were electroporated into Huh7.5 cells and
replication was assessed by immunostaining against NS5A.
133
Construction of Intra- and Intergenotypic Recombinants
Days post-electroporation

































































Figure 4.12: Recombinants J2a2a and J5a5a and their viability in Huh7.5 cells.
Results from 2 independent experiments are presented (JxxA, J xB). RNA transcripts
from J2a2a (top) and J5a5a (bottom) were electroporated intoHuh7.5 cells and repli-
cation was assessed by immunostaining against NS5A.
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Figure 4.13: Recombinants J3a3a and J6a6a and their viability in Huh7.5 cells.
Results from 2 independent experiments are presented (JxxA, J xB). RNA transcripts
from J3a3a (top) and J6a6a (bottom) were electroporated intoHuh7.5 cells and repli-
cation was assessed by immunostaining against NS5A.
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Investigation of the replication defect of the J1a1a recombinant
To investigate whether the defect in replication in the J1a1a recombinant was due to
the genotype 1a NS3 protease, the genotype 1a NS4A cofactor or incompatibilities
between these and the genotype 2a backbone, both proteins were replaced with that of
genotype 3a. The J1a1a NS3 protease or the NS4A cofactor was replaced with that
of genotype 3a, which are compatible with the genotype 2a backbone, to create J1a3a
and J3a1a. J1a3a contains the NS3 protease of genotype 1a andthe NS4A cofactor
of genotype 3a. J3a1a contains the genotype 3a NS3 protease and the NS4A cofactor
from genotype 1a (Fig. 4.14). Neither of the 2 recombinants replicated to detectable
levels in Huh7.5 cells, indicating that incompatibility issues of NS3 protease or NS4A
alone is not responsible for the defect in replication. Replacement of the NS3 protease
gene in J1a1a with that of patient-derived protease genes partly rescued the replication
defective phenotype of J1a1a, as described in section 4.2.3.
Figure 4.14: Genome map of the recombinants J1a3a and J3a1a. Genome map of
cDNA clones (pJ6CF, dark grey; pJFH1, white). The NS3 protease gen of JFH1 was
replaced with the corresponding intergenotypic gene (replaced region, coloured) using
the genetically engineered restriction sites BstBI and BglII. The NS4A gene of JFH1
was replaced with another corresponding intergenotypic geneusing the genetically
engineered restriction sites BlpI and MluI.
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Role of Huh7.5 cells in recombinant replication kinetics
Huh7.5 cells lose their susceptibility to support HCV replicat on when they are left to
grow to confluency. During passaging of Huh7.5 cells it was therefore made sure they
never reached more than 70-80 % confluency. Nevertheless, HCVRNA replicated
to lower levels in cells that have been passaged for several weeks before they were
transfected compared to fresh cells grown up from liquid nitrogen (Fig. 4.15). A large
number of Huh7.5 aliquots was therefore prepared, stored inliquid nitrogen and for
each transfection a fresh batch of cells grown up.
Days post-electroporation
































Figure 4.15: Passaging of J3a3a in fresh and passaged Huh7.5 cells.J3a3a repli-
cates more efficiently in fresh Huh7.5 cells than Huh7.5 cells that have been passaged
several times and have reached high confluency.
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4.2.3 Replication kinetics of J1a1a, J1b1b, J3a3a, J4a4a and J6a6a
containing NS3 protease genes derived from HCV-infected
patient plasma
This part investigates whether the differing replication ki etics of recombinants con-
structed from different genotypes were a consistent genotype-associated property or
whether it originated from naturally occurring variability between HCV variants within
a genotype. For this purpose recombinants from protease genes amplified from multi-
ple patients infected with genotypes 1a, 1b, 3a, 4a or 6a thatshowed markedly different
replication kinetics and abilities to generate infectiousvirus (Fig. 4.11, 4.12 and 4.13;
Table 4.1), were constructed. For each genotype, recombinants were created using
PCR-amplified protease sequences from epidemiologically unlinked patients infected
with genotypes 1a, 1b, 3a, 4a or 6a, which were then cloned into the corresponding
intergenotypic recombinant. From the 32 genotype 3a variants alysed in chapter 3,
the protease genes of 4 were used to replace the protease domain of J3a3a. Clones con-
taining amino acid polymorphisms not found in any other sequence in the Los Alamos
HCV sequence database, GenBank or the consensus sequences in our dataset (Fig. 3.3)
were discarded, ensuring representation of naturally occurring polymorphism, except
for J3a3a-6. J3a3a-6 has an Asn at position 1046, which is a polymorphic site with
Ser/Gly/Arg. Asn did not occur in the analysed dataset, but Ser1046Asn is a conserva-
tive amino acid change and might occur naturally. Clone J3a3a-6 possibly represents
a non-dominant viral variant of patient R11354 it was amplified from. Recombinants
with patient-derived NS3 protease genes were named Jxx-number of patient. All 4
constructs (J3a3a-3, -6, -8, -11) yielded replicating virus b t with different replication
kinetics (Fig. 4.16 top). J3a3a-11 (R11276) replication wasdetected in most cells on
day 9, slightly earlier than with J3a3a. J3a3a-8 (R11288) andJ3a3a-3 (R11482) spread
occurred after an eclipse phase of 28 days and that of J3a3a-6(R11354) after 37 days.
It was unclear whether the differences in the replication kinetics of the J3a3a recombi-
nants represented different degrees of compatibility betwe n the patient-derived pro-
tease sequences and the NS4A cofactor sequence derived fromthe reference strain or
whether there were specific compatibility problems with thegenotype 2a backbone
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sequence. To investigate this, we compared the NS4A sequences of the prototype
(HCV3a-Gla) with those of the 4 subjects (Table C.3, Appendix C). All J3a3a recom-
binants’ NS4A cofactor sequences were identical at the amino acid level, except for
a Leu1670Ile amino acid substitution in the J3a3a-11 recombinant. Leu1670 is domi-
nant among genotype 3a variants, although 14 sequences withVal and 3 with Phe were
identified among the 180 variants analysed. These observations indicate that reduced
compatibility between the NS3 protease and the prototype HCV3a-Gla NS4A is most
likely not a determinant for the observed differences in thereplication kinetics of the
J3a3a recombinants. Differences in replication kinetics between the different J3a3a
recombinants are therefore most likely due to the protease itself.
By the same methods, J1a1a recombinants with patient-deriveproteases were created.
From the 29 genotype 1a variants analysed in chapter 3, the prot ase genes of 9 were
used to replace the protease domain of J1a1a. 7 recombinantsreplicated to detectable
levels, J1a1a-1 (R11188), -2 (R11159), -3 (R11148), -4 (R11143), -5 (R11296), -6
(R11256) and -8 (R11249). J1a1a-7 (R11256) and J1a1a-9 (R11220)did not produce
any detectable virus (Fig. 4.18). However, none spread to more than 0.08 % of the
cell culture and all cells were NS5A-negative after 30 days.Except for J1a1a-1, all
J1a1a recombinants contained naturally occurring amino acid polymorphisms repre-
sented among sequences of the 570 variants available from the databases and the 31
variants analysed in chapter 3 (Table C.2, Appendix C). In contrast, J1a1a-1, which
was the recombinant showing the best replication kinetics,contained one amino acid
substitution (Glu1056Gly) that does not occur in any other variant analysed. To in-
vestigate whether the H77*-NS4A cofactor was responsible for the severally impaired
replication fitness of the J1a1a recombinants, NS4A amino acid sequences of subjects
whose proteases were used in the recombinants, were compared with that of H77*.
The membrane segment and the NS3 cofactor region showed amino cid identity (Ta-
ble C.2, Appendix C). Some polymorphisms occurred in the C-terminal domain of the
NS4A cofactor, which though, is not involved in the direct interaction with the NS3
protease (Brasset al. (2008)). Differences in replication kinetics between the differ-
ent J1a1a recombinants are therefore most likely due to the prot ase itself. Whether
the overall poor replication kinetics of the J1a1a recombinants can be attributed to
139
Construction of Intra- and Intergenotypic Recombinants
the reduced enzymatic function of the 1a proteases or their incompatibility with the
remaining type 2a sequence remains to be investigated.
The generation of J4a4a patient-derived protease recombinants resulted in a replicat-
ing virus in 3 (J4a4a-7, -8, -19) out of 4 (J4a4a-7, -8, -9, -10) recombinant viruses
(Fig. 4.17 bottom). A total of 40-50 % of all cells were positive for NS5A 4 days
post-electroporation with J4a4a-7 and J4a4a-19 RNA, whereas J4 4a-8 only repli-
cated to very low levels. J4a4a-ED43* (Ala1048 and Ile1064), J a4a-7 (Thr1039 and
Arg1056), J4a4a-10 (Pro1169) and J4a4a-19 (Ile1153) all show amino acid polymor-
phisms which do not exist in any other genotype 4a variant analysed (n = 39) (Table
C.4, Appendix C). Only recombinant J4a4a-8 shows an amino acidpolymorphism that
also exists within the 4a variants from the database. It is unclear which amino acid
polymorphism contributes to the impaired replication phenotype in J4a4a-ED43* and
J4a4a-10.
The generation of J1b1b patient-derived protease recombinants resulted in replicating
virus for both of the generated recombinants J1b1b-2 and J1b1b- 2, with both showing
similar replication kinetics to the prototype recombinantJ1b1b (Fig. 4.17 top). All
amino acid polymorphisms in the 2 recombinants are naturally occurring (Table C.1,
Appendix C). The same was true for J6a6a patient-derived protease recombinants
(Fig. 4.16 bottom). J6a6a-4 immediately infected 70-80 % ofthe cell culture, whereas
J6a6a-8 took 30 days to spread to the rest of the cell culture,similar to the prototype
recombinant J6a6a. All amino acid polymorphisms in the 2 recombinants are naturally
occurring (Table C.5, Appendix C).
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Figure 4.16: J3a3a and J6a6a patient-derived protease recombinants andtheir vi-
ability in Huh7.5 cells. The protease region of J3a3a (top) and J6a6a (bottom) was
replaced with that of 2 or 4 patient-derived protease genes and their replication ca-
pacity assessed in the Huh7.5 cells.
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Figure 4.17: J1b1b and J4a4a patient-derived protease recombinants andtheir vi-
ability in Huh7.5 cells. The protease region of J1b1b (top) and J4a4a (bottom) was
replaced with that of 2 or 4 patient-derived protease genes and their replication ca-
pacity assessed in the Huh7.5 cells.
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Figure 4.18: J1a1a patient-derived protease recombinants and their viability in
Huh7.5 cells. The protease region of J1a1a was replaced with that of 9 patient-
derived protease genes and their replication capacity assessed in the Huh7.5 cells.
The replication levels of the J1a1a recombinants were very low and the scale adjusted
accordingly.
143
Construction of Intra- and Intergenotypic Recombinants
4.2.4 Identification of adaptive and attenuating mutations in re-
covered Jx and Jxx viruses
J5a, J6a6a and the patient-derived recombinants J3a3a-3, J3a a-6 and J3a3a-8 only
spread in the cell culture after an eclipse phase. To investigate whether the delay in
replication reflected a requirement for adaptive mutationst allow efficient replica-
tion, the nt sequence from the NS3 protease and NS4A gene regions amplified from
cell culture supernatants after the recombinant had spreadto 80 % of the cell culture
was determined (Table 4.2). The gene region from nt position2863 to 4178, which
included the 3’end of NS2 and the 5’end of the NS3 helicase andnt position 5230 to
5536, including NS4A, were sequenced at peak infectivity ofthe individual viruses.
In the recovered genome of passaged J3a3a-6, mutations weredetected within NS2
(A3364G), the NS3 protease (A3478G) and the NS3 helicase domain (A4005T) in all 5
clones analysed. These led to a Gln1008Arg amino acid changein NS2, a Asn1046Ser
amino acid change in the NS3 protease domain and a Thr1222Seramino acid change
in the NS3 helicase domain. In the recovered genomes of passaged J3a3a-8 and J3a3a-
3, no substitutions were detected except in NS4A, where all 5clones analysed had the
C5328G and T5329C substitutions among others. The resultingLeu1663Arg amino
acid substitution only became dominant in the J3a3a recombinant after 43 days pas-
saging in the cell culture.
J5a had 2 substitutions within the NS3 protease domain (A3649G and C3854G), lead-
ing to the amino acid substitutions Asn1103Ser and Cys1171Trp. Within the type 2a
NS4A, one nt substitution (G5430A) led to the amino acid change Asp1679Asn. The
J6a6a recombinant virus had 2 substitutions (A3558G and G3439T), resulting in a
Val1040Leu amino acid change within the N-terminal part of the NS3 protease. This
amino acid is highly conserved among all genotypes, only allowing Leu, Val or Ile
(Brasset al. (2008)). Both J2a2a and J5a5a replicated to high levels in cell culture,
accompanied by increased cell death. After an initial clearance of the virus, both spread
in cell culture again, indicating the acquisition of attenuating mutations (Fig. 4.12). A
C3538G nt change within the protease domain of J2a2a leads to aThr1066Ser amino
acid change. Within J5a5a, 3 nt changes (C3416G, T3968C and A4081T), leading to
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a Gln1247Leu amino acid change, were identified (Table 4.2).
Table 4.2: Mutations of Jx and Jxx recombinants during passaging in Huh7.5 cells.
Nt positions are numbered according to the H77 (AF009606) reference position.
Viral variant NS2 NS3 protease NS3 helicase NS4A
J5a A3649G + C3854G G5430A
J2a2a C3538G
J3a3a C5328G + T5329C
J3a3a-3
Clone 1,4,5 C5328G + T5329C
Clone 2 C5328G + T5329C + T5365C
Clone 3 C5328G + T5329C + T5447C
Clone 6 C5328G + T5329C + T5358C
J3a3a-6
Clone 1-4 A3364G A3478G A4005T
Clone 5 A3364G A3478G A4005T + A3362G
J3a3a-8
Clone 1,3,5 C5328G + T5329C
Clone 2 C5328G + T5329C + T5389C
+ A5434G
Clone 4 C5328G + T5329C + A5472G
J5a5a C3416G T3968C + A4081T
J6a6a A3458G + G3459T
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4.2.5 Recombinant adapted/attenuated viruses efficiently infect
Huh7.5 cells
To identify whether the substitutions occurring in NS4A accounted for the differences
in replication kinetics of the J3a3a-3 and -8 recombinant viruses, mutations were in-
troduced into the original plasmids and their viability tested in Huh7.5 cells. Both
J3a3a-3-L1663A and J3a3a-8-L1663A spread directly within the cell culture and after 11
and 17 days, respectively, almost all cells were infected, with replication kinetics sim-
ilar to that of J3a3a and J3a3a-11 (Fig. 4.19). The Leu1663Ala amino acid change at
the 5’end of NS4A was therefore sufficient to restore efficient r plication. In contrast,
J3a3a-6-Q1008R,N1046S,T1222Sinfected 4 % of Huh7.5 cells after only 3 days compared to
the original J3a3a-6, which took 20 days before any Huh7.5-positive cells could be
detected (Fig. 4.20 top). The mutant failed to subsequentlyspread to the rest of the
cell culture, indicating the likely presence of mutations outside of the sequenced NS3
protease and NS4A gene region in the original adapted clone.
Reintroducing the Val1040Leu amino acid change into J6a6a generated a recombi-
nant (J6a6a-V1040L) which showed improved replication kinetics as well (Fig. 4.20 bot-
tom). At 2 days post-electroporation, J6a6a-V1040L replicated in 80 % of the cell culture
and continued to infect most of the cell culture 14 days post-electroporation. J2a2a
and J5a5a both replicated to high levels but replication wasaccompanied by increased
cell death. Reintroducing the identified mutations (Table 4.2) generated 2 attenuated
viruses, J2a2a-T1066S and J5a5a-Q1247L (Fig. 4.21). Both J2a2a-T1066S and J5a5a-Q1247L
were immediately able to infect about 80 % of the cell cultureand continued to infect
the majority of cells 14 days post-electroporation. Decreased cell death was observed
as well.
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Figure 4.19: Recombinants J3a3a-3 and J3a3a-8 including adaptive mutations and
their viability in Huh7.5 cells. Viability of J3a3a-3-L1663A and J3a3a-8-L1663A were
assessed by anti-NS5A immunostaining.
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Figure 4.20: Recombinants J3a3a-6 and J6a6a including adaptive mutations and
their viability in Huh7.5 cells.Viability of J3a3a-6-Q1008R,N1046S,T1222Sand J6a6a-V1040L
were assessed by anti-NS5A immunostaining.
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Figure 4.21: Recombinants J2a2a and J5a5a including attenuating mutations and
their viability in Huh7.5 cells.Viability of J2a2a-T1066Sand J5a5a-Q1247Lwere assessed
by anti-NS5A immunostaining.
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Genetic stability of J3a3a
To investigate whether recombinant virus secreted into thesupernatant of the cell cul-
ture infects näıve cells, TCID50 measurements were performed (Table 4.1). Using
the J3a3a recombinant it was also investigated how this infectious viral recombinant
spreads within a cell culture of naı̈ve Huh7.5 cells. J3a3a cell culture derived super-
natant was passed through a 0.2µm filter to remove all cells, diluted 1 in 5 and used
to infect näıve Huh7.5 cells. Supernatants collected from the J3a3a passaging exper-
iment (Fig. 4.13 top, J3a3aA) on day 15 and day 30 were compared (Fig. 4.22).
Day 30 supernatant spread faster than day 15 supernatant, indicat g that the infec-
tivity of cell culture supernatant has increased during theinitial cell culture passaging
experiment. After 24 days of passaging, the entire genome ofday 30 supernatant re-
covered virus was sequenced. Besides the before described cell culture adaptive muta-
tion (Leu1663Ala), no additional mutations were identifiedin the consensus sequence,
indicating stable replication of J3a3a in Huh7.5 cells.
Sequencing
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Figure 4.22: Passaging of J3a3a supernatant (SN) in naı̈ve Huh7.5 cells. Super-
natant collected on day 13 and day 30 from the J3a3a passagingexperiment (Fig. 4.13
top, J3a3aA) was used to infect naı̈ve Huh7.5 cells and spread within the cell culture
followed by anti-NS5A immunostaining. The arrow indicates the day of supernatant
collection for whole genome sequencing.
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4.2.6 Summary of results
A panel of intra- and intergenotypic recombinants based on the full-length replication-
competent clone Jc1 were constructed and their replicationssessed in the Huh7.5 cell
culture system. Using naturally occurring restriction site o replace a fragment in-
cluding the NS3 protease plus parts of NS2 and the NS3 helicaswith that of Jc1,
resulted in replication defective recombinants. The introduction of unique restriction
sites on the boundaries of the NS3 protease led to a replication competent intergeno-
typic recombinant for genotype 5a. Including the NS4A cofactor gene in the recom-
binant construction rescued the intergenotypic recombinants of genotype 1b, 3a and
6a. For genotype 1a and 4a including the homologous NS4A was not ufficient to re-
store replication. However, additional replacement of theNS3 protease with that of
patient-derived ones improved replication kinetics to detectable levels. Intra- and in-
tergenotypic recombinants varied widely in their replication kinetics. Some required
adaptive, others attenuating cell culture mutations. Reintroducing these into the orig-
inal viruses resulted in stably replicating intra- and intergenotypic recombinants. The
generated intergenotypic recombinants provide an effectiv ell culture system for the
assessment of antiviral susceptibilities and resistance dev lopment of NS3 protease
genes for the 6 major genotypes of HCV.
4.3 Discussion
The genetic variability of HCV proteins of different genotypes influences the molecular
structure of protease and polymerase enzymatic sites and potentially limits the effec-
tiveness of antiviral therapy targeting viral replicationproteins (Holland-Staleyet al.
(2002)). As discussed in section 1.8.1, the PI BILN 2061 showsa nearly 2 log weaker
binding affinity to genotype 2 and 3 proteases than to type 1 proteases (Thibeaultet al.
(2004)), a difference that translates to much weaker antiviral efficacy of BILN 2061
among patients with HCV genotype 2 or 3 infection (Reiseret al. (2005)) than those
with genotype 1 (Lamarret al. (2003)). The reduced effectiveness of antiviral drugs
on certain genotypes also potentially facilitates the development of resistance muta-
151
Construction of Intra- and Intergenotypic Recombinants
tions. Another PI, VX-950, showed similar efficacy in genotype 1a, 1b and 2a, but
lower efficacy in genotype 3a (Perniet al. (2006); Reesinket al. (2006)).
Current drug discovery and optimisation is mostly dependenton laboratory-optimised
standard replicons. However, the standard replicon systemonly allows the evaluation
of a limited number of laboratory strains that do not reflect the great genetic inter- and
intragenotypic diversity of HCV. Different replicon-basedvector approaches have to
date been limited to the investigation of the activity of compounds against different
HCV variants from genotype 1 to 4 (Bindert al. (2007); Qiet al. (2009)). However,
the replicon based system does not include structural genesand therefore does not rep-
resent the full viral life cycle of HCV. This chapter describes the development of a full-
length HCV cell culture system, allowing the study of the NS3 protease of the 6 major
genotypes. Recombinant viruses were constructed from Jc1, an intr genotypic geno-
type 2a recombinant, which replicates efficiently in Huh7.5cells (Pietschmannet al.
(2006)). The resulting recombinant viruses encode the NS3 protease or the NS3 pro-
tease and NS4A gene from genotype 1a, 1b, 2a, 3a, 4a, 5a or 6a prototy e strains or
different clinical variants, respectively.
At the beginning only Huh7 cells and pJFH1, the first full-length HCV RNA to repli-
cate efficiently in Huh7 cells, were available and recombinants were constructed with
pJFH1 as a backbone (Wakitaet al. (2005)). Initially, naturally occurring restriction
sites were used to swap a fragment of JFH1 including the NS3 protease with the equiv-
alent from genotype 1a or 3a prototype plasmids. The fragment also contained part
of the NS2 protein and the NS3 helicase domain, resulting in intergenotypic NS2 and
NS3 helicase proteins. The replication kinetics of the resulting recombinants, Fn1an
and Fn3an, were assessed in the Huh7 cell culture system by immunostaiing for the
non-structural protein NS5A. Neither of the recombinants produced detectable virus,
suggesting that the recombinants were either replication incompetent or the replication
fitness was too low to be detected by immunostaining. The generated intergenotypic
NS2 and NS3 helicase proteins are possibly not functional. The 3D structure of a pro-
tein is important for its function and changing amino acids within a protein will most
likely alter its 3D structure and thereby affect the function. The replication defect of
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the recombinants might also be due to incompatibilities betwe n the genotype 1a/3a
proteins and the genotype 2a backbone. The genotype 2a sequenc of the NS3 protease
differs considerably to that of genotype 1a and 3a (Fig. 4.23). Furthermore, the NS3
protease closely interacts with its cofactor NS4A and genotype 1a/3a proteases might
work less efficiently with a genotype 2a NS4A cofactor, as discus ed below.
Figure 4.23: Comparison of genotype 1a, 1b, 2a, 3a, 4a, 5a and 6a NS3 protease
and NS4A cofactor sequences.Top, alignment of NS3 protease residues (in black)
from recombinants J1a1a, J1b1b, J2a2a, J3a3a, J4a4a, J5a5aand J6a6a to JFH1
(NCBI accession number AB047639). Bottom, alignment of NS4A protease cofactor
residues (in black) from recombinants J1a1a, J1b1b, J2a2a,J3 3a, J4a4a, J5a5a and
J6a6a to JFH1. Dots indicate amino acid sequence identity.
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Because recombinants based on the JFH1 clone were not replicating to detectable lev-
els in the Huh7 cell culture system, further recombinants were constructed based on
the Jc1 backbone. Jc1 is an intragenotypic genotype 2a recombinant, which replicates
efficiently in Huh7.5 cells and yields infectious titres 100to 1,000-fold higher than
JFH1 (Pietschmannet al. (2006)). Furthermore, Huh7 cells were replaced with the far
more permissive Huh7 subclone Huh7.5, in which HCV variants replicate to higher
levels (Blightet al. (2002); Sumpteret al. (2005)).
To reduce a possible influence of intergenotypic NS2 and NS3 helicase proteins on re-
combinant viability, 2 unique restriction sites were introduced at the boundaries of the
NS3 protease. This allowed the construction of intra- and intergenotypic recombinants
including the NS3 protease alone from another genotype. However, the attempt to re-
place the NS3 protease alone was not successful in creating replication competent in-
tergenotypic viruses, except for genotype 5a (J5a) (Fig. 4.7), which only spread within
the cell culture after acquiring adaptive mutations (Table4.2). Two adaptive mutations
were identified within the NS3 protease (Asn1103Ser and Cys1171Thr) and one within
NS4A (Asp1697Asn). Asn1103 is the dominant amino acid within all genotypes ex-
cept those of type 2a, where Ser is dominant. This suggests that the Asn1103Ser amino
acid change towards type 2a consensus sequence is a rescue for the incompatibility be-
tween the type 5a NS3 protease and the remaining type 2a sequence. Cys1171 is part
of the zinc binding site Cys1123, Cys1125, Cys1171 and His1175,playing a struc-
tural role (De Francescoet al. (1996); Kimet al. (1996)). It has been reported that
these 3 Cys are necessary within NS3 (Tedbury & Harris (2007)), though one geno-
type 1b variant with Trp1171 and one genotype 3a variant withTyr1171 can be found
among GenBank variants. It cannot be excluded that those arosdue to Taq errors or
represent non-viable variants, but as the consensus sequence of a viable variant was
sequenced here, it is unlikely that Cys1171Thr is a Taq error.As Thr is bulkier and
bigger than Cys, this amino acid change might result in changes in the 3D structure
of the protease to better interact with the remaining type 2aproteins. Asp1697Asn is
part of the C-terminal acidic domain of NS4A, which has been shown to fold into an
α-helix in a pH-dependent manner. Using Ala substitutions ithas been demonstrated
that Asp1697, among other residues within the C-terminus, iscrucial in RNA repli-
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cation (Lindenbachet al. (2007)). Also, Asp1697 is dominant among all genotypes,
supporting a crucial role of Asp at this site. However, Asn1697 is tolerated as well,
as some genotype 1 sequences within GenBank have an Asn1697. The Asp1697Asn
amino acid change might therefore play a structural role as well. Introducing the indi-
vidual adaptive mutations into the original J5a recombinant would be necessary to get
conclusive results on the influence of the individual mutations on the replicative fitness
of J5a.
Jc1 including the 2 unique restriction sites (Jc1-BB) and the intragenotypic recom-
binant J2a replicated similarly to the parental strain (Fig. 4.5 and 4.7), indicating
that the introduction of new restriction sites and fragmentswapping has not a major
affect on the replication ability of Jc1. Since the NS3 protease forms a stable com-
plex with NS4A (Bartenschlageret al. (1995)) and is required for itstrans cleavage
activity and membrane anchoring (Faillaet al. (1994, 1995); Tanjiet al. (1995)), it
was reasoned that the poor replication ability of most Jx constructs may have origi-
nated through incompatibilities between these 2 protease components. Due to their
close interaction and the substantial sequence variability in he NS4A contact zone
of genotype 2a and the other genotypes (Fig. 4.23), it might be expected that cofac-
tors of different genotypes might attenuate protease activity. However, it has been
shown that the NS3 protease domain can functionally cross-interact with the NS4A
cofactor from another genotype (Francoet al. (2008); Wright-Minogueet al. (2000))
and NS3 protease genes from different genotypes cloned into1b/2a reference strain
replicons do produce replication competent replicons. Attempts by other groups to in-
clude full-length NS3/4A genes of other genotypes, including the helicase, in the 1b
or 2a chimaeric replicon system generally failed to create effici ntly replicating repli-
cons, although in the latter case this may reflect a further compatibility restriction for
the helicase to be of the same genotype as the RNA polymerase encoded by NS5B
(Binderet al. (2007); Qiet al. (2009)).
The NS4A of genotype 2 has been shown to be much less efficient in heterologous
combinations than those of other genotypes (Wright-Minogueet al. (2000)), which
might explain why most of our recombinant viruses containing the type 2a cofactor
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did not replicate efficiently enough for detection. NS4A of genotype 1a, 1b, 3a, 4a, 5a
and 6a are more similar to each other on the amino acid sequence l vel than they are to
genotype 2a (Fig. 4.23). Why though the genotype 5a protease forms a viable complex
with the 2a backbone and the others do not remains unclear.
To resolve this compatibility issue, the corresponding homol gous genotype specific
NS4A cofactor was included in the construction of the recombinant viruses (Fig. 4.8
and 4.9). This led to viable recombinants for genotypes 1b, 2a, 3a, 5a and 6a (Fig. 4.11,
4.12 and 4.13). Preliminary experiments in Huh7 cells, comparing the JFH1 based
recombinant F3a3a with the Jc1 based recombinant J3a3a, showed as expected that
recombinants based on the Jc1 backbone replicated more effici ntly (Fig. 4.10). J1a1a
and J4a4a were impaired in their replication, but replacement of the NS3 protease gene
in J4a4a with that of patients allowed the generation of replication competent 4a re-
combinants (Fig. 4.11 bottom and 4.17 bottom). As expected,J2a2a replicated most
efficiently and immediately spread within the cell culture (Fig. 4.12 top) and J5a5a
also spread to most cells within 2 days (Fig. 4.12 bottom), both c mparable with the
parental Jc1. Similarly, the spread of Jc1 and these 2 recombinant viruses was also ac-
companied by increased cell death, followed by proliferation of HCV-NS5A negative
Huh7.5 cells, as described in previous studies (Zhonget al. (2006); Gottweinet al.
(2007); Mateuet al. (2008); Scheelet al. (2008)). Reintroduction of attenuating mu-
tations into J2a2a and J5a5a (Table 4.2) allowed the generation of 2 recombinants
which immediately and continuously infected the cell culture and were associated with
decreased cell death (Fig. 4.21). The Thr1066Ser amino acidchange within the NS3
protease of J2a2a is a change towards the JFH1 sequence, which has Ser1066. Thr1066
is dominant among genotype 2 sequences, but Ser1066 occurs as well and is therefore
naturally occurring. The attenuating effect of Thr1066Seron J2a2a is in accordance
with the lower replication kinetics of JFH1 compared to Jc1.For J5a5a an attenuating
amino acid change was found within the NS3 helicase domain, Gln1247Leu. Gln1247
is dominant across genotypes, indicating a crucial role of Gln at this position. A non-
conservative amino acid change away from the consensus sequence of HCV explains
the attenuating effect of Gln1247Leu.
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In contrast, the observed clearance of J1b1b and J4a4a-19 after tr nsfection is the likely
consequence of their failure to generate any infectious virus (Fig. 4.11). Unlike the
other recombinant viruses, where spread is reduced after anclipse phase, J3a3a con-
tinuously infected about 80 % of the cell culture, with high frequencies of infected
cells even after 70 days of passaging in cell culture (Fig. 4.13 top). As it has been
shown that the catalytic efficiencies of genotype 1a, 3a and 4a proteases are similar
(Francoet al. (2008)), the inability of genotype 1a and some genotype 4a recombi-
nants to replicate efficiently likely is a consequence of theincompatibility between the
NS3 protease/NS4A and the remaining type 2a sequence.
J1a1a and J4a4a both differ from the prototype sequences H77and ED43 by one (H77-
Met1205Thr) and 4 (ED43-Thr1048Ala, Thr1064Ile, Ile1160Thr and Arg1176Ala)
amino acids, respectively, in the protease gene, whereas both are homologous to H77
and ED43, respectively, in the NS4A gene (Table C.2 and C.4, Appendix C). Met1205
is predominant among genotype 1a variants, although one of the 570 available se-
quences of other genotype 1a variants contained a Thr residue at this site, one a Val
and one an Ile. Four of 459 genotype 1b variants in the HCV database contained the
Thr residue at this position as well, largely discounting this substitution as a cause
of the poor replication ability of the J1a1a clone. In contrast, the Thr1048Ala muta-
tion in genotype 4a is, with one exception in a genotype 3a variant (Ala1048), absent
among protease gene sequences of all genotypes including all available genotype 4a
sequences (n = 39). The presence of an Ala at this site is therefor certainly con-
sistent with the poor/impaired replication of J4a4a. The same is true for Thr1064,
which is, with the exception of one variant, conserved amongthe analysed variants of
genotype 1a, 1b, 3a, 4a and 6a. However, in genotype 2 variants a Thr/Ser polymor-
phism can be found at this position, suggesting that mutation at this site is tolerated.
Nevertheless, Thr1064Ser is a conservative amino acid change, whereas Thr1064Ile is
non-conservative and possibly affecting the fitness of J4a4a. Thr1160 and Ala1176 are
the predominant amino acids at these positions within the genotype 4a variants anal-
ysed, making these substitutions unlikely candidates for the poor replication kinetics
of J4a4a.
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The J6a6a recombinant only spread within the cell culture aft r an eclipse phase,
indicating adaptive mutations (Fig. 4.13 bottom). The identified mutation within
the NS3 protease (Val1040Leu) is a change at a position with ahighly conserved
Leu/Val/Phe/Met polymorphism and reintroducing it into the original recombinant res-
cued its impaired replication kinetic (Fig. 4.20 bottom). Val1040 is part of a highly
conserved NS3 amino acid segment (residue 1036-1050) that forms anα-helix. The
hydrophobic residues at positions 1039, 1040, 1043, 1044 and 1047 are conserved
among all HCV genotypes and form the very strong hydrophobic side of the helix on
the protein surface (Brasset al. (2008)). Val1040Leu is a conservative amino acid
change maintaining the hydrophobic character, but changing towards the more domi-
nant amino acid at a polymorphic site, explaining the big impact Val1040Leu has on
the replication fitness of J6a6a.
Even though the NS3 protease is considered one of the more conserved proteins en-
coded by the HCV genome, different genotypes do show substantial mino acid se-
quence variability that potentially influences its structure and function (Holland-Staley
et al. (2002); Lodriniet al. (2003); Valletet al. (2005); Winterset al. (2006)). Fur-
thermore, it has been demonstrated that catalytic efficiencies within a subtype can vary
widely, especially within genotype 1b, whereas genotype 3aproteases showed the most
homogenous range of activities (Francoet al. (2008)). Cloning of patient-derived NS3
protease genes of genotype 1 into the 1b replicon construct has s own 2- to 7-fold dif-
ferences in the replication capacities of the constructs (Qi et al. (2009)). To investigate
the influence of these intrasubtype sequence differences onrec mbinant viability, NS3
protease gene sequences from study patient plasma samples wer directly amplified
and cloned into the corresponding J1a1a, J1b1b, J3a3a, J4a4a and J6a6a recombinant
viruses.
All 4 J3a3a recombinants constructed from the original J3a3a and patient-derived pro-
tease genes generated viable recombinants (Fig. 4.16 top).The 2 recombinants J3a3a-3
and -8, which showed diminished replication kinetics, could be rescued by introducing
an adaptive Leu1663Ala amino acid change within the membrane segment of NS4A
(Fig. 4.19). The Leu1663Ala amino acid change presumably iscrucial for efficient and
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continuous spread of the J3a3a recombinants as it was observed within the J3a3a re-
combinant as well after 43 days in cell culture (Table 4.2). Furthermore, Leu1663Ala is
an amino acid change towards the consensus genotype 2a sequenc , suggesting adap-
tation to the Jc1 backbone sequence. Position 1663 is part ofthe membrane segment
and the amino acid repertoire of 26 reference positions is Val/Ala/Leu, with Val being
the most frequent one (Brasset al. (2008)). The Leu1663Ala is therefore an amino
acid change towards the more frequently occurring amino acid, explaining its posi-
tive effect on the replicative fitness of J3a3a-3 and -8. Passaging J3a3a supernatant in
näıve Huh7.5 cells did not reveal any further mutations, indicating that J3a3a stably
replicates in Huh7.5 cells. Three adaptive mutations were ident fied in virus recovered
from the J3a3a-6 cell culture. Gln1008Arg (NS2 protein) andThr1222Ser (NS3 heli-
case domain) are both amino acid changes from genotype 2 to genotype 3 sequence.
This suggests that these residues are interacting with the NS3 protease and the substi-
tutions counteract incompatibilities between the genotype 3a protease and the type 2a
NS2 and NS3 helicase proteins. Ser1046Asn is an amino acid change back towards
consensus genotype 3 sequence. This suggests that the chosen lon represents a qua-
sispecies with reduced fitness and the mutation towards consensu sequence rescues it.
Reintroduction of these into the original J3a3a-6 resulted in a virus that immediately
was detectable in Huh7.5 cells but did not spread any faster than the wild type after an
initial spread to 10 % of the cell culture. This suggests thatt ere are other determinants
for efficient spread of this recombinant (4.20 top).
Similarly, NS3 proteases from patients infected with genotype 1b, 4a or 6a were cloned
into the corresponding J1b1b, J4a4a and J6a6a recombinants. Bo h J1b1b recombi-
nants with patient derived protease genes replicated to thesam extent as the prototype
J1b1b, indicating that patient-derived sequences can be easily swapped and analysed
(Fig. 4.17 top). Replacement of the NS3 protease gene of the J4a4a prototype recom-
binant with those amplified from genotype 4a-infected patients reversed the impaired
replication phenotype in 3 (J4a4a-7, -8, -19) out of 4 cases (Fig. 4.17 bottom). J4a4a-7
and J4a4a-19 replicated similarly to J1b1b, whereas J4a4a-8 replication kinetics were
very low and those of J4a4a and J4a4a-10 were below detectionlimit. To which amino
acid polymorphism this discrepancy is due is unclear, as noto ly J4a4a and J4a4a-10,
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but also J4a4a-19 and -7 have an amino acid polymorphism thatdoes not occur in any
other sequence of the analysed dataset. Replacing the J6a6a NS3 protease with that of
patient-derived genes resulted in replicating recombinants in both cases (J6a6a-4 and
-8) (Fig. 4.16 bottom). J6a6a-4 immediately spread within te cell culture and main-
tained a continuous infection, whereas J6a6a-8 showed a replication profile similar to
that of prototype J6a6a. As discussed above, Val1040Leu hasbeen identified to be a
crucial adaptive change for J6a6a. J6a6a-8 also contains a Val at position 1040 whereas
J6a6a-4 contains an Ile, a bulkier amino acid similar to Leu which may underlie its im-
proved replication kinetics.
In a similar manner, NS3 proteases from patients infected with genotype 1a were
cloned into the corresponding J1a1a recombinants. The replication kinetics of the
resulting recombinants were very low or below detection limit and none of the viruses
were able to acquire adaptive mutations; all Huh7.5 cell cultures were NS5A-negative
after 30 days (Fig. 4.18). It has been reported that thein vitro catalytic efficiency of the
genotype 1a NS3 protease is similar to those of 3a and 4a, bothof w ose recombinants
were replication competentin vitro (Francoet al. (2008)). It is therefore unlikely
that the J1a1a recombinants reproduce less efficiently thanthe J3a3as and J4a4a-7 and
J4a4a-19 because of differences in the enzymatic activity of he proteases. This sug-
gests that genotype 1a NS3 protease/NS4A are less compatible with the genotype 2a
backbone than genotype 1b, 3a, 4a, 5a and 6a.
To investigate why J5a was replication competent and the othr Jxs not and why J5a5a,
J3a3a and J6a6a replicated more efficiently than J1a1a, J1b1b and J4a4a, their nt and
amino acid sequence within the NS3 protease and NS4A gene were compared to that
of JFH1 (Table 4.3). No significant difference between the sequence divergence of the
different Jxxs to JFH1 could be identified, suggesting that te differences in replication
kinetic are due to specific individual amino acids rather than the overall sequence.
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Table 4.3: Nucleotide and amino acid sequence divergence within the NS3protease
and the NS4A gene between JFH1 and Jxx.The nt and amino acid sequence of
the NS3 protease and the NS4A cofactor gene of each Jxx were compared with that
of JFH1. Using p-value calculations the sequence divergence between JFH1 and Jxx
was determined (JFH vs. Jxx, JFH1 sequence compared to the corr sp nding Jxx
sequence).
JFH1 vs. Jxx Nucleotide sequence Amino acid sequence
divergence (%) divergence (%)
NS3
JFH1 vs. J1a1a 34.6 28.0
JFH1 vs. J1b1b 33.9 30.0
JFH1 vs. J2a2a 10.5 7.0
JFH1 vs. J3a3a 35.5 27.0
JFH1 vs. J4a4a 35.7 29.0
JFH1 vs. J5a5a 34.8 26.0
JFH1 vs. J6a6a 34.4 24.0
NS4A
JFH1 vs. J1a1a 35.7 32.1
JFH1 vs. J1b1b 35.7 32.1
JFH1 vs. J2a2a 12.5 5.4
JFH1 vs. J3a3a 41.7 35.7
JFH1 vs. J4a4a 42.9 33.9
JFH1 vs. J5a5a 40.5 33.9
JFH1 vs. J6a6a 38.7 33.9
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4.4 Conclusion
This chapter describes the development of a full-length HCV cell culture system, which
allows the investigation of protease gene function in all 6 major genotypes, a much
greater range than the genotype 2a and 1a full-length replication competent clones de-
scribed previously (Lindenbachet al. (2005); Wakitaet al. (2005); Yiet al. (2006b);
Murayamaet al. (2007a)). Replacing the NS3 protease alone only generated a replica-
tion competent intergenotypic recombinant for genotype 5a. Including the NS4A gene
in the recombinant construction resulted in replication competent intra- and intergeno-
typic recombinants representing all 6 major genotypes. Through introduction of cell
culture adaptive/attenuating mutations, stably replicating recombinants could be cre-
ated for genotype 2a, 3a, 5a and 6a. The developed system represents a powerful tool
to study the NS3 protease within the full viral life cycle andadds to the currently avail-
able JFH1-based systems for the study of the non-structuralgenes (Pietschmannet al.
(2006); Gottweinet al. (2007); Yiet al. (2007); Jensenet al. (2008); Scheelet al.
(2008); Gottweinet al. (2009)). This system allows the assessment of antiviral sus-
ceptibilities and resistance development of HCV NS3 protease genes from genotypes
1 to 6, which will be described in chapter 5 and 6. The ease withhich protease gene
sequences directly amplified from clinical specimens can beins rted in the expres-
sion vector of the appropriate genotype, allows quick assessm nt of the huge diversity
within HCV genotypes, subtypes and quasispecies variants.
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Chapter 5
Susceptibility of Different HCV
Genotypes to PIs
5.1 Introduction
The HCV-NS3 serine protease is essential for viral replication and therefore an attrac-
tive target for HCV-specific antiviral therapy (Pawlotsky & McHutchison (2004)). As
discussed in section 1.8.1 and chapter 3, the genetic variability of HCV proteins en-
coded by different genotypes results in substantial differences in the molecular struc-
ture of protease and polymerase enzymatic sites. Because antiviral drugs are often
specifically designed for the protease of one genotype, theycan show limited efficacy
in other genotypes (Holland-Staleyt al. (2002)). One of the first PIs developed was
BILN 2061, which is a small, orally bioavailable molecule identified in a substrate-
based approach (Fig. 5.1 left) (Lamarreet al. (2003)). BILN 2061 was specifically
developed for genotype 1 enzymes and was the first PI to enter clinical trials. Geno-
type 1 infected patients showed an impressive reduction in HCV RNA levels after only
2 days, with some patients even reaching undetectable levels within 24-28 hours after
administration (Lamarret al. (2003)). Due to structural differences in the protease
protein, BILN 2061 showed weaker binding affinity for genotype 2 and 3 proteases
(Thibeaultet al. (2004)) and as expected lower efficacy in patients infected with geno-
type 2 and 3 (Reiseret al. (2005)). However,Ki values for nongenotype 1 NS3/4A
proteins are still below 100 nM, making it a potent and competitiv inhibitor for all
genotypes. Even though further development of BILN 2061 had to be halted due
to cardiotoxicity in laboratory animals, it is a good PI for proof of concept studies
(Vanwolleghemet al. (2007)).
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VX-950 is another PI with potent activity against genotype 1and 2 NS3/4A proteins
(Fig. 5.1 right) (Reesinket al. (2006)), but lower efficacy against genotype 3a pro-
teases (Perniet al. (2006); Paulsonet al. (2009); Fosteret al. (2009)). The case of
BILN 2061, and VX-950 later, demonstrated very early on that it is crucial to inves-
tigate drug efficacies in all 6 genotypes. Incomplete eradication of the virus due to
reduced efficacy of antiviral drugs on certain genotypes also potentially facilitates the
development of resistance mutations, also see section 1.8.4.
This chapter describes the assessment of antiviral susceptibilities of HCV NS3 protease
genes from HCV genotypes 1 to 6. Using the cell culture system dscribed in chapter
4, BILN 2061 and VX-950 efficacies on the NS3/4A protease of all6 major genotypes
were assessed and compared. Intragenotypic differences insusceptibility to BILN
2061 between patient-derived proteases were additionallyi vestigated.
Figure 5.1: HCV protease inhibitors. Chemical structure of the HCV PIs BILN 2061
(left) and VX-950 (right).
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5.2 Results
5.2.1 Susceptibility of Jxx recombinants to BILN 2061
Effect of BILN 2061 on supernatant infectivity
Intra- and intergenotypic recombinants derived from genotype 2a, 3a, 5a and 6a that
produced infectious virus were evaluated for PI sensitivity. This section describes how
the activity of BILN 2061 is affected by the sequence differences of enzymes from
various genotypes (Fig. 4.23). Huh7.5 cells were infected with virus containing su-
pernatant (MOI of 0.015), then the reduction in FFU/ml upon BILN 2061 treatment
assessed (Fig. 5.2a-d). Supernatant infectivities of all recombinant viruses were inhib-
ited, but to different extents. J2a2a, J3a3a and J5a5a showed similar dose-responses
(IC50 = 210 nM, 80 nM and 110 nM, respectively), whereas J6a6a (IC50 = 2 nM) was
40- to 100-fold more susceptible to BILN 2061. To visually compare the reduction in
supernatant infectivity between the different genotypes,lots from Fig. 5.2 were also
plotted against each other (Fig. 5.3).
Effect of BILN 2061 on viral replication
Since no infectious virus could be generated for J1b1b and J4a4a-19, PI susceptibility
was also assessed after synthetic RNA had been electroporated into fresh Huh7.5 cells
(Fig. 5.4 and 5.5). After 24 hours, PI was added and the reduction in the frequency
of NS5A positive cells was assessed at 96 hours post-electroporation. J1b1b, J4a4a-
19 and J6a6a showed 100- to 1,000-fold greater susceptibility (IC50 = 3 nM, 2 nM
and 1 nM, respectively) than J2a2a, J3a3a and J5a5a (IC50 = 720 nM, 105 nM and
480 nM, respectively). To visually compare the reduction inviral replication between
the different genotypes, plots from Fig 5.4 and 5.5 were alsoplotted against each other
(Fig. 5.6).
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Figure 5.2: Antiviral inhibition of Jxxs; reduction in supernatant infectivity. After
8 hours inoculation with (a) J2a2a, (b) J3a3a, (c) J5a5a and (d) J6a6a (MOI 0.015),
Huh7.5 cells were washed and incubated in media containing 0.1% DMSO, as a car-
rier control, with or without the indicated doses of BILN 2061.Inhibition was calcu-
lated at 72 hours post-infection as reduction in supernatant infectivity (FFU/ml; mean
±SEM; n = 3) after antiviral addition compared to infectivityof the control without
antiviral.
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Figure 5.3: Antiviral inhibition of Jxxs; comparing reduction in supernatant in-
fectivity. To compare the reduction in supernatant infectivity betweenthe different
genotypes, plots from Fig. 5.2 were plotted against each other.
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Figure 5.4: Antiviral inhibition of (a) J1b1b, (b) J4a4a-19 and (c) J6a6a; reduc-
tion in viral replication. 1-10µg RNA was electroporated into Huh7.5 cells and in-
cubated for 24 hours. Cells were then washed and incubated in media containing
0.1 % DMSO, as a carrier control, with or without the indicated doses of BILN 2061
for further 72 hours. The percent inhibition of replicationwas determined at 96 hours
post-electroporation (mean±SEM; n = 3) and calculated as the ratio of NS5A-positive
cells in BILN 2061-treated cells to those of the control without antiviral.
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Figure 5.5: Antiviral inhibition of (a) J2a2a, (b) J3a3a and (c) J5a5a; reduction in
viral replication. 1-10µg RNA was electroporated into Huh7.5 cells and incubated for
24 hours. Cells were then washed and incubated in media containig 0.1 % DMSO,
as a carrier control, with or without the indicated doses of BILN 2061 for further
72 hours. The percent inhibition of replication was determined at 96 hours post-
electroporation (mean±SEM; n = 3) and calculated as the ratio of NS5A-positive
cells in BILN 2061-treated cells to those of the control without antiviral.
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Figure 5.6: Antiviral inhibition of Jxxs; comparing reduction in viral replication.
To compare the reduction in viral replication between the different genotypes, plots
from Fig. 5.4 and 5.5 were plotted against each other.
170
Susceptibility of Different HCV Genotypes to PIs
Effect of naturally occurring sequence variability on BILN 2061 efficacy
To investigate whether naturally occurring sequence variability within a genotype led
to differences in antiviral susceptibilities, the J3a3a recombinants with patient-derived
proteases including adaptive mutations (J3a3a-3-L1663A, J3a3a-8-L1663A and J3a3a-11)
were subjected to BILN 2061 treatment as described above. TheJ3a3a recombi-
nant generated from the HCV3a-Gla prototype sequence showedan IC50 value of
130 nM, comparable to previous assays (Fig. 5.5), but 2- to 3-fold lower than IC50s
of the patient-derived sequences (310 nM for J3a3a-11, 300 nM for J3a3a-8-L1663A and
240 nM for J3a3a-3-L1663A) (Fig. 5.7). Although requiring further evaluation of more
replicates’ antiviral dilutions to establish formal statistical significance, these small
differences in apparent susceptibility suggest that some of the naturally occurring se-
quence variability within a subtype or genotype might have adirect and potentially
clinically significant effect on response to antiviral therapy.
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Figure 5.7: Antiviral inhibition of J3a3a-recombinants with patient-derived pro-
teases; reduction in viral replication.1-10µg of RNA was electroporated into Huh7.5
cells and incubated for 24 hours. Cells were then washed and incubated in media
containing 0.1 % DMSO, as a carrier control, with or without theindicated doses of
BILN 2061 for further 72 hours. The percent inhibition of replication was determined
at 96 hours post-electroporation (mean±SEM; n = 3) and calculated as the ratio of
NS5A-positive cells in BILN 2061-treated cells to those of the control without antiviral.
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5.2.2 Susceptibility of Jxx recombinants to VX-950
Effect of VX-950 on viral replication
Initially VX-950 susceptibility was assessed for the intergenotypic recombinants J1b1b,
J3a3a and J4a4a-19. Following electroporation of synthetic RNA into Huh7.5 cells,
VX-950 was added and the reduction in the frequency of NS5A positive cells was
assessed at 96 hours post-electroporation. J1b1b (IC50 = 870 nM) showed about 2-
fold greater susceptibility to VX-950 than J3a3a (IC50 = 1,520 nM) and about 3-fold
greater susceptibility than J4a4a-19 (IC50 = 2,330 nM) (Fig. 5.8a-c). VX-950 sus-
ceptibility testing for genotype 2a, 5a and 6a was carried out with the cell culture
attenuated/adapted recombinants. J5a5a-Q1247L (IC50 = 1,230 nM) showed similar sus-
ceptibility to VX-950 as J3a3a, whereas J2a2a-T1066Sand J6a6a-V1040L showed similar
susceptibility to J1b1b (IC50 = 1,020 nM and 650 nM, respectively) (Fig. 5.9a-c). To
visually compare the reduction in viral replication between the different genotypes,
plots from Fig. 5.8 and 5.9 were additionally plotted against each other (Fig. 5.10).
Further dilutions of VX-950 concentrations have to be assessed between 500 nM and
10,000 nM to get more accurate results on the IC50 values of J2a2a, J5a5a and J6a6a.
5.2.3 Summary of results
The J6a6a recombinant was about a 100-fold more susceptibleto BILN 2061 than
J2a2a, J3a3a and J5a5a, whether assessed by reduction in super atant infectivity or
viral replication. Genotype 1b and 4a based recombinants showed similar susceptibil-
ity to BILN 2061 as genotype 6a. Subtle differences in susceptibility to BILN 2061
were also found between J3a3a recombinants with patient-derive proteases. Likewise,
genotype specific differences in susceptibility were observed upon VX-950 treatment.
J1b1b, J2a2a-T1066Sand J6a6a-V1040L were most susceptible to VX-950, whereas J3a3a
and J5a5a-Q1247Lshowed intermediate susceptibility and J4a4a-19 proved tobe he most
resistant recombinant. Overall BILN 2016 was about a 100-fold more potent on Jxx
recombinants than VX-950.
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Figure 5.8: Antiviral inhibition of (a) J1b1b, (b) J3a3a and (c) J4a4a-19; reduction
in viral replication. 1-10µg RNA was electroporated into Huh7.5 cells and incubated
for 24 hours. Cells were then washed and incubated in media containi g 0.1 % DMSO,
as a carrier control, with or without the indicated doses of VX-950 for further 72 hours.
The percent inhibition of replication was determined at 96 hours post-electroporation
(mean±SEM; n = 3), and calculated as the ratio of NS5A-positive cellsin VX-950-
treated cells to those of the control without antiviral.
174
Susceptibility of Different HCV Genotypes to PIs
a J2a2a-T1066S




































no AV 10 100 500 1000 10000
b J5a5a-Q1247L



































no AV 10 100 500 1000 10000
c J6a6a-V1040L



































no AV 10 100 500 1000 10000
VX-950 concentration (nM)
VX-950 concentration (nM)
Figure 5.9: Antiviral inhibition of (a) J2a2a-T1066S, (b) J5a5a-Q1247L and (c)
J6a6a-V1040L; reduction in viral replication. 1-10µg RNA was electroporated into
Huh7.5 cells and incubated for 24 hours. Cells were then washed and incubated in
media containing 0.1 % DMSO, as a carrier control, with or without the indicated
doses of VX-950 for further 72 hours. The percent inhibitionof replication was de-
termined at 96 hours post-electroporation (mean±SEM; n = 3), and calculated as
the ratio of NS5A-positive cells in VX-950-treated cells to th se of the control without
antiviral.
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Figure 5.10: Antiviral inhibition of J2a2a, J5a5a and J6a6a; comparing reduction
in viral replication. To compare the reduction in viral replication between the different
genotypes, plots from Fig. 5.8 and 5.9 were plotted against each other.
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5.3 Discussion
The PI BILN 2061 has been shown to rapidly reduce HCV RNA plasma levels in
patients infected with genotype 1 (Lamarreet al. (2003)). The drug development of
this PI has been targeted to genotype 1 proteases, because genotype 1 infected patients
respond poorly to the current standard care of treatment andalso represent the majority
of HCV patients in the developed world. However, other genotypes, such as type 2 and
3, account for many infections around the world as well, whereas genotype 4-6 are
mainly found in Asia and Africa, also see section 1.3.3. Due to intergenotypic genetic
differences, PIs that are highly optimised to bind the 3D structure of proteases of one
genotype do not efficiently bind to proteases of other genotypes. Inin vitro sensitivity
studies, BILN 2061 showed decreased affinity for the NS3/4A protease of genotype
2 and 3 (Thibeaultet al. (2004)). As expected, patients infected with HCV genotype
2 and 3 were less susceptible to BILN 2061 treatment (Reisert al. (2005)). It is
therefore crucial to assess the antiviral efficacy of PIs on different genotypes before
they go into clinical trials.
In this chapter, the antiviral susceptibility of NS3/4A proteases of all 6 major geno-
types towards BILN 2061 and VX-950 were assessed. Even thoughBILN 2061 de-
velopment had been halted due to cardiotoxicity in laboratory animals, it is a good PI
to test the practicality of the cell culture system described in chapter 4 and to estimate
IC50s of PIs towards the 6 major genotypes (Vanwolleghemet al. (2007)). Using the
intra- and intergenotypic recombinants described in chapter 4, J1b1b was shown to
be more susceptible to BILN 2061 than J2a2a and J3a3a, as has been demonstrated
previouslyin vitro and in vivo (Reiseret al. (2005); Thibeaultet al. (2004)). Thein
vitro affinity of BILN 2061 to genotype 1 proteases has been described to be about
100-fold higher than for those of genotype 2 and 3, which reflects the observed 35- to
240-fold difference in susceptibility between J1b1b and J3a3a and J2a2a, respectively
(Thibeaultet al. (2004)).
177
Susceptibility of Different HCV Genotypes to PIs
Interestingly, J4a4a-19 and J6a6a were equally susceptiblto BILN 2061 as J1b1b
and J5a5a similarly to J2a2a and J3a3a. Experiments using expressed proteins showed
similar IC50 values for genotype 1a, 1b, 4a, 5a and 6a, whereas a lower susceptibil-
ity of J5a5a towards BILN 2061 was observed in this study (Seiwertet al. (2008);
Massariolet al. (2009)). In the study by Massariol, the NS3 protein from genotype
1b and 2a replicon as well as from clinical strains of genotype 4-6 were expressed
and assessed for their cleavage efficiency at the NS5A-NS5B junction. The reported
IC50 values for genotype 2a and 5a are about 20- to 100-fold lower than those described
here. However, a comparison is difficult as purified proteases outside the context of the
remaining virus were analysed, whereas this study assessedprot ase activity within the
full viral lifecycle (Massariolet al. (2009)). Furthermore, only the cleavage efficiency
at the NS5A-NS5B junction was analysed. The study by Seiwertet al., which analysed
biochemical potencies of purified proteins as well, also repo ted 10- to 50-fold lower
IC50 values for genotype 3a and 5a, respectively (Seiwertet al. (2008)). The discrep-
ancy between these studies and the results described here, most certainly are due to
differences in the assay itself. The IC50 values for genotype 1b compared to 3a and 2a
(35- and 240-fold differences) reported here, reflect closely the in vivo described effi-
cacies of BILN 2061 on genotype 1 compared to 2 and 3 (10- to 100-fold difference
in HCV RNA level reduction) (Lamarret al. (2003); Reiser (2003)). The system de-
scribed here therefore reflects the efficacy of PIs in patients infected with the different
viral strains more accurately than protein based kinetic studies. Although BILN 2061
is no longer in development, the observed similar IC50 values for genotype 1b, 4a and
6a suggest that future PIs of that class developed for genotype 1 may be effective not
only against genotype 1, but also against genotype 4a and 6a proteases.
Equivalent differences in susceptibility to BILN 2061 sensitivity were observed whether
determined by supernatant infectivity reduction or inhibition of replication (Fig. 5.3
and 5.6). Differences in susceptibility extended even to variants within a genotype,
with IC50 values ranging from around 130 nM to 310 nM in a panel of patient-derived
and reference genotype 3a protease sequences (Fig. 5.7). This 2- to 3-fold difference
may influence the effectiveness of antiviral therapy as well.
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Even though BILN 2061 has been specifically developed for genotype 1 protease en-
zymes, the residues that are in direct contact with the inhibtor are well conserved,
suggesting that this class of PI should be active against allgenotypes and subtypes
(Thibeaultet al. (2004)). X-ray crystallography of the NS3/4A protease complexed
with a macrocyclic tripeptide inhibitor, identified 19 residues within 5Å of the in-
hibitor, of which 13 were conserved among genotype 1, 2 and 3 variants (Thibeaultet
al. (2004)). Positions 78, 79 and 80 of the NS3 protease differedbetween genotype
1 and genotype 2 sequences and position 123 and 168 between genotype 1 and 3 se-
quences. Position 132 was replaced in both genotype 2 and 3 when compared to type
1. Mutational analysis has suggested that substitutions atthese 5 residues are respon-
sible for 80 % of the binding energy difference for BILN 2061 binding to proteases of
different genotypes (Thibeaulte al. (2004)).
The Jxx recombinants described in chapter 4 all have Val78 and Asp79 except for
J2a2a, discounting those residues for the differences between J1b1b, J4a4a-19, J6a6a
and J5a5a recombinant susceptibility (Fig. 4.23) (J4a4a and J4a4a-19 are identical on
the amino acid level in all positions discussed here). J5a5ais the only recombinant
with a charged amino acid at position 80, possibly partly accounting for its decreased
susceptibility. Substitutions at position 123 and 132 within genotype 3 variants have
also been suggested to play a role in BILN 2061 binding differences (Thibeaultet al.
(2004)). However, amino acid residue 123 is identical amongJ1b1b, J2a2a, J4a4a-
19, J5a5a and J6a6a recombinants and the polymorphism at position 132 is conserva-
tive. These 2 residues therefore do not explain the difference i susceptibility between
J5a5a and J1b1b, J4a4a-19 and J6a6a. Furthermore, residue 122 has been described to
play a role in inhibitor binding (Thibeaultet al. (2004)). J2a2a is the only recombi-
nant with a charged residue (Lys) at position 122, whereas all the other recombinants
have polar neutral amino acids (Thr/Ser), suggesting residu 122 plays a role in type
2 specific binding. Finally, the genotype 3a residue Gln168 has been identified as
the major determinant for the reduction in affinity of BILN 2061 binding to genotype
3a proteases. Although residue 168 does not directly interact with the inhibitor, it
has been shown to be a crucial determinant of inhibitor binding, as the development
of resistance mutations have been mapped to this position (section 1.8.4). Asp168
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is conserved among genotype 1, 2, 4 and 6 and interacts with Arg123 and Arg155
that are connected to BILN 2061. The Gln168 substitution in J3a3a results in ab-
rogation of salt bridges to residues 123 and 155, which are therefore less stabilised
and the binding affinity to BILN 2061 is reduced. The Glu168 substitution within
the J5a5a recombinant maintains the negative charge and thesalt bridges are not af-
fected. However, the Glu side chain is longer than that of Asp, possibly pushing the
2 BILN 2061 binding residues Arg123 and Arg155 out of their optimal interaction
position (Courcambecket al. (2006)). J4a4a-19 and J6a6a have identical amino acids
to genotype 1 at the described positions, providing one possible explanation for their
similarity in susceptibility towards BILN 2061. Interestingly, genotype 1b, 4a and 6a,
which showed the highest susceptibility to BILN 2061, are also the genotypes show-
ing lower response rates to the current IFN-α/ribavirin combination treatment. This
could suggest that genotype 6a is closely related to genotype 1 and 4, which have
been shown to be marginally closer related to each other thanto the other genotypes
(Simmondset al. (2005)).
VX-950 is currently the most advanced PI in clinical trials.A previousin vitro study
has reported about 2-fold higher susceptibility of the genotype 1a/1b replicon to VX-
950 when compared to the genotype 2a replicon (Paulsonet al. (2009)). Biochemical
cleavage analysis with purified proteases showed that genotype 3a is about 10- to 40-
fold and genotype 4 about 5- to 10-fold less susceptible to VX-950 than the other
genotypes (Seiwertet al. (2008)). In an ongoing phase IIa clinical trial VX-950 has
demonstrated substantial activity in genotype 2 infected patients, but only limited ef-
ficacy in genotype 3 infected individuals, for whom treatment as a result was stopped
(Fosteret al. (2009)). As demonstrated by these studies, VX-950 shows coniderable
differences in potency against different genotypes like BILN 2061, which highlights
again how important it is to evaluate PIs on all genotypes before clinical assessment.
Susceptibility testings of Jxxs upon VX-950 treatment haveshown highest susceptibil-
ity for the J1b1b, J6a6a-V1040L and J2a2a-T1066Srecombinants. The measured IC50 val-
ues (600-1,000 nM) are slightly higher than those reported pr viously (Seiwertet al.
(2008); McCownet al. (2009); Paulsonet al. (2009)). For the J1b1b recombinant
the IC50 value described here (870 nM) is similar to the IC50 value reported from the
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replicon system (625 nM) (Paulsonet al. (2009)). However, IC50 values measured in
biochemical cleavage studies are 5- to 15-fold lower for allgenotypes except for geno-
type 3a, for which they are almost identical (Seiwertet al. (2008)). Comparisons are
difficult though, due to the considerable differences in theassays. Furthermore, that
study does not specify which subtypes of genotype 4, 5 and 6 were used. In agreement
with that study though, the genotype 6a recombinant shows the highest susceptibility
towards VX-950, followed by genotype 1 and 2. However, the low susceptibility of
J3a3a and J5a5a-Q1247L and the very low susceptibility of J4a4a-19 are in disagreement
with that study (Seiwertet al. (2008)). A clinical trial using VX-950 monotherapy
has been conducted with genotype 4 infected patients, but nopublished results could
be found online. From the here described preliminary results it would be expected that
genotype 4a infected patients do not respond to VX-950 therapy, whereas genotype
6a infected patients should show good response rates. Genotyp 5a infected patients
would be expected to show only a minimal response, similar togenotype 3 infected
individuals (Fosteret al. (2009)).
Residues identified during resistance development studies in the Con1b replicon (NS3
protease residues Val36, Thr54, Arg155, Ala156 and Val170)(Heet al. (2008)), are
identical to Con1b amino acid sequence in all Jxxs, except at position 36 and 170.
The recombinants J1b1b and J6a6a-V1040L, which were most susceptible to VX-950,
have Val36, whereas J2a2a-T1066S, J3a3a, J4a4a-19 and J5a5a-Q1247L have Leu36. The
Val36Leu substitution has been described to show some resistance to VX-950, provid-
ing a possible explanation for the reduced susceptibility of J2a2a-T1066S, J3a3a, J4a4a-
19 and J5a5a-Q1247L (Zhouet al. (2008)). However, J2a2a-T1066Sstill is more suscepti-
ble than J3a3a, J4a4a-19 and J5a5a-Q1247L, indicating that further residues play a role
in the variability of VX-950 binding. Residue 170 is a polymorphic site with amino
acid Val/Leu occurring across genotypes. As all the recombinants described here have
Val/Leu170, it is unlikely that this position plays a role inthe variability of suscepti-
bilities between Jxxs.
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5.4 Conclusion
The intra- and intergenotypic recombinants developed and described in chapter 4 were
used in this chapter to demonstrate that different NS3 proteins r act differently to the
same PI. Previously published results on differences between genotypes upon their
sensitivity towards the PIs BILN 2061 and VX-950 have been confirmed, underscoring
the usefulness of the developed cell culture system. Furthermor , data is presented
on inhibitor sensitivity of genotype 4, 5 and 6, which have not been studied in the
full-length viral lifecycle yet. Any PI identified in high-throughput screening can be
evaluated for its efficacy on different genotypes and treatmn s designed according to
the outcome. Antiviral susceptibilities can be tested through assessment of reduction
in both supernatant infectivity and replication kinetics.This and the fact that the whole
viral lifecycle can be studied is a major advantage to the replicon system. Protease
genes from patients naı̈ve to treatment can also be easily assessed for their sensitivity
towards PIs, providing a valuable tool for individually tailored treatment options.
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Chapter 6
Identification and Phenotyping of
Resistance Mutations against HCV PIs
6.1 Introduction
A major issue in HCV treatment is the rapid selection of drug-resistant genetic vari-
ants. Viral variants with drug-resistant phenotypes have been observed in patients ex-
periencing viral rebound during therapy with STAT-C agents(Sarrazinet al. (2007a)).
Due to the huge pool of genetically different variants circulating in an individual, the
so-called quasispecies, resistant variants may already bepres nt in a patient. For ex-
ample, the resistance mutation Ala156Thr has been found to be present in close to 1 %
of NS3 sequences within the liver quasispecies of a treatment-näıve chronic patient
(Cuberoet al. (2008)). Other reports have found pre-existing protease-re istant vari-
ants in treatment-naı̈ve patients with a frequency of 0.2-2.8 % (Bartelst al. (2008);
Colsonet al. (2008); Kuntzenet al. (2008)). Furthermore, resistance mutations were
also identified in the replicon system, even though it does not represent the huge diver-
sity of a quasispecies pool within an infected individual (Trozziet al. (2003); Luet al.
(2004); Linet al. (2004); Tonget al. (2008)). This shows that antivirals not only
rapidly select for pre-existing resistant variants, but that resistance mutations can also
be rapidly induced due to the high replication and error rateof he RdRp.
Resistance mutations often have a major impact on the fitness of a viral variant, be-
cause a mutation affecting inhibitor binding is also likelyto impair enzymatic func-
tion. Accordingly, compensatory mutations have been identfi d within resistant vari-
ants (Yiet al. (2006a)). For effective treatment with STAT-C agents, it isherefore
crucial to eradicate a viral population before resistance mutations can arise. As the
development of resistance mutations in monotherapy with current drugs is almost cer-
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tain, combination treatment with other STAT-C agents and/or IFN-α and ribavirin is
inevitable.
To screen patients for possible pre-existing PI resistant vriants, which would make
them unresponsive towards that PI, resistance mutations have to be identifiedin vitro.
Furthermore, the identification of the resistance profile ofdifferent PIs will allow the
design of combination treatment of drugs that do not select for the same resistant vari-
ants.
In this chapter, thein vitro selection of Jxx recombinants with decreased BILN 2061
and VX-950 susceptibility is described. In addition, the influence of the identified
resistance mutations on the phenotype and PI susceptibility of the corresponding Jxx
recombinant was investigated. Because all NS3/4A PIs bind tothe same active site
of the protease, their resistance profile is often very similar. For example, residue
156 of the NS3 protease has been described as a resistance locus for several PIs and
mutations at residue 168 have been reported in BILN 2061 and ITMN-191 resistance
(Lin et al. (2004); Luet al. (2004); Tonget al. (2006); Seiwertet al. (2006)). As
BILN 2061 and ITMN-191 are both macrocyclic inhibitors, their resistance profile
is very similar and identification of resistance mutations uder BILN 2061 will help
understand resistance development for macrocyclic inhibitors n general. The results
on resistance development in nongenotype 1 viruses presented in his chapter add to
the current knowledge of resistance mutations which are mostly based on the genotype
1b replicon andin vivo analysis. Table 6.1 summarises the resistance mutations that
have been described in the literature as to date.
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Table 6.1: Resistance mutations described in the literature. Mutations that con-
fer high level resistance are in bold. (Linet al. (2004); Luet al. (2004); Linet al.
(2005a); Moet al. (2005); Seiwertet al. (2007a); Sarrazinet al. (2007a,b); Heet al.
(2008); McCownet al. (2008); Susseret al. (2008); Tonget al. (2008); Welschet al.
(2008); Thompson & McHutchison (2009)).
V36 V36+T54 Q41 F43 T54 S138
VX-950 M/A V36M+T54A R C A
SCH503034 M/A R C(S) A
ITMN-191 R S T
BILN 2061
R155 R155+V36 A156 A156+V36 D168 V170
VX-950 K/Q/T R155K+V36M S/V/T A156T+V36M A
SCH503034 K/Q/T R155K+V36M S/T n.d. A
ITMN-191 K /Q/T R155K+V36M S/V/T n.d. V/A/E
BILN 2061 K/Q/T R155K+V36M T/V n.d. V/A
n.d., not described in literature but association with antiviral resistance has been suggested.
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6.2 Results
6.2.1 In vitro selection of BILN 2061-resistant recombinant viruses
To select for resistance mutations, intra- and intergenotypic recombinants described
in chapter 4 were passaged in initially subinhibitory but increasing concentrations of
BILN 2061 beyond the IC50s determined for each genotype. For simplicity the NS3
protease residues 1027 to 1207 (absolute numbering) are numbered 1 (1027) to 181
(1207) in this chapter.
To establish the protocol for the passaging experiment, themost stably replicating re-
combinant J3a3a was passaged under increasing concentrations of BILN 2061, starting
with 0.3× IC50. The PI concentration was then increased every 4 or 5 days to reach
about 70× IC50. Every 4 or 5 days RNA was extracted from the supernatant and the
NS3 protease gene sequenced. Mutations at position 168 of the NS3 protease gene
started to appear at a concentration of 3× IC50. In a second approach, the PI was
directly added at a concentration of 3.3× IC50 and increased to 70× IC50 after 7 days.
Substitutions at residue 168 of the NS3 protease gene were idntified at day 10 of the
passaging experiment. The following passaging experiments were therefore started
at PI concentrations of 10× IC50. Because the J6a6a cell culture adaptive mutation
(V1040L) had not been identified at the start of the passagingexperiment, J6a6a was
first passaged in Huh7.5 cells for 35 days before PI was added and PI addition started
from 1 × IC50. For genotype 2a and 5a the original recombinants J2a2a and J5a5a
were initially used for the passaging experiment, startingwith PI concentrations of 10
× IC50. The RT-PCR on RNA extracted from day 12 supernatant was unsucce sful,
because RNA levels were relatively low. To increase the amount f RNA for further
experiments, cell pellets were collected for RNA extractions. Furthermore, the cell cul-
ture attenuated recombinants J2a2a-T1066Sand J5a5a-Q1247L were constructed and used
for resistance development studies in genotype 2a and 5a. Inddition, PI concentra-
tions for type 2a and 5a were kept at 1× IC50. Table 6.2 gives the individual schedules
for each passaging experiment.
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Table 6.2: Schedule for inducing antiviral (AV) resistance upon BILN 2061 treat-
ment. PE, post-electroporation.
Clone Day PE of AV addition AV concentration Days of AV pressure
J1b1b 3 1 day 23 nM, 8
7 days 230 nM
J2a2a-T1066S 4 8 days 500 nM, 22
14 days 1,000 nM
J3a3a 2 7 days 350 nM 21
14 days 7,000 nM
J4a4a-19 3 3 days 10 nM 13
10 days 100 nM
J5a5a-Q1247L 4 21 days 500 nM 21
J6a6a 35 10 days 1 nM 28
18 days 10 nM
Recombinants were passaged for 3 weeks and each passaging experim nt was carried
out in duplicate and without antiviral addition as a control. At the end of passaging,
RNA was extracted and subjected to RT-PCR to amplify the codingregion of the HCV
NS3 protease domain. To delineate the identity and frequency of substitutions, the RT-
PCR product from each genotype passage was subcloned into theTOPO vector, and
10 individual colonies of 2 replicates and the control were subjected to sequencing.
As J1b1b and J4a4a-19 do not stably replicate in Huh7.5 cells, clonal analysis was
performed on day 8. Initially the primers JFH1-s and -as (Table A.13, Appendix A)
were used to amplify the protease gene and their restrictionsites used for cloning the
fragment into TOPO. Using this approach, fragments including resistance mutations
could be directly cloned into the corresponding Jxx recombinants and their phenotype
assessedin vitro, section 6.2.3. However, in J4a4a-19 clonal analysis only oe clone
contained a mutation at a resistance locus. The RT-PCR protocol was therefore op-
timised to be more sensitive by using primers without additional restriction sites and
that would generate a shorter PCR product (JFH-3265 and xBglIIas, Table A.12 and
A.5, Appendix A). With this approach, RNA could be extracted an successfully am-
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plified from the J4a4a-19 cell culture on day 13. Clonal analysis identified resistance
mutations at either position 156 or 168 in all 10 clones analysed of each duplicate. Fig-
ures 6.1 to 6.6 show the alignment of 10 clones from each passaging experiment. The
NS4A cofactor was not analysed because no resistance loci have been described within
the NS4A gene in the literature. All 6 genotypes showed substit tions at position 168,
although this position differed in both the identity of the wild type encoded amino
acid and the substitutions that arose during passaging (Table 6.3). In contrast, this site
remained invariant in each control passage experiment performed in parallel without
addition of BILN 2061. Genotypes 1b, 2a, 3a and 4a showed complete replacement
of the wild type codon in both replicate passages, while replacement frequencies of
genotype 5a and 6a ranged from 70-90 %. Genotypes 1b and 4a additionally showed
a further substitution of the Ala residue at position 156 to Val and Gly in a proportion
of clones (Table 6.3). Wherease double mutants occurred within genotype 1b clones,
genotype 4a clones contained either a mutation at position 156 or 168. One of the 2
replicates from the genotype 2a recombinant showed a changeat position 195 in half
of the clones analysed. All other substitutions recorded among clones in either BILN
2061 or control passages occurred infrequently (0-3 among each set of 10 clones), at
variable positions and were equally frequent among BILN 2061-passaged and control
virus populations. The Val14Leu substitution in genotype 6a clones corresponds to the
Val1040Leu cell culture adaptive mutation described in chapter 4.
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Figure 6.1: Acquisition of mutations in J1b1b-NS3 during passaging under BILN
2061.NS3 residue 1 (1027) to 144 (1170), continued on next page.
189
Identification and Phenotyping of Resistance Mutations against HCV PIs
Figure 6.1: Acquisition of mutations in J1b1b-NS3 during passaging under BILN
2061. NS3 residue 145 (1171) to 227 (1253). The J1b1b recombinant waspassaged
in Huh7.5 cells under increasing concentrations of BILN 2061 (23-230 nM). On day 8
of the passaging experiment viral RNA was extracted from cells and the NS3 protease
gene cloned into the TOPO cloning vector. The passaging experiment was carried out
in duplicate and 10 clones analysed in each (J1b1b-A1 to -A10, J b1b-B1 to -B10). As
a control J1b1b was passaged without BILN 2061 and 10 clones analysed (J1b1b-c1
to -c10). Previously described residues where resistance mutations can arise under
BILN 2061 are indicated in red; the NS3 protease domain is indicated in black; the
NS2 3’end and the NS3 helicase 5’end are indicated in grey.
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Figure 6.2: Acquisition of mutations in J2a2a-T1066S-NS3 during passaging under
BILN 2061. NS3 residue 1 (1027) to 139 (1165), continued on next page.
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Figure 6.2: Acquisition of mutations in J2a2a-T1066S-NS3 during passaging under
BILN 2061. NS3 residue 140 (1166) to 227 (1253). The J2a2a-T1066S recombinant
was passaged in Huh7.5 cells under increasing concentrations of BILN 2061 (500-
1,000 nM). On day 22 of the passaging experiment viral RNA was extracted from cells
and the NS3 protease gene cloned into the TOPO cloning vector.The passaging exper-
iment was carried out in duplicate and 10 clones analysed in each (J2a2a-T1066S-A1 to
-A10, J2a2a-T1066S-B1 to -B10). As a control J2a2a-T1066Swas passaged without BILN
2061 and 10 clones analysed (J2a2a-T1066S-c1 to -c10). Previously described residues
where resistance mutations can arise under BILN 2061 are indicated in red; the NS3
protease domain is indicated in black; the NS2 3’end and the NS3helicase 5’end are
indicated in grey.
192
Identification and Phenotyping of Resistance Mutations against HCV PIs
Figure 6.3: Acquisition of mutations in J3a3a-NS3 during passaging under BILN
2061.NS3 residue 1 (1027) to 144 (1170), continued on next page.
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Figure 6.3: Acquisition of mutations in J3a3a-NS3 during passaging under BILN
2061.NS3 residue 145 (1171) to 227 (1253). The J3a3a recombinant waspassaged in
Huh7.5 cells under increasing concentrations of BILN 2061 (35-7,000 nM). On day 21
of the passaging experiment viral RNA was extracted from cells and the NS3 protease
gene cloned into the TOPO cloning vector. The passaging experiment was carried out
in duplicate and 10 clones analysed in each (J3a3a-A1 to -A10, J3a3a-B1 to -B10). As
a control J3a3a was passaged without BILN 2061 and 10 clones analysed (J3a3a-c1
to -c10). Previously described residues where resistance mutations can arise under
BILN 2061 are indicated in red; the NS3 protease domain is indicated in black; the
NS2 3’end and the NS3 helicase 5’end are indicated in grey.
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Figure 6.4: Acquisition of mutations in J4a4a-19-NS3 during passaging under
BILN 2061. NS3 residue 1 (1027) to 144 (1170), continued on next page.
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Figure 6.4: Acquisition of mutations in J4a4a-NS3 during passaging under BILN
2061.NS3 residue 145 (1171) to 181 (1207). The J4a4a-19 recombinant was passaged
in Huh7.5 cells under increasing concentrations of BILN 2061 (10-100 nM). On day 13
of the passaging experiment viral RNA was extracted from cells and the NS3 protease
gene cloned into the TOPO cloning vector. The passaging experiment was carried out
in duplicate and 10 clones analysed in each (J4a4a-19-A1 to -A10, J4a4a-19-B1 to
-B10). As a control J4a4a-19 was passaged without BILN 2061 and10 clones analysed
(J4a4a-19-c1 to -c10). Previously described residues whereresistance mutations can
arise under BILN 2061 are indicated in red; the NS3 protease domain is indicated in
black; the NS2 3’end is indicated in grey.
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Figure 6.5: Acquisition of mutations in J5a5a-Q1247L-NS3 during passaging under
BILN 2061. NS3 residue 1 (1027) to 144 (1170), continued on next page.
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Figure 6.5: Acquisition of mutations in J5a5a-Q1247L-NS3 during passaging under
BILN 2061. NS3 residue 145 (1171) to 224 (1250). The J5a5a-Q1247L recombinant
was passaged in Huh7.5 cells under BILN 2061 (500 nM). On day 21of the passaging
experiment viral RNA was extracted from cells and the NS3 protease gene cloned into
the TOPO cloning vector. The passaging experiment was carried out in duplicate
and 10 clones analysed in each (J5a5a-Q1247L-A1 to -A10, J5a5a-Q1247L-B1 to -B10).
As a control J5a5a-Q1247L was passaged without BILN 2061 and 10 clones analysed
(J5a5a-Q1247L-c1 to -c10). Previously described residues where resistance mutations
can arise under BILN 2061 are indicated in red; the NS3 protease domain is indicated
in black; the NS2 3’end and the NS3 helicase 5’end are indicatedin grey.
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Figure 6.6: Acquisition of mutations in J6a6a-NS3 during passaging under BILN
2061.NS3 residue 1 (1027) to 144 (1170), continued on next page.
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Figure 6.6: Acquisition of mutations in J6a6a-NS3 during passaging under BILN
2061. NS3 residue 145 (1171) to 224 (1250). The J6a6a recombinant waspassaged
in Huh7.5 cells under increasing concentrations of BILN 2061 (1-10 nM). On day 28
of the passaging experiment viral RNA was extracted from cells and the NS3 protease
gene cloned into the TOPO cloning vector. The passaging experiment was carried out
in duplicate and 10 clones analysed in each (J6a6a-A1 to -A10, J6a6a-B1 to -B10). As
a control J6a6a was passaged without BILN 2061 and 10 clones analysed (J6a6a-c1
to -c10). Previously described residues where resistance mutations can arise under
BILN 2061 are indicated in red; the NS3 protease domain is indicated in black; the
NS2 3’end and the NS3 helicase 5’end are indicated in grey.
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Table 6.3: Summary of mutations acquired within the Jxx NS3 protease gene during
passaging under BILN 2061.
Viral variant BILN 2061 Day Position WT % remaining WT (mutations2)
(nM)1 Replicate 1 Replicate 2 Control
J1b1b 230 8 168 D 0 (7G, 1A, 1E, 1V) 10 (3G, 1A, 5E) 100
156 A 60 (4V) 90 (1V) 100
J2a2aT1066S 1,000 22 168 D 0 (8V, 2Y) 0 (4V, 6Y) 100
195 Q 100 40 (6H) 100
J3a3a 7,000 21 168 Q 0 (4L, 5R, 1K) 0 (8L, 2K) 100
J4a4a-19 100 13 168 D 20 (6G, 2V) 20 (4G, 2A, 2E) 100
156 A 80 (2V) 80 (2T) 100
J5a5aQ1247L 500 21 168 E 0 (7A, 1V, 2G) 10 (9A) 100
J6a6a 10 28 168 D 30 (4V, 2E, 1H) 30 (3V, 1E, 3N) 100
1Final passaging concentration of BILN 2061.
2Proportion of clones retaining original amino acid in 2 replicate passaging experiments (10 clones
analysed in each) and in a control passaged without BILN 2061(10 clones analysed). Mutations were
included in this table if they occurred in at least 4 clones, or at a position of previously identified
resistance mutations. WT, wild type.
6.2.2 In vitro selection of VX-950-resistant recombinant viruses
The development of antiviral resistance in the Jxx recombinants upon VX-950 treat-
ment was investigated as described in section 6.2.1 for BILN 2061. As resistance
development was observed with BILN 2061 concentrations as low as 1-2× IC50 and
because only a limited amount of VX-950 was available, the passaging experiment was
just carried out with the 3 recombinants J1b1b, J3a3a and J4a4a-19 and PI concentra-
tions of 2-3× IC50. An additional obstacle were the relatively high IC50 values for
VX-950 on Jxxs (650-2,230 nM). Table 6.4 provides the indiviual schedules for each
passaging experiment. As described in section 6.2.1, RNA wasextracted from cell
pellets at the end of the passaging experiments and clonal analysis of the NS3 protease
gene performed (Fig. 6.7 to 6.9). None of the genotypes showed significant substitu-
tion rates at any of the described resistance loci (NS3 protease residues 36, 41, 43, 54,
155, 156 and 170) (Table 6.1). This is presumably due to the low PI concentrations in
combination with short passaging times (for genotype 1b and4a). Nevertheless, a few
potential resistance mutations were identified (Table 6.5).
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Table 6.4: Schedule for inducing antiviral (AV) resistance upon VX-950 treatment.
PE, post-electroporation.
Clone Day PE of AV addition AV concentration Days of AV pressure
J1b1b 3 13 days 1,800 nM 13
J3a3a 3 23 days 5,000 nM 23
J4a4a-19 3 13 days 5,000 nM 13
One genotype 1b clone had a Val36Ala substitution, a resistance mutation described in
the literature (Table 6.1). In addition, replacement of thewild type codon was observed
at position 174 in both replicates. Even though this residuehas not been described
previously as a resistance locus, the fact that it developedin both replicates but in no
other passaging experiment, strongly suggests that it is a re istance mutation towards
VX-950. Genotype 3a showed almost complete replacement of the wild type codon at
position 77. Again, this position has not been described as are istance locus towards
VX-950, but as it developed in both replicates, involvementin resistance towards VX-
950 is suggested. Genotype 4a showed no obvious resistance development. However,
one clone each contained a substitution at position 36, 54 and 156, which have been
described as resistance loci in the literature (Table 6.1).
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Figure 6.7: Acquisition of mutations in J1b1b-NS3 during passaging under VX-
950. NS3 residue 1 (1027) to 181 (1207). The J1b1b recombinant was passaged in
Huh7.5 cells under VX-950 (1,800 nM) for 13 days. Viral RNA wasextracted from
cells and the NS3 protease gene cloned into the TOPO cloning vector. The passaging
experiment was carried out in duplicate and 10 clones analysed in ach (J1b1b-A1 to
-A10, J1b1b-B1 to -B10). Previously described residues where resistance mutations
can arise under VX-950 are indicated in red; the NS3 protease domain is indicated in
black; the NS2 3’end is indicated in grey.
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Figure 6.8: Acquisition of mutations in J3a3a-NS3 during passaging under VX-
950. NS3 residue 1 (1027) to 181 (1207). The J3a3a recombinant was passaged in
Huh7.5 cells under VX-950 (5,000 nM) for 23 days. Viral RNA wasextracted from
cells and the NS3 protease gene cloned into the TOPO cloning vector. The passaging
experiment was carried out in duplicate and 10 clones analysed in ach (J3a3a-A1 to
-A10, J3a3a-B1 to -B10). Previously described residues where resistance mutations
can arise under VX-950 are indicated in red; the NS3 protease domain is indicated in
black; the NS2 3’end is indicated in grey.
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Figure 6.9: Acquisition of mutations in J4a4a-19-NS3 during passaging under VX-
950. NS3 residue 1 (1027) to 181 (1207). The J4a4a-19 recombinant was passaged
in Huh7.5 cells under VX-950 (5,000 nM) for 13 days. Viral RNAwas extracted from
cells and the NS3 protease gene cloned into the TOPO cloning vector. The passaging
experiment was carried out in duplicate and 10 clones analysed in each (J4a4a-19-
A1 to -A10, J4a4a-19-B1 to -B10). Previously described residues where resistance
mutations can arise under VX-950 are indicated in red; the NS3protease domain is
indicated in black; the NS2 3’end is indicated in grey.
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Table 6.5: Summary of mutations acquired within the Jxx NS3 protease gene during
passaging under VX-950.
Viral variant VX-950 Day Position WT % remaining WT (mutations2)
(nM)1 Replicate 1 Replicate 2 Control
J1b1b 1,800 13 36 V 100 90 (1A) 100
174 S 60 (4P) 70 (3P) 100
J3a3a 5,000 23 77 N 10 (9S) 0 (10S) 100
J4a4a-19 5,000 13 36 L 100 90 (1P) 100
54 T 100 90 (1A) 100
156 A 100 90 (1V) 100
1Final passaging concentration of VX-950.
2Proportion of clones retaining original amino acid in 2 replicate passaging experiments (10 clones
analysed in each) and in a control passaged without VX-950 (10 clones analysed). Mutations were
included in this table if they occurred in at least 4 clones, or at a position of previously identified
resistance mutations. WT, wild type.
6.2.3 Influence of BILN 2061-resistance mutations on recombinant
viruses replication kinetics
To investigate the influence of the resistance mutations identifi d in section 6.2.1, in-
dividual mutations were reintroduced into the corresponding Jxx recombinants. For
genotype 2a, 3a, 5a and 6a, where extracted RNA levels were high, t e fragment in-
cluding the NS3 protease gene plus resistance mutations wasdirectly ligated into the
corresponding Jxx recombinant. For genotype 2a, 5a and 6a the cell culture atten-
uated/adapted recombinants were used for mutant construction. Jxxs including only
one resistance mutation and no other mutations were identified through clonal anal-
ysis and RNA prepared from the desired clone. For genotype 1b and 4 , where ex-
tracted RNA levels were low and alternative primers without restriction sites had to be
used, mutations were introduced through site directed mutagenesis. To reduce poten-
tial PCR-induced errors, the naturally occurring restriction sitesNotI and SpeI were
used to subclone a fragment including the HCV NS3 protease domain into TOPO. Af-
ter site directed mutagenesis on the TOPO clone and sequencev rification, the insert
was cloned back into the corresponding Jxx recombinant and RNA prepared from it.
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The replication fitness of each mutant recombinant was then assessed in the Huh7.5
cell culture system (Fig. 6.10 to 6.12).
The J1b1b-D168G mutant replicated to similar levels as the wild type J1b1b, whereas
replication fitness of the J1b1b-A156V and the J1b1b-A156V-D168G mutants were
slightly reduced (Fig. 6.10 top). The D168V substitution completely abrogated the
replication ability of J2a2a-T1066S or reduced it to undetectable levels, whereas the
J2a2a-T1066S-D168Y mutant replicated similarly to wild type (Fig. 6.10 bottom). The 2
genotype 3a mutants J3a3a-Q168L and -Q168K replicated similarly to the wild type,
whereas the Q168R mutation reduced the replicative fitness of J3a3a after an initial
spread (Fig. 6.11 top). For genotype 5a 3 mutants were tested. The E168A mutation
did not noticeably affect the replication kinetics of J5a5a-Q1247L. The E168G mutation
reduced the fitness of J5a5a-Q1247L after an initial spread, whereas the E168V muta-
tion slowed the spread of J5a5a-Q1247L (Fig. 6.11 bottom). The replication kinetics
of J6a6a-V1040L were not noticeably affected by the D168E and D168H mutation, but
detectable replication was completely abrogated by the D168V mutation (Fig. 6.12).
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Figure 6.10: Influence of BILN 2061-resistance mutations on the recombinats
J1b1b and J2a2a-T1066S. Resistance mutations identified during passaging of the J1b1b
(top) or J2a2a-T1066S(bottom) recombinant under BILN 2061 were introduced into the
original recombinant and their replication kinetics assesd in the Huh7.5 cell culture
system. 10µg of RNA was electroporated into Huh7.5 cells and cells incubated for 24
hours. The cells were then stained for NS5A or alternatively passaged and assessed
for NS5A positive cells every 3 to 4 days. The transcript from the J2a2a-T1066S-D168V
clone showed no detectable replication (all values lying on thex-axis line).
208
Identification and Phenotyping of Resistance Mutations against HCV PIs
Days post-electroporation





































































Figure 6.11: Influence of BILN 2061-resistance mutations on the recombinats
J3a3a and J5a5a-Q1247L. Resistance mutations identified during passaging of the J3a3a
(top) or J5a5a-Q1247L (bottom) recombinant under BILN 2061 were introduced into the
original recombinant and their replication kinetics assesd in the Huh7.5 cell culture
system. 10µg of RNA was electroporated into Huh7.5 cells and cells incubated for 24
hours. The cells were then stained for NS5A or alternatively passaged and assessed
for NS5A positive cells every 3 to 4 days.
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Figure 6.12: Influence of BILN 2061-resistance mutations on the J6a6a-V1040L re-
combinant. Resistance mutations identified during passaging of the J6a6a recombi-
nant under BILN 2061 were introduced into the original recombinant and their repli-
cation kinetics assessed in the Huh7.5 cell culture system.10µg of RNA was elec-
troporated into Huh7.5 cells and cells incubated for 24 hours. The cells were then
stained for NS5A or alternatively passaged and assessed for NS5A positive cells every
3 to 4 days. The transcript from the J6a6a-V1040L-D168V clone showed no detectable
replication (all values lying on thex-axis line).
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6.2.4 BILN 2061 susceptibility of recombinant viruses including
BILN 2061-resistance mutations
To assess the impact of resistance mutations identified in section 6.2.1 on BILN 2061
susceptibility, IC50 values of Jxx recombinants including resistance mutationsdescribed
in section 6.2.3, were measured and compared with the wild type (Fig. 6.13-6.17, Table
6.6).
The cell culture adapted/attenuated recombinants J6a6a-V1040L, J2a2a-T1066Sand J5a5a
-Q1247L showed similar IC50 values as the wild type recombinants J6a6a, J2a2a and
J5a5a (Table 6.6). The A156V mutation provided about 4-foldhigher resistance to
J1b1b towards BILN 2061 than the D168G mutation (277- vs. 67-fold change in IC50
value). Surprisingly, the double mutant J1b1b-A156V-D168G was more susceptible
to the PI than J1b1b-A156V but more resistant than J1b1b-D168G. The genotype 2a
resistance mutation D168Y only resulted in a very moderate 7-fold increase in the IC50
value of J2a2a-T1066S, whereas the genotype 3a resistance mutations Q168K, Q168L
and Q168R increased the resistance profile of the J3a3a recombinant 51-, 30- and
43-fold, respectively. Mutations identified for genotype 5a rendered the J5a5a-Q1247L
recombinant only moderately resistant, with E168A increasing the IC50 value 5-fold,
E168G 1.6-fold and E168V 8-fold. The highest impact on resistance towards BILN
2061 had the D168H mutation on the J6a6a-V1040L recombinant. The J6a6a-V1040L-
D168H mutant recombinant was 527-fold less susceptible to BILN 2061 than the wild
type recombinant J6a6a-V1040L. The second mutation identified in genotype 6a, D168E,
resulted in a 60-fold increased resistance profile for J6a6a-V1040L.
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Figure 6.13: BILN 2061 susceptibility of J1b1b recombinants including resistance
mutations (J1b1b-rm).Resistance mutations identified during passaging of the J1b1b
recombinant under BILN 2061 were introduced into the original J1b1b recombinant
to create J1b1b-A156V, J1b1b-D168G and J1b1b-A156V-D168G. 1-10µg (a) J1b1b
and (b)-(d) J1b1b-rm RNA was electroporated into Huh7.5 cells and incubated for 24
hours. Cells were then washed and incubated in media containing0.1 % DMSO, as a
carrier control, with or without the indicated doses of BILN 2061 for further 72 hours.
The percent inhibition of replication was determined at 96 hours post-electroporation
(mean±SEM; n = 3) and calculated as the ratio of NS5A-positive cells in BILN 2061-
treated cells to those of the control without antiviral. n.d., not determined.
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Figure 6.14: BILN 2061 susceptibility of J2a2a recombinants including attenuating
and resistance mutations (J2a2a-rm).Resistance mutations identified during passag-
ing of the J2a2a-T1066Srecombinant under BILN 2061 were introduced into the origi-
nal J2a2a-T1066Srecombinant to create J2a2a-T1066S-D168V and J2a2a-T1066S-D168Y. 1-
10µg (a) J2a2a, (b) J2a2a-T1066Sand (c) J2a2a-T1066S-D168Y RNA was electroporated
into Huh7.5 cells and incubated for 24 hours. Cells were then washed and incubated
in media containing 0.1 % DMSO, as a carrier control, with or without the indicated
doses of BILN 2061 for further 72 hours. The percent inhibition of replication was de-
termined at 96 hours post-electroporation (mean±SEM; n = 3) and calculated as the
ratio of NS5A-positive cells in BILN 2061-treated cells to thse of the control without
antiviral. J2a2a-T1066S-D168V recombinant replication was below detection limit and
was not assessed for BILN 2061 susceptibility.
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Figure 6.15: BILN 2061 susceptibility of J3a3a recombinants including resistance
mutations (J3a3a-rm).Resistance mutations identified during passaging of the J3a3a
recombinant under BILN 2061 were introduced into the original J3a3a recombinant
to create J3a3a-Q168K, J3a3a-Q168L and J3a3a-Q168R. 1-10µg (a) J3a3a and (b)-
(d) J3a3a-rm RNA was electroporated into Huh7.5 cells and incubated for 24 hours.
Cells were then washed and incubated in media containing 0.1 % DMSO, as a car-
rier control, with or without the indicated doses of BILN 2061 for urther 72 hours.
The percent inhibition of replication was determined at 96 hours post-electroporation
(mean±SEM; n = 3) and calculated as the ratio of NS5A-positive cells in BILN 2061-
treated cells to those of the control without antiviral.
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Figure 6.16: BILN 2061 susceptibility of J5a5a recombinants including attenuating
and resistance mutations (J5a5a-Q1247L-rm).
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Figure 6.16: BILN 2061 susceptibility of J5a5a recombinants including attenuating
and resistance mutations (J5a5a-Q1247L-rm). Resistance mutations identified during
passaging of the J5a5a-Q1247L recombinant under BILN 2061 were introduced into the
original J5a5a-Q1247L recombinant to create J5a5a-Q1247L-E168A, J5a5a-Q1247L-E168G
and J5a5a-Q1247L-E168V. 1-10µg (a) J5a5a, (b) J5a5a-Q1247Land (c)-(e) J5a5a-rm RNA
was electroporated into Huh7.5 cells and incubated for 24 hours. Cells were then
washed and incubated in media containing 0.1 % DMSO, as a carrier control, with or
without the indicated doses of BILN 2061 for further 72 hours.The percent inhibition
of replication was determined at 96 hours post-electroporati n (mean±SEM; n = 3)
and calculated as the ratio of NS5A-positive cells in BILN 2061-treated cells to those
of the control without antiviral. n.d., not determined.
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Figure 6.17: BILN 2061 susceptibility of J6a6a recombinants including adptive
and resistance mutations (J6a6a-V1040L-rm). Resistance mutations identified during
passaging of the J6a6a-V1040L recombinant under BILN 2061 were introduced into the
original J6a6a-V1040L recombinant to create J6a6a-V1040L-D168E, J6a6a-V1040L-D168H
and J6a6a-V1040L-D168V. 1-10µg (a) J6a6a, (b) J6a6a-V1040L and (c)-(d) J6a6a-V1040L-
rm RNA was electroporated into Huh7.5 cells and incubated for24 hours. Cells were
then washed and incubated in media containing 0.1 % DMSO, as a carrier control,
with or without the indicated doses of BILN 2061 for further 72 hours. The percent in-
hibition of replication was determined at 96 hours post-electroporation (mean±SEM;
n = 3) and calculated as the ratio of NS5A-positive cells in BILN 2061-treated cells
to those of the control without antiviral. J6a6aa-V1040L-D168V recombinant replication
was below detection limit and was not assessed for BILN 2061 susceptibility.
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Table 6.6: Influence of resistance mutations on BILN 2061 susceptibility, fold
change in IC50. WT, wild type.
























1Recombinants including resistance mutations generated from cell culture adapted/attenuated recombi-
nants were compared to the corresponding adapted/attenuatd recombinant.
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6.2.5 Summary of results
Intra- and intergenotypic recombinants constructed from HCV genotype 1 to 6 were
passaged in initially subinhibitory but increasing concentrations of BILN 2061 to in-
vestigate whether antiviral resistance could be inducedin vitro. Clonal analysis of
the HCV NS3 protease gene identified substitutions at position 168 for all genotypes.
The identity of the amino acid that replaced the wild type differed between genotypes,
where genotype 1b, 2a, 4a and 6a have the same wild type residue but type 3a and 5a
an alternative one. Genotype 1b and 4a showed the same substitutions, type 2a, 5a and
6a similar ones and substitutions identified within type 3a did not occur in any other
genotype. In genotype 1b and 4a, substitutions were also identified at position 156.
Most substitutions did not affect recombinant replicationkinetics substantially, except
for Asp168Val which reduced the replicative fitness of J2a2a-T1066S and J6a6a-V1040L
below detection limit. All mutants created showed an increase in resistance towards
BILN 2061 when compared with the wild type recombinant, with the J6a6a-V1040L-
D168H mutant followed by the J1b1b-A156V mutant showing thehighest fold change
in PI susceptibility. Substitutions induced upon VX-950 treatment were identified at
previously described resistance loci 36, 54 and 156, but also at the so far undescribed
positions 77 and 174.
6.3 Discussion
The rapid selection of viral variants displaying drug-resistant phenotypes is a major
concern in HCV treatment. Several resistant phenotypes havebeen observed in pa-
tients experiencing viral rebound during therapy, as well as in replicon experiments
(Lin et al. (2005a); Luet al. (2004); Cuberoet al. (2008); Kuntzenet al. (2008)).
Antiviral drug treatment favours the selection and spread of variants including resis-
tance mutations. Both the relative resistance of a variant and its viral fitness influence
the replication phenotype of a resistant variant. Often variants that show high levels
of resistance are impaired in their replication kinetics and o ly circulate in low fre-
quencies. However, upon antiviral drug treatment antiviral susceptible variants will
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be cleared and the antiviral resistant variants can spread (section 1.8.4). Resistance
mutations arising under BILN 2061 pressure have been describd at the 3 main posi-
tions Arg155, Ala156 and Asp168 (Linet al. (2005a); Luet al. (2004); Cuberoet al.
(2008)).
In this study, several newin vitro resistance mutations in the NS3 protease gene of
all 6 major genotypes were identified. The dominant resistance mutations observed
against BILN 2061 occurred at position 168, where the Asp residue n genotypes 1b,
2a, 4a and 6a changed to Gly/Glu/Ala/Val (genotype 1b and 4a), V l/Tyr (2a) and
to Val/Asn/Glu/His (6a). In the genotype 3a protease gene a substitution of Gln168 to
Leu/Arg/Lys was detected, while in genotype 5a Glu168 was sub tit ted with Ala/Gly/-
Val. Although conserved in position, a striking feature of this pattern of mutation
was the variable nature of the substituted amino acid, suggestin great flexibility in
the nature of the structural disruption to the protease induce by these resistance-
associated changes. The observation that resistance-associated mutations in one geno-
type (such as Asp168Glu substitution in genotype 1b, 4a and 6) may occur as the
wild type amino acid in another (genotype 5a), is consistentwith significant struc-
tural differences in the protease gene implied by the differences between genotypes
in their susceptibility to inhibition by BILN 2061.In vitro studies with the genotype
1b replicon have associated mutations towards Val/Ala withBILN 2061 resistance
at position 168 (Heet al. (2008)). Interestingly, the Asp168Glu mutation has been
described in literature as well, but in association with resistance to ITMN-191, an-
other macrocyclic PI (Seiwertet al. (2007a)). Resistance mutations towards a third
macrocyclic inhibitor, TMC435, also identified a variety of resistance mutations at po-
sition 168 (Asp168Tyr/Glu/His/Ile/Thr/Asn), which support the results described here
(Lenzet al. (2010)). The Asp168Ile/Thr mutation was not observed, possibly due to
the fact that 2 nucleotide changes are necessary for this change nd the PI pressure
applied here was not high enough to induce this.
These results demonstrate that resistance towards macrocyclic inhibitors can be in-
duced by a variety of viable changes and that the resistance profile towards the differ-
ent members of one class of PIs is similar. The fact that all genotypes show mutations
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at the same position suggests a similar escape route from BILN2061, something that
has been also suggested for TMC435 (Lenzt al. (2010)).
All escape mutations resulted from one single nucleotide change. It is unclear why
genotype 1b, 4a and 6a show a higher variability in substitutions than genotype 2a.
The type 2a resistance mutations Asp168Tyr/Val showed 10- to 100-fold higher resis-
tance to BILN 2061 in the type 1b replicon system than Asp168Ala/His/Glu/ Gly/Asn
(Lenzet al. (2010)). However, the J2a2a-T1066S-D168Y mutant only showed 7-fold in-
crease in resistance, which is 355-fold lower than that described in the type 1b replicon
system. The low level resistance increment of Asp168Tyr in type 2a could possibly ex-
plain why only Asp168Tyr/Val arose in type 2a, as the type 2a passaging experiment
was shorter than the type 6a and involved relatively lower PIconcentrations than the
type 1b and 4a experiment. The resulting low PI pressure would not be enough to
induce high level resistance mutations. It would be interesting to see whether further
substitutions would arise within the genotype 2a recombinant if it was passaged under
higher PI concentrations. The discrepancy between the results described here and those
reported elsewhere are presumably due to the differences inthe genetic backgrounds.
The genotype 5a wild type amino acid at position 168 is Glu, which is very similar to
Asp in genotype 1b, 2a, 4a and 6a (both are polar and negatively charged), except that
it is one methyl chain longer. As expected, the resistance profile in genotype 5a was
very similar with Glu168Ala/Val/Gly substitutions occurring. Substitutions identified
within genotype 3a on the other hand were different to those in all other genotypes,
reflecting the charge difference in the wild type amino acid at position 168 (Gln is
polar neutral).
Although further mutations at positions 155 and 156 have been associated with BILN
2061 resistance (Linet al. (2005a); Luet al. (2004)), substitutions at position 156
were only observed in a minority of genotype 1b and 4a clones.The Ala156Val sub-
stitution was found in both genotypes, whereas the Ala156Thr substitution was only
found in genotype 4a (Table 6.3). It is unclear why the Ala156Thr substitution only
occurred in genotype 4a and not in 1b. Both, Ala156Val and Ala156Thr only need one
nucleotide change and should be accessible to all genotypes. However, these geno-
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type specific differences are consistent with a report that described the occurrence of
the Ala156Val substitution in the genotype 1b, but not in thegenotype 1a replicon
(Lenzet al. (2010)). Residue 195 in genotype 2a has not been described as aresis-
tance locus before and it is unclear what effect the Gln195His substitution has on the
recombinant replication and resistance profile.
Interestingly, no substitutions were identified at position 155. The Arg155Gln muta-
tion has been observed duringin vitro studies in the genotype 1b replicon system, but
was associated with lower resistance than the Ala156Thr andAsp168Val mutations
(Lu et al. (2004)). In that study, Ala156Thr has been shown to confer thhighest
fold increase in resistance to BILN 2061, followed by Asp168Val and Arg155Gln.
These findings could explain the appearance of substitutions at position 156 for only
the genotype 1b and 4a passaging experiment. In these, the PIconcentrations reached
100× IC50, whereas it was about 70× IC50 for type 3a, 10× IC50 for type 6a and
only 1-2× IC50 for type 2a and 5a. The observed pattern of substitutions in all 6 geno-
types (Table 6.3) suggests that resistance mutations at position 156 only arise when PI
concentrations reach 100× IC50. Two other studies reporting higher resistance for the
Ala156Val/Thr mutation than for the Asp168Val/Ala mutation, support these findings
(Lu et al. (2004); Heet al. (2008)). However, contradictory results showing slightly
higher levels of resistance for the Asp168Tyr/Val mutationwhen compared with the
Ala156Val mutation, were reported elsewhere (Lenzt al. (2010)). These differences
are likely a result of differences in the genetic backgrounda type of assay, demon-
strating how important it is to characterise resistance mutations in all HCV genotypes.
The time of AV pressure does not seem to have a major influence othe resistance
profile, as type 1b and 4a were only passaged for 8 and 13 days, respectively.
Using specific site directed mutagenesis, the phenotypic effe ts of substitutions were
determined. Whereas the Asp168Val mutation reduced the replicative fitness of the
J2a2a-T1066S and J6a6a-V1040L recombinant below the detection limit, it only slowed
down the spread of the J5a5a-Q1247L recombinant (Fig. 6.10 to 6.12). This deleteri-
ous effect on genotype 2a and 6a is surprising, as the Asp168Val substitution in the
genotype 1b replicon only partly reduced its replicative fitness (Heet al. (2008)). Pre-
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sumably these discrepancies are due to differences in the different genotypic NS3 pro-
tease sequences. Viral variants with the Asp168Val mutation potentially have compen-
satory secondary mutations outside the NS3 protease region. The J3a3a-Q168R and
the J5a5a-Q1247L-E168G recombinant initially spread like the wild type recombinant,
but were then diluted out as the cell culture was split, suggesting inefficient spread
between cells as observed for J1b1b and J4a4a-19 (Fig. 6.11 and 4.11). The remaining
tested substitutions did not show any major impact on recombinant fitness. However,
as no quantitative real-time PCR was performed it cannot be excluded that there are
differences in intra- and extracellular RNA levels between wild type and mutant re-
combinants.
The different substitutions identified during the selection experiment had different ef-
fects on BILN 2061 susceptibility and did not correlate with their effect on replication
fitness (Table 6.6). The J6a6a-V1040L-D168H mutant that conferred the highest level of
resistance of the mutants analysed, replicated with similar efficiency in the cell culture
as the wild type (Table 6.6 and Fig. 6.12). Within genotype 3aand 5a, all mutants
analysed showed a similar increase in resistance towards BILN 2061, although the
replication of some was impaired (Fig. 6.11). Only within genotype 1b was higher
resistance associated with slightly lower replication leve s (Fig. 6.10 top). The fold
increase in resistance in J1b1b induced by the Asp168Glu/Gly mutation was about the
same as described in the literature, whereas the measured inc ase for Ala156Val was
2- to 10-fold and for Asp168Tyr in genotype 2a 100-fold lowerthan described be-
fore. The observed increase in resistance for the Asp168Hismutation in genotype 6a
is about twice as high as reported before (Heet al. (2008); Lenzet al. (2010)). How-
ever, comparisons should be made with caution as the cited studie were performed
using the genotype 1b replicon, whereas results presented ithis chapter are derived
from 6 different genotypic backgrounds.
The resistance mechanism of HCV to BILN 2061 has been describedin great detail
(Courcambecket al. (2006)). Two different mechanisms were demonstrated. The
direct mechanism is based on the contact between the 2 mutated residues Arg155Gln
and Ala156Thr and the inhibitor. Arg155 and Ala156 are part of the S2 binding pocket,
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which interacts with the large P2 moiety of BILN 2061. The S2-P2 interaction is the
functionally most important interaction for BILN 2061 potency. Important electrostatic
interactions between Arg155 and the PI are lost when position 155 is replaced with
an uncharged amino acid like Gln, explaining the Arg155Gln mutation. Ala156 is
also in close interaction with the PI and a change towards a larger and bulkier amino
acid like Thr produces strong steric constraints on the interaction with BILN 2061.
This markedly affects the affinity of BILN 2061 for the NS3/4A protease and explains
the Ala156Thr substitution. Val is also bulkier than Ala, explaining the Ala156Val
substitution.
The second, indirect mechanism involves Asp168, which doesnot directly interact
with BILN 2061. However, Asp168 builds 2 salt bridges with Arg123 and Arg155,
2 residues that directly interact with BILN 2061. Mutations at position 168 prevent
the formation of these salt bridges and alter the conformation of Arg123 and Arg155,
thereby preventing optimal binding of BILN 2061 (Fig. 6.18).Arg is a positively
charged amino acid and will need a negatively charged amino acid to build a salt
bridge. All amino acid substitutions towards nonpolar, positively charged or neutral
amino acids will therefore disrupt the salt bridges betweenresidue 168 and Arg123
and Arg155, thereby inducing BILN 2061 resistance. All substitutions observed at
Asp168 (Ala/Asn/Gly/His/Tyr/Val) are nonpolar, neutral or positively charged, ex-
plaining the resistance mechanism of these substitutions (Fig. 6.19). The exception
is the Asp168Glu substitution, a change towards another polar and negatively charged
amino acid, which would not disrupt the building of the salt bridges. However, the Glu
side chain is one carbon atom longer than the Asp side chain, possibly pushing Arg123
and Arg155 further away and rearranging the optimal spatialrr ngement.
The highest fold resistance was induced by the Asp168His subtit tion, which is the
only substitution with a positive charge. His168 not only disrupts the salt bridges
but also repulses the positively charged residues Arg123 and Arg155, inducing more
extensive spatial rearrangements and explaining the increased resistance.
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Figure 6.18: Structural perspective on Asp168 resistance mechanism.The catalytic
triad is depicted in orange and Asp168 in white with nitrogen inred and oxygen in
blue. The negatively charged residue Asp168 makes 2 salt bridges with the 2 positively
charged residues Arg123 and Arg155 (in blue), which directlybind to BILN 2061. Dis-
ruption of these salt bridges changes the optimal PI bindingconformation of Arg123
and Arg155.
The resistance mechanism for genotype 5a works on a similar basis, with changes
from the polar and negatively charged amino acid Glu to nonpolar amino acids like
Ala/Gly/Val (Fig. 6.20). In genotype 3a, the polar and neutral amino acid Gln is the
wild type residue. Furthermore, residue Thr123 is a neutralamino as well, suggest-
ing a slightly different resistance mechanism. Gln can temporarily be positively and
negatively charged, as it has an amine and hydroxyl group. Itcan thereby build a salt
bridge with the positively charged Arg155 and the free hydroxyl group of Thr123. All
substitutions observed within genotype 3a are towards positively charged residues or
nonpolar amino acids that can not undergo both salt bridges and thereby destabilise the
interaction between BILN 2061 and the NS3/4A protease (Fig. 6.21).
Analogously to BILN 2061, VX-950 resistance was inducedin vitro through passaging
Jxxs under VX-950 pressure. Due to the limiting amounts of VX-950 available, the
PI concentration was kept at 2-3× IC50. None of the genotypes showed significant
substitution rates at any of the resistance loci described in the literature (NS3 residue
36, 41, 43, 54, 155, 156 and 170) (Table 6.1). As discussed above, this is presumably
due to the to low PI concentrations used. Nevertheless, within genotype 1b and 3a
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one position (Ser174Pro and Asn77Ser, respectively) showed significant substitution
rates in both replicates, suggesting a resistance mutation(F g. 6.7 and 6.8). Both are
at a position which has not been described as a resistance locus and due to the low PI
concentrations this suggests a low level resistance mutation. Residue Asn77 lies on a
surfaceβ-sheet and it is unclear what the exact phenotypic effect of aSer substitution
would have on fitness and resistance of a viral variant. Ser174 is part of anα-helix and
close to the S2 binding pocket. A change towards the bulkier amino acid Pro possibly
has a structural impact on PI binding. To get conclusive results on the effect of these
mutations, specific site directed mutagenesis and IC50 determinations are required.
No significant substitutions were observed within genotype4a, which can be explained
with the high IC50 value of J4a4a-19 (2,330 nM). Nevertheless, one clone each ws
identified carrying a substitution at previously describedr sistance loci (Leu36Pro,
Thr54Ala and Ala156Val, respectively) (Table 6.1 and 6.5).Although it cannot be
excluded that these mutations arose due to Taq errors, the fact that they have been de-
scribed previously, strongly suggests that they representtrue resistance mutations. Pas-
saging under higher PI concentrations should allow the identification of more clones
containing resistance mutations.
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Figure 6.19: Structural perspective on Asp168 resistance mutations.The catalytic
triad is depicted in orange and Asp168 and Ala156 in white with nrogen in red and
oxygen in blue. Mutations observed during passaging experiments with Jxx under
BILN 2061 are depicted in pink.
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Figure 6.20: Structural perspective on Glu168 resistance mutations.The catalytic
triad is depicted in orange and Glu168 in white with nitrogen inred and oxygen in
blue. Mutations observed during passaging experiments withJxx under BILN 2061
are depicted in pink.
Figure 6.21: Structural perspective on Gln168 resistance mutations.The catalytic
triad is depicted in orange and Gln168 in white with nitrogen inred and oxygen in
blue. Mutations observed during passaging experiments withJxx under BILN 2061
are depicted in pink.
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6.4 Conclusion
To identify resistance mutations developing during PI treatment, Jxx recombinants of
HCV genotype 1 to 6 were passaged under increasing concentratio s of BILN 2061.
Several newin vitro resistance mutations were identified at the previously ident fi d
resistance residues 156 and 168. The dominant resistance mutations observed against
BILN 2061 occurred at position 168, but within genotype 1b and4a resistance mu-
tations were also observed at position 156. A high diversityof substitutions was ob-
served at position 168, suggesting great flexibility in the spatial arrangement of the
protease to evade PI binding. Using specific site directed mutagenesis allowed inves-
tigation of the effects identified resistance mutations have on viral fitness and antiviral
resistance. Strikingly, the Asp168Val mutation completely abrogated detectable viral
replication, whereas other substitutions only had minor impacts on viral fitness. Amino
acid changes from polar and negatively to polar and positively charged residues had the
highest impact on viral susceptibility to BILN 2061. Similarly, resistance development
upon VX-950 treatment was investigated. Two previously unide tified potentially low
level resistance loci were observed together with sporadicmutations at known resis-
tance loci.
Identification of previously described resistance mutations for BILN 2061 and VX-950
underscore the usefulness of the Jxx-recombinant system develop d here. Progress
towards characterisation of these mutations and combinatio s will in the long term
provide the necessary data for the development of genotype specific drug-resistance
databases analogous to those developed for HIV-1.
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Chapter 7
Concluding Remarks and Outlook
HCV is globally widespread and a major health concern. It is one f the main causes
of severe liver diseases, such as cirrhosis and hepatocellular carcinoma, which can lead
to death. The considerable genetic diversity between the 7 gnotypes (>30 %) leads
to substantial differences in persistence, disease associtions and treatment response.
Furthermore, the pre-existing huge pool of genetically different variants within an in-
dividual, the so-called quasispecies, allows a rapid adaptation of HCV to selection
pressures, such as immunological recognition and antiviral tre tment. The current stan-
dard IFN-α/ribavirin combination treatment is associated with severside effects and
patients with genotype 1 and 4 only respond poorly to this treatm nt. The development
of specific antiviral drugs is therefore highly desired. To date, drug development has
mainly been based on genotype 1a or 1b-based enzyme structures and the genotype 1b
replicon system, leading to genotype 1 specific drugs. Becausof substantial sequence
divergence between genotypes within the enzymatic gene regions, antivirals developed
upon genotype 1 enzymatic structures often show lower efficacies in nongenotype 1 en-
zymes. The case of the first PI to enter clinical trials, BILN 2061, demonstrated very
early on the immense impact structural differences within ge otypes can have on drug
efficacies. The genotype 1 specific PI showed high efficacy in genotype 1 infected pa-
tients, whereas genotype 2 and 3 infected patients were onlyweakly or non-responsive
to BILN 2061 treatment (Lamarret al. (2003); Reiseret al. (2005)).
Another problem identified early on in clinical trials with HCV antivirals, was the
rapid emergence of antiviral resistance mutations. As shown f r HIV-1, large popula-
tion sizes and the relatively high error rate of the RNA polymeras are the main factors
for the huge genetic diversity of HCV. Pre-occurring viral variants with resistance mu-
tations can therefore readily be selected for during antiviral treatment. As shown in the
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replicon system, new antiviral specific resistance mutations can also be rapidly induced
upon antiviral treatment.
The variable efficacies of PIs on different genotypes and theinfluence genotypes might
have on the effect of naturally occurring resistance mutations demand the development
of an in vitro system to investigate the effectiveness of antivirals for different geno-
types. The aim of the PhD project presented here was to develop an intra- and in-
tergenotypic cell culture system that would allow thein vitro assessment of HCV NS3
proteases from genotype 1 to 6.
In a first part, the natural polymorphism within the NS3 proteas and NS4A cofactor
of genotype 1a and 3a clinical variants was analysed. It was shown that the NS3/4A
protease is flexible enough to tolerate substitutions despit the different functional con-
straints. No mutations were identified within the functional domains of the catalytic
triad, the S1 and S2 binding pocket or the zinc binding domain. However, natural poly-
morphism outside of the functional domains was observed, which might potentially
influence the 3D structure of the protease and affect functioal sites. The identification
of polymorphic sites within the NS3 protease will be valuable in designing new PIs.
Inhibitor development could be designed targeting areas which are conserved across
genotypes and subtypes, ensuring efficacy in all genotypes and ubtypes. In addition,
identification of individual polymorphism, known to be associated with treatment fail-
ure, will enable patient specific treatment options.
The main part of this PhD project was the development of a full-length HCV cell
culture system, which allows the investigation of proteasegene function in all 6 ma-
jor genotypes. This extends the range of available full length replication competent
clones that allow analysis of the NS3 protease gene from genotype 2a and 1a to all 6
major genotypes (Lindenbachet al. (2005); Wakitaet al. (2005); Yiet al. (2006b);
Murayamaet al. (2007a)). Genetically engineered restriction sites on theNS3 pro-
tease boundaries allowed the generation of an intergenotypic re lication competent
clone for genotype 5a. Extending the cloning strategy to include the homologous
NS4A cofactor in the recombinant construction resulted in replication competent intra-
and intergenotypic recombinants representing all 6 major genotypes. Different cell
231
Concluding Remarks and Outlook
culture adaptive/attenuating mutations were identified that allowed the generation of
stably replicating recombinant clones for genotype 2a, 3a,5a and 6a. The cell cul-
ture system presented here provides a powerful tool to studythe NS3 protease within
the full viral life cycle and adds to the currently availableJFH1-based systems for the
study of the non-structural genes (Pietschmannet al. (2006); Gottweinet al. (2007);
Yi et al. (2007); Jensenet al. (2008); Scheelet al. (2008); Gottweinet al. (2009)).
The genetically engineered restriction sites allow the insrtion of protease genes am-
plified from clinical specimens directly into the expression vector. Protease genes from
all genotypes and subtypes can thereby easily be assessed for pre-existing antiviral re-
sistance mutations and their antiviral susceptibility.
Using the intra- and intergenotypic recombinants it could be demonstrated that dif-
ferent NS3 proteases react differently to the same PI. The genotype 1b protease was
shown to be more susceptible to BILN 2061 than the genotype 2a and 3 derived pro-
teases, confirming previously reported results and underscoring the practicality of the
system (Thibeaultet al. (2004)). Furthermore, inhibitor sensitivity testing within the
full length viral lifecycle could be extended to genotype 4a, 5 and 6a. Compared to the
replicon system, this cell culture system allows the assessm nt of antiviral susceptibil-
ities in the context of the entire life cycle of the virus. Theeffect of antiviral efficacies
on replication kinetics as well as supernatant infectivitycan be assessed. Analogously,
genotype specific differences in susceptibility to VX-950 were also demonstrated.
Passaging the intra- and intergenotypic recombinants under i cr asing BILN 2061 con-
centrations allowed thein vitro induction of resistance mutations. Several newin vitro
resistance mutations were identified at previously described resistance loci, emphasis-
ing again the practicality of the system. Whereas all genotypes developed resistance
mutations at position 168, only genotype 1b and 4a also developed resistance muta-
tions at position 156. The fact that higher PI concentrations were used in type 1b
and 4a passaging experiments suggests that mutations at position 156 confer higher
levels of resistance than those at position 168. The great diversity of resistance mu-
tations observed between the different genotypes demonstrate the flexibility of the
HCV protease and highlights the importance of phenotypic characterisation of resis-
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tance mutations for all genotypes. Phenotypic characterisation of the individual resis-
tance mutations identified during passaging experiments identified mutations with no
or dramatic effects on viral replication kinetics. All substitutions that were assessed
conferred an increase in antiviral resistance, providing proof that they are real resis-
tance mutations and that the cell culture system described here can be used to identify
them. Investigation of resistance development upon VX-950treatment identified previ-
ously unidentified substitutions as well as substitutions at already identified resistance
loci.
Replication competent intra- and intergenotypic recombinants have successfully been
created for genotype 1b, 2a, 3a, 4a, 5a and 6a. The generationof a well replicating
recombinant based on the important genotype 1a would complete th set of Jxx recom-
binants. Possible strategies to create a well replicating J1a1a recombinant include the
insertion of further patient-derived protease genes and more extensive laboratory pas-
saging to hopefully induce adaptive mutations. Furthermore, the cloning strategy could
be extended to include the NS2 protein in the recombinant construction. NS2 is a zinc-
stimulated cysteine protease that cleaves the NS2-NS3 junction, for which it requires
the N-terminal part of NS3 as a cofactor (Schregelet al. (2009)). Incompatibilities
between the heterologous NS2 and NS3 protease proteins in the J1a1a recombinant
might contribute to its poor replication kinetic.
Possible next steps in the project also involve the development of a diagnostic pheno-
typic assay for antiviral resistance. Instead of ligating amplified protease sequences
into the expression vector and choosing individual clones representing one viral vari-
ant, a more rapid approach involving direct RNA transcription from the ligation prod-
uct could be pursued. Because the cloning step is omitted, theRNA transcript popula-
tion will reflect the diversity of HCV sequences within the quasispecies population of
the sample. Minor populations of variants including resistance mutations may there-
fore contribute to resistance development depending on their in vivoabundance.
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In summary, during this PhD project a full length HCV cell culture system, which al-
lows the investigation of protease gene function in all 6 genotypes within the full viral
life cycle, has been developed. Using this system, it could be emonstrated that differ-
ent NS3 proteins react differently to the same PI. Any PI identifi d in high-throughput
screening can be evaluated for its efficacy on different genotypes and treatments de-
signed according to the outcome. Passaging the recombinants in sub-inhibitory con-
centrations of antiviral drugs allowed the identification of p tential resistance muta-
tions to BILN 2061 and VX-950 and will therefore be of considerable value in pre-
clinical assessment of resistance induction and genotypicvar ability for newly devel-
oped compounds.
The ease with which protease gene sequences directly amplified from clinical spec-
imens can be inserted in the expression vector of the appropriate genotypes allows
for the first time direct monitoring of antiviral drug inhibition for specific proteases
through assessment of reduction in both supernatant infectvity and replication kinet-
ics. Protease genes from study subjects naı̈ve to treatment can then easily be assessed
for sensitivity to a range of antiviral drugs and screened for pre-occurring resistance
mutations, as well as providing a phenotypic assay for the rapid ssessment of emerg-
ing resistance during therapy and the influence of specific mutations on treatment out-
come.




Table A.1: Primers used for amplification of the NS3 protease gene from plasma,
genotype 1a. OS, outer sense; OA, outer anti-sense; IS, inner sense; IA,inner anti-
sense; OMS, outer middle sense; OMA, outer middle anti-sense; MS, middle sense;
MA, middle anti-sense.

















Table A.2: Primers used for amplification of the NS3 protease gene from plasma,
genotype 3a.OS, outer sense; OA, outer anti-sense; IS, inner sense; IA, inner anti-
sense; MS, middle sense; MA, middle anti-sense.









Table A.3: Primers used for amplification of the NS3 protease gene from plasmids.
OS, outer sense; OA, outer anti-sense.















Table A.4: Primers used for amplification of the NS4A gene, genotype 1a and 3a.
OS, outer sense; OA, outer anti-sense; IS, inner sense; IA, inner anti-sense.









Table A.5: Primers used for the amplification of the NS3 protease gene from plasmid
or plasma, introducing restriction sites.xBstBI-s, primers including a BstBI restric-
tion site; xBglII-as, primers including a BglII restriction site.

















Table A.6: Primers used for the amplification of the NS4A gene from plasmids,
introducing restriction sites.xSapI-s, primers including a SapI restriction site; xMluI-
as, primers including a MluI restriction site.















Table A.7: Primers used for the amplification of the core gene as a positive control.
OS, outer sense; OA, outer anti-sense; IS, inner sense; IA, inner anti-sense.







Table A.8: Primers used for the introduction of point mutations.(a) Introduction
of BstBI into pJFH1, (b) introduction of BglII into pJFH1, (c) introduction of BlpI
into pJFH1, (d) introduction of MluI into pJFH1, (e) mutation of BglII restriction site
within p4a, (f) introduction of cell culture adaptive L1663Aamino acid mutation, (g)
mutation of SpeI restriction site within the Jc1 backbone.
Primer Position Sequence (5’-3’)
(a)
BstBI-sQC 3384 GCTGATGGCTACACTTCGAAGGGGTGGAAGC























Table A.9: Primers used for whole genome sequencing of JFH1, Jc1 and the in-
tergenotypic recombinants.JFH-B, sense primers; JFH-C, anti-sense primers.






































Table A.10: Primers used for whole genome sequencing of JFH1, Jc1 and the in-
tergenotypic recombinants.JFH-F, anti-sense primers.




































Table A.11: Primers used for sequencing of TOPO vector inserts.
Primer Position Sequence (5’-3’)
M13F - GTAAAACGACGGCCAG
M13R - CAGGAAACAGCTATGAC
Table A.12: Primers used for whole genome sequencing of JFH1, Jc1 and the in-
tergenotypic recombinants.


















Table A.13: Primers used for amplification of RNA from supernatant.





Table A.14: Primers used for introduction of resistance mutations.















Common Solutions and Buffers
4% Paraformaldehyde. In a foom hood, 8 mg of paraformaldehyde were added to
100 ml dH2O, followed by 2 ml 1 M NaOH. The mixture was styred gently and icu-
bated at 60°C until completely dissolved. 20 ml 10X PBS were added and the solution
allowed to cool to room temperature. After adjusting the pH to 7.4, using 1 M HCl,
dH2O was added to a final volume of 200 ml. The solution was then filtered through a
0.45µm filter and aliquoted to 30 ml in 50 ml falcon tubes. Aliquots were wrapped in
aluminium foil and stored at -20°C.
Mowiol mounting medium. 2.4 g Mowiol (Calbiochem) were added to 6 g of glycerol
and thoroughly stirred. 6 ml dH2O were added and the mixture incubated at room
temperature for 2 hours. Following the addition of 12 ml 0.2 mM Tris (pH 8.5) the
solution was incubated at 55°C until Mowiol had dissolved. The solution was clarified
by centrifugation at 1,500× g for 20 minutes and 1,4-diazobicyclooctane (DABCO,
antifade agent, Sigma) added to 2.5 %. Aliquots were stored at -20°C.
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Table B.1: Reagents used in this thesis.
Reagent Company/Source
Cell Lines
Huh7 and Huh7.5 cell lines Gifts from Mark Harris, Leeds
DMEM media Invitrogen




Plastic ware Nunc/Thermo Fisher Scientific
DMSO Hybri-MAX® Sigma-Aldrich
RNA Work
RNA/DNA extraction and purification kits QIAGEN
T7 RiboMAXTM for RNA production Promega
PCR
Primers Sigma-Aldrich
Access RT-PCR system Promega
GoTaq® DNA polymerase Promega
SuperScriptTM III RT-PCR system Invitrogen
KOD Hot Start DNA polymerase NOVAGEN
VentR® polymerase New England BioLabs
FastStart Taq DNA polymerase Roche
SYBR Green I Invitrogen
Cloning Techniques
LB-agar and broth Merck
Glycine Sigma-Aldrich
2-mercaptoethanol, min 98 % Sigma-Aldrich
Glycerol Fisher Scientific Ltd
Phenol:chloroform:isoamyl-alcohol:25:24:1 Fluka/Sigma-Aldrich
Quick-change site directed mutagenesis kit Stratgene
pCR®-blunt II-TOPO vector Invitrogen
TOP10 One Shot® chemically competentE.Coli Invitrogen
NEB 5-α New England BioLabs
NEB 10-β New England BioLabs
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Table B.2: Reagents used in this thesis.
Reagent Company/Source
Enzymes
Restriction enzymes New England BioLabs
Mung Bean nuclease New England BioLabs
Antarctic Phosphatase New England BioLabs
T4 DNA Ligase New England BioLabs
Immunostaining




Sheep anti-NS5A serum Gift from Mark Harris, Leeds
Alexa Fluor 488 donkey anti-sheep IgG Invitrogen
Protease Inhibitors
BILN 2061 Gift from GlaxoSmithKline
VX-950 Acme Bioscience, Inc. CA.
Table B.3: Recipe used to make up 1X PBS.
Reagent Quantity
Sodium chloride 8 g
Potassium chloride 0.2 g
Di-sodium hydrogen phosphate 1.15 g
Potassium dihydrogen phosphate 0.2 g
dH2O to a final volume of 1 l
pH 7.3
Table B.4: Recipe used to make up 50X TAE.
Reagent Quantity
Tris-acetate 242 g
Glacial acetic acid 57.1 ml
0.5 mM EDTA (pH 8.0) 100 ml
dH2O to a final volume of 1 l
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Potassium acetate 50 mM
Tris-acetate 20 mM






Table C.1: Amino acid diversity among NS3 sequences derived from HCV-infected
plasma of genotype 1b.Sequences were compared to 459 sequences retrieved from the
Los Alamos HCV database project (Kuikent al. (2005)) and NCBI GenBank. First
letter indicates the amino acid in HC-J4 (D10750), if not dominant in lower case letter.
Dominant amino acids are in big capital letters, minor occurring ones at polymorphic
sites in lower case. Amino acids not occurring in any other variant are in italic. Amino
acid positions are numbered according to their position in the H77 (AF009606) refer-
ence strain.
NS3-1b
HC-J4 v/L1039(m,p) I/V1074(t) S1087(t,p,a,c) L/Q1106(k,r) M/L1120
J1b1b
J1b1b-2 L T Q L
J1b1b-12 L V Q L
NS3-1b
HC-J4 S/T1124(a) S1151(a) v/A1176(I,l,t) v/I1179(l) I/V1196
J1b1b
J1b1b-2 T A A I V
J1b1b-12 T A I V
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Table C.2: Amino acid diversity among NS3 and NS4A sequences derived from
HCV-infected plasma of genotype 1a.Sequences were compared to 570 NS3 and
NS4A sequences retrieved from the Los Alamos HCV database project (Kuikenet al.
(2005)), NCBI GenBank and those in chapter 3. First letter indicates the amino acid in
H77 (AF011751), if not dominant in lower case letter. Dominant amino acids are in big
capital letters, minor occurring ones at polymorphic sitesin lower case. Amino acids
not occurring in any other variant are in italic. Amino acid positions are numbered
according to their position in the H77 (AF009606) referencestrain.
NS3-1a












H77 I1090(m,l,v) P1093(s,a) P1112(s,l, t,a,q) A1113(s,v,l,t,c) S/A/T1117(g) S1127(a)
J1a1a-H77*
J1a1a-1 A









H77 H1136(q,n,r) S1148(g) I/L1179(v) N/S1200(d,g,k) G/E1202 M1205(i,t,v)
J1a1a-H77* T
J1a1a-1 G I S E T
J1a1a-2 I S E T
J1a1a-3 I T
J1a1a-4 I S T
J1a1a-5 G I S T
J1a1a-6 I S T
J1a1a-7 I E T
J1a1a-8 Q I E T
J1a1a-9 I E T
NS4A-1a
H77 K1691(r) I/V1694(l,m) P1696(y) Q/R1703(k) C1711
J1a1a-H77*







Table C.3: Amino acid diversity among NS3 and NS4A sequences derived from
HCV-infected plasma of genotype 3a.Sequences were compared to 242 NS3 and 180
NS4A sequences retrieved from the Los Alamos HCV database project (Kuikenet al.
(2005)), NCBI GenBank and those in chapter 3. First letter indicates the amino acid
in HCV3a-Gla, if not dominant in lower case letter. Dominant amino acids are in big
capital letters, minor occurring ones at polymorphic sitesin lower case. Amino acids
not occurring in any other variant are in italic. Amino acid positions are numbered
according to their position in the H77 (AF009606) referencestrain.
NS3-3a
HCV3a-Gla A/T1033(p) S1046(g,r) V1054(g,l,m) A1065(s,t) i/V11074(l) A/V1093(I,n,p,s,t)
J3a3a-3 T
J3a3a-6 N
J3a3a-8 G L V P
J3a3a-11 T V
NS3-3a
HCV3a-Gla A1117(t,v) A/T1124(s) D1136(e,n) A1177(m,t,v) T1200(a,s)
J3a3a-3 A T T
J3a3a-6 T
J3a3a-8 A T T









Table C.4: Amino acid diversity among NS3 sequences derived from HCV-infected
plasma of genotype 4a. Sequences were compared to 39 NS3 sequences retrieved
from the Los Alamos HCV database project (Kuikenet al. (2005)) and NCBI Gen-
Bank. First letter indicates the amino acid in ED43 (Y11604), if not dominant in lower
case letter. Dominant amino acids are in big capital letters, minor occurring ones at
polymorphic sites in lower case. Amino acids not occurring inany other variant are
in italic. Amino acid positions are numbered according to their position in the H77
(AF009606) reference strain.
NS3-4a
ED43 L1039(m) F1040(c,l,v) S1041(g,n) V/I1044 T1048 C1056
J4a4a-ED43* A
J4a4a-7 T L G I R
J4a4a-8 I
J4a4a-10 M L G I
J4a4a-19 M L G I
NS3-4a
ED43 V1059(l) T1064 V/I1074 a/S1087(g) R/K1118(t) A/T1121(v,s)
J4a4a-ED43* I
J4a4a-7 I I S K
J4a4a-8 I S K T
J4a4a-10 I I S K
J4a4a-19 I I S K
NS3-4a
ED43 S/A1127 a/S1128 Y1131(f) i/V1140 L1153 i/T1160(l)
J4a4a-ED43* T
J4a4a-7 S F V T
J4a4a-8 A S V T
J4a4a-10 S F V T
J4a4a-19 A S F V I T
NS3-4a
ED43 L1169 r,A1176(v) M1173(l,q) I1179(v,l)
J4a4a-ED43* A
J4a4a-7 V L L
J4a4a-8 A




Table C.5: Amino acid diversity among NS3 sequences derived from HCV-infected
plasma of genotype 6a.Sequences were compared to 15 NS3 sequences retrieved
from the Los Alamos HCV database project (Kuikenet al. (2005)) and NCBI GenBank.
First letter indicates the amino acid in EUHK2 (Y12083), if not dominant in lower
case letter. Dominant amino acids are in big capital letters, minor occurring ones at
polymorphic sites in lower case. Amino acids not occurring inany other variant are
in italic. Amino acid positions are numbered according to their position in the H77
(AF009606) reference strain.
NS3-6a
EUHK2 T1030(s) V/L1040(m,f,i) d/A1065 v/L1070 N1075(s) p/A1085
J6a6a-EUHK2* A L A
J6a6a-4 S I A L A
J6a6a-8 A L S A
NS3-6a
EUHK2 f/S1087(a) K1094(r) l/K1106(q) n/T1124(a) s/N1148 A/T1121(v,s)
J6a6a-EUHK2* S R
J6a6a-4 S K T N
J6a6a-8 S K A N T
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